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Abstract
The Community IntraVenous Antibiotic Study (CIVAS): a
mixed-methods evaluation of patient preferences for and
cost-effectiveness of different service models for delivering
outpatient parenteral antimicrobial therapy
Jane Minton,1* Carolyn Czoski Murray,2 David Meads,2
Stephane Hess,3 Armando Vargas-Palacios,2 Elizabeth Mitchell,2
Judy Wright,2 Claire Hulme,2 David K Raynor,4 Angela Gregson,5
Philip Stanley,6 Kate McLintock,2 Rachel Vincent1 and
Maureen Twiddy2
1Leeds Teaching Hospitals NHS Trust, Leeds, UK
2Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
3Institute of Transport Studies, University of Leeds, Leeds, UK
4School of Healthcare, University of Leeds, Leeds, UK
5Leeds Community Healthcare Trust, Leeds, UK
6Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK
*Corresponding author janeminton@nhs.net
Background: Outpatient parenteral antimicrobial therapy (OPAT) is widely used in most developed
countries, providing considerable opportunities for improved cost savings. However, it is implemented only
partially in the UK, using a variety of service models.
Objectives: The aims of this research were to (1) establish the extent of OPAT service models in England
and identify their development; (2) evaluate patients’ preferences for different OPAT service delivery
models; (3) assess the cost-effectiveness of different OPAT service delivery models; and (4) convene a
consensus panel to consider our evidence and make recommendations.
Methods: This mixed-methods study included seven centres providing OPAT using four main service
models: (1) hospital outpatient (HO) attendance; (2) specialist nurse (SN) visiting at home; (3) general nurse
(GN) visiting at home; and (4) self-administration (SA) or carer administration. Health-care providers were
surveyed and interviewed to explore the implementation of OPAT services in England. OPAT patients were
interviewed to determine key service attributes to develop a discrete choice experiment (DCE). This was
used to perform a quantitative analysis of their preferences and attitudes. Anonymised OPAT case data
were used to model cost-effectiveness with both Markov and simulation modelling methods. An expert
panel reviewed the evidence and made recommendations for future service provision and further research.
Results: The systematic review revealed limited robust literature but suggested that HO is least effective
and SN is most effective. Qualitative study participants felt that different models of care were suited to
different types of patient and they also identified key service attributes. The DCE indicated that type of
service was the most important factor, with SN being strongly preferred to HO and SA. Preferences were
influenced by attitudes to health care. The results from both Markov and simulation models suggest that a
SN model is the optimal service for short treatment courses (up to 7 days). Net monetary benefit (NMB)
values for HO, GN and SN services were £2493, £2547 and £2655, respectively. For longer treatment,
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SA appears to be optimal, although SNs provide slightly higher benefits at increased cost. NMB values for
HO, GN, SN and SA services were £8240, £9550, £10,388 and £10,644, respectively. The simulation
model provided useful information for planning OPAT services. The expert panel requested more guidance
for service providers and commissioners. Overall, they agreed that mixed service models were preferable.
Limitations: Recruitment to the qualitative study was suboptimal in the very elderly and ethnic minorities,
so the preferences of patients from these groups might not be represented. The study recruited from
Yorkshire, so the findings may not be applicable nationally.
Conclusions: The quantitative preference analysis and economic modelling favoured a SN model, although
there are differences between sociodemographic groups. SA provides cost savings for long-term treatment
but is not appropriate for all.
Future work: Further research is necessary to replicate our results in other regions and populations and to
evaluate mixed service models. The simulation modelling and DCE methods used here may be applicable in
other health-care settings.
Funding: The National Institute for Health Research Health Service and Delivery Research programme.
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Glossary
Discrete choice experiment A survey that presents respondents with multiple hypothetical choice tasks
and collects data on their choices. These data are then analysed using choice models.
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Plain English summary
Intravenous (i.v.) antibiotics are sometimes necessary to treat infections either because of the severity ofthe infection or because there is no effective oral (tablet) medication available. Many developed countries
provide i.v. antibiotics to patients living in the community if they have no other need to be hospitalised.
Such services, known as outpatient parenteral antimicrobial therapy (OPAT), have been slow to become
established in the UK, with four different service models in existence [attendance at hospital outpatient
departments, self-administration (SA) or carer administration, and either a specialist nurse (SN) or general
nurse visiting the patient at home].
The aim of this project was to compare patient preferences for, and the cost-effectiveness (value for
money) of, the different OPAT service models. We evaluated the existing literature and then carried out
qualitative studies with both patients and health-care professionals to determine key aspects of OPAT
services. This enabled us to develop a discrete choice experiment, a survey that presents respondents with
multiple hypothetical choice tasks and collects data on their choices. These data were then analysed using
choice models to measure the relative importance of the OPAT-related choices available to patients.
We also collected anonymised data from participants undergoing OPAT through seven centres, which
between them use all four service models, and we used two different health economics techniques to
analyse which model was most cost-effective.
The results favoured the SN visiting at home, as that was preferred by most patients groups and was the
most cost-effective, although SA did provide cost savings for longer treatments provided that patients were
appropriately trained.
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Scientific summary
Background
Intravenous (i.v.) antibiotic treatment was developed for patients in hospital, but for some years it has been
accepted practice in most developed countries to provide this to patients living in the community; this
practice is known as outpatient parenteral antimicrobial therapy (OPAT). There is evidence that it is safe
and generally welcomed by patients and that there are opportunities for improved cost-effectiveness and
increased hospital capacity. However, OPAT has been slow to become established in the UK, with service
provision being limited to clinical providers with effective, enthusiastic champions delivering a variety
of different models of care. There is limited evidence available for NHS health-care providers and
commissioners to facilitate service development.
Objectives
The aim of this research project is to:
1. establish the types of OPAT services available in England and to identify barriers to the use of each
service type
2. evaluate patients’ preferences for different service models of delivering OPAT
3. assess the cost-effectiveness of different service models for the delivery of OPAT.
Methods
Using a mixed-methods approach, the study included seven centres providing OPAT and covering four
main service models:
1. hospital outpatient (HO) attendance
2. specialist nurse (SN) visiting at home
3. general nurse (GN) visiting at home
4. self-administration (SA) or carer administration.
Systematic review
We searched the usual bibliographic databases (e.g. MEDLINE, EMBASE, The Cochrane Library) from 1993
to March 2015. Exclusion criteria included children, papers that aggregated outcomes for all patient
groups, non-i.v. antibiotics and no description of the OPAT service. Titles and abstracts were screened (and
checked for quality by a second reviewer) and full-text versions of potential papers were obtained for
detailed review.
Survey of health-care professionals
We sought the views of health-care professionals involved in OPAT through an online survey, which
offered the opportunity to participate in in-depth interviews. These were semistructured and mostly
conducted by telephone.
Qualitative study of patient perceptions of outpatient parenteral
antimicrobial therapy
Patients were recruited from four sites, which between them provided the following models of care:
HO attendance, nurse at home (GN and SN models) and SA. Participants were invited to take part in a
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focus group or a qualitative interview. The interviews and focus group discussions were semistructured and
explored patient satisfaction, issues and preferences. Data analysis followed the standard methodology for
thematic content analysis and also used aspects of framework analysis. The research team and patient
representatives met to discuss the relevance and suitability of the themes produced, the ways in which the
themes were linked and candidate attributes.
Quantitative analysis of patient preferences
We developed a discrete choice experiment (DCE) based on the systematic literature review data and
patient interviews to identify possible attributes and levels. Six key attributes were identified for inclusion in
the DCE, along with a number of attitudinal questions. Patients were given eight hypothetical choice
scenarios, each time involving the four models of care: HO attendance, GN or SN visit at home and SA.
The characteristics of the models of care were described in the form of attributes (e.g. number of
treatments per day) and levels within attributes (e.g. once daily, twice daily). The specific combinations of
values for the different characteristics to be shown in a given choice task were determined on the basis of
a D-efficient experimental design and varied across the eight tasks shown. The aim of this process is to
produce data that can then be used in a choice model to understand how the individual characteristics of
the service influence the choice patients make between models of care. We conducted a pilot study with
30 patients to gather their feedback on the survey. The main study recruited participants from six NHS
acute hospital trusts representing both teaching and district general hospitals and included both short-term
(requiring up to 7 days’ treatment) and long-term treatment. The data were analysed using an advanced
discrete choice model. Attitudinal data were analysed using principal component analysis with Varimax
with Kaiser normalisation to identify the underlying structure within the data. These attitudinal constructs
were then also used in the choice models.
Cost-effectiveness study
Our health economics workstream examined the value for money of different OPAT service models using
two different approaches: cohort Markov modelling and simulation modelling. Two populations were
modelled separately: those with skin and soft tissue infections (SSTIs) and other short-term infections and
those with longer-term or chronic infections such as joint and bone infections and cystic fibrosis. Data to
populate the model came from systematic literature reviews and retrospective hospital data from seven
OPAT centres. For the retrospective hospital data, a research nurse reviewed case notes after consent was
provided by the patient. These data included patient characteristics (sociodemographic and clinical),
measures of infection severity, type of service received, duration of treatment, adverse events, and primary
(e.g. general practitioner visits) and secondary (e.g. hospital stays) health-care resource use. Cohort Markov
models were constructed with daily cycles until the cohort was healed (or switched to oral antimicrobials)
or died.
Expert panel review
The expert panel consisted of clinical experts, researchers, commissioners and a patient representative.
All panel members were asked to undertake preparatory reading (systematic review and summaries
of the patient interviews, health professional interviews, DCE and economic modelling). The reports each
contained an executive summary method section with key results. On the day of the meeting, summary
presentations were made to the panel by the research team with the opportunity for questions and initial
discussion. The participants were then divided into workshops and asked to consider key questions arising
from the project work, prior to reconvening for final discussions and recommendations.
Ethics approval
The study was approved by the Proportionate Review Sub-Committee of the National Research Ethics
Committee South West – Frenchay (reference 13/SW/0060).
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Results
Systematic review
The search strategy identified 7214 papers, 606 of which met the inclusion criteria and were subject to
detailed review. An additional 17 papers were identified from references. The final analysis included
128 papers. The majority were set in the UK, Europe and North America, often with relatively small
sample sizes. There were 12 randomised controlled trials, none of which reported the trial methodology.
Only 21 studies included a usual-care comparator (hospital inpatient) when evaluating safety and clinical
effectiveness. Synthesised studies revealed mixed results for cure/improvement; however, when OPAT
models are considered individually, outpatient attendance is least effective and SN is most effective.
Survey of health-care professionals
The response rate to the survey was low, although a wide range of staff and settings was covered.
Much more information was obtained from the interviews with OPAT professional leads who delivered
services in a range of settings. Service models varied from being well organised with regularly updated
business plans to being ad hoc according to professional leads. Interviewees made a number of
suggestions on how OPAT service provision might be improved, in particular with regard to commissioning
and clinical governance.
Qualitative study
One focus group (four participants) and 28 interviews took place. A good service involved staff who were
perceived to be competent and highly skilled. Poor communication could leave patients without the
knowledge and confidence needed to be a competent collaborator in their own care and could affect their
perceptions of the service. Each of the care pathways was viewed as having its own strengths and
weaknesses, and the importance people attached to different attributes seemed to be linked to the age
and health of the patient. A nurse at home model was perceived to be particularly well suited to older
patients, those needing longer courses of i.v. treatment and those with more complex care needs. Hospital
attendance was considered to be most suitable for those who were fitter and younger and who required
once daily, short courses (< 1 week) of i.v. treatment. Patients using SA found it convenient but there were
some concerns about its safety.
Quantitative analysis of patient preferences
The quantitative analysis provides estimates of the importance of different characteristics of the different
models of care. We found that, on average, the type of treatment itself had the biggest influence on
choices, with patients showing a strong overall preference for the nurse at home model over hospital
treatment and SA. However, the characteristics of the models of care themselves also influenced the choice.
The most important effect here was observed in a strong preference for once-daily treatment versus two or
continuous treatments closely followed by the preference for the lowest level of adverse event risk. Although
other attribute levels were significant in determining respondent’s choices, they were less important. People
preferred a SN to a doctor or GN to deliver their treatment, preferred having an appointment time to not
having one and preferred to communicate with someone they know regarding their care. The order of
attribute preference was relatively stable across the short- and long-term infection groups. The choices
people make about their health care are influenced by a number of patient characteristics as well as by more
general attitudes towards health care. Younger patients tend to prefer to come to hospital for their care,
and older people tend towards a preference for a nurse at home model, compared with the alternative
treatments. Overall, there was a preference for once-daily antimicrobials and for patients to be followed up
face to face rather than by telephone at the end of their treatment.
Cost-effectiveness study
In both short- and long-term infection Markov models, the difference in expected effectiveness [quality-adjusted
life-years (QALYs)] across service models was negligible. This is because the time horizon employed (3 and
12 months for short-term and long-term infections, respectively) is relatively short, and, for many, the health
event of interest is transient in nature with a very low risk of mortality, as the selection of those suitable for
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OPAT excludes the most seriously ill patients. Furthermore, the risk of adverse events was very low across
all services. In contrast, there were significant cost differentials between the services, which drove the
cost-effectiveness results.
The results from the simulation modelling largely corroborated the Markov model results. A notable
difference was a change in the decision for long-term infections based on the deterministic analysis.
The results from both Markov and simulation models suggest that the SN is the optimal service in the short
term. In the long term, SA appears to be optimal, although the SN model provides slightly higher benefits,
but at a higher cost. The simulation yielded several additional useful pieces of information. It showed
that net benefit was inversely related to the number of treatment delays and that when resources are
exhausted, delays and costs increase and QALYs decrease (especially in the long term). The results also
suggested that long-term infections may best be served by a combination of SA and SN services.
Expert panel review
We presented the results to a panel of expert researchers and health-care professionals in the field.
We asked them to review the findings and to give their opinions on a number of questions.
There was broad agreement that OPAT services could be based either in an acute hospital trust or in the
community. The panel agreed that there needs to be flexibility to accommodate patients with different
needs and, therefore, that within any one OPAT service there should be more than one care pathway
(e.g. SA, HO attendance, nurse at home).
The health economics evidence suggested that a SN service was the most cost-effective for short- and
long-term infections, with SA being less expensive for long-term infections. There was agreement that
OPAT services should focus on antimicrobials that can be administered once a day, provided that the
treatment selected is clinically appropriate, as this provided the greatest potential for services to treat more
patients (thereby freeing up staff who would otherwise be involved in repeat administrations).
It was thought that a nationally commissioned service is needed, rather than local negotiation with clinical
commissioning groups. It was agreed that patient choice is important, but that any service should also offer
good value for money to the NHS and be appropriate for the individual patient’s clinical needs. Local
services must both support the needs of the whole community and take into account the skill set of the
available providers. The group discussed the implications of patient attitudes when considering the push to
move to community-based care. It was agreed that the findings of the study indicate that there may be a
need for an attitudinal/behavioural shift by both NHS staff and patients to accept these new ways of
delivering health care in the community in general, not just i.v. services. It was suggested that the attitudinal
questionnaire developed as part of the DCE would be useful to commissioners for service monitoring within
local contracts and would make a welcome component of a commissioner toolkit.
Patient and public involvement
Patients were consulted during the initial design of the project, with one becoming a co-applicant.
Owing to the ill health of the patient representatives at times and to the length of the project, we
recruited more patients to become part of the patient advisory group, who contributed extensively to
the project, in particular through helping with the writing of the patient information leaflets and the
design of the DCE and through attending the expert panel meeting.
Conclusions
Our survey of OPAT provision and interviews with health-care providers in England makes it clear that
great variation remains both in the extent of services provided and models of care in existence. In addition,
some respondents were struggling to maintain or even set up OPAT services because of the lack of clear
commissioning directives and/or engagement by senior managers.
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Our qualitative studies, while confirming that most patients prefer to receive treatment through OPAT
services, did highlight some organisational shortcomings, for example where patients were kept waiting for
long periods to receive treatments or where aftercare expectations were not met. This suggests that the
governance of such services needs to be improved to meet both specific and general clinical standards.
Our DCE modelling data collected on patient preferences showed that most patients preferred to be
treated at home, although certain sociodemographic groups would rather attend a hospital clinic. The
health economics workstream similarly showed that the visiting nurse model was the most cost-effective
overall. SA is also cost-effective for patients willing and competent to be trained to do this; in practice, this
is useful only for those requiring longer or repeated courses of treatment. The simulation model provides a
useful method of calculating the capacity of services according to the number of staff employed.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Background
Outpatient parenteral antimicrobial therapy
The delivery of intravenous (i.v.) antibiotics to patients outside a hospital setting was first described on a
small scale in the 1970s in North America. By the end of the 1990s, an estimated quarter of a million
patients annually were receiving i.v. antibiotics on an outpatient basis as a result of cost savings, patient
preference, better i.v. devices, the introduction of antimicrobial agents that needed administration only once
or twice a day and the development of dedicated service providers. A wide variety of infections have been
treated through this system, in particular skin and soft tissue infections (SSTIs), but also bone and joint
infections, bacteraemia, wound infections, pneumonia, complicated urinary tract infection, intra-abdominal
infections, device-related infections, endocarditis and central nervous system infections. Although widely
accepted as the standard of care in countries such as the USA and Australia, such services are largely limited
to patients with appropriate health insurance cover.1 Clinical efficacy and safety has been addressed in
many different clinical areas and using a variety of models of care, largely using retrospective analysis of
single-centre experience.2–5 Some risks of community-based i.v. therapy have been identified, and projects
have been initiated to minimise these.6 The potential for treatment of micro-organisms resistant to
antimicrobials and for limiting the spread of health-care-associated infection has been highlighted as an
outpatient parenteral antimicrobial therapy (OPAT) benefit.7 Newer antimicrobial agents have been assessed
for their potential for OPAT use, usually because they have long half-lives with less frequent dosing required
and may be effective against resistant micro-organisms such as meticillin-resistant Staphylococcus aureus
(MRSA).8,9 However, such agents are much more expensive, so increase the cost of the service.
Clinical practice in the UK
Over the last 10 years, OPAT services have been developed in more areas of the UK, in both the NHS and
private sectors, in response to local pressures in combination with health-care staff initiatives.7 This has led
to many service variations using different heath-care professional groups which can be grouped into four
main categories:
1. Outpatient attendance at a health-care facility
i. A variety of NHS hospital departments have set up systems for providing i.v. antibiotics for patients
attending on a daily basis, including both specialist and general services. The main disadvantage to
this system is the inconvenience to the patient in having to travel, the fact that it is limited to patients
who are fit to travel and the cost of transport.
2. Self-administration (SA) of i.v. antibiotics
i. Particularly where patients require very long or repeated courses of antibiotics, patients or carers have
been taught to self-administer the treatment. This system is likely to be cheaper insofar as less
professional time is required once the patient has been trained, but there are potential risks to
unsupervised administration, including non-compliance.
3. Visiting general nurse (GN) model
i. There are instances of NHS community nurses (e.g. district nurses) administering i.v. antibiotics; this
can be efficient as they can perform other tasks such as wound management at the same visit and
with minimal travelling as they are based locally. However, they are likely to be less confident and
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skilled in i.v. antibiotic management, as this makes up a small percentage of their work and they may
have insufficient time to add this to their caseload.
4. Visiting specialist nurse (SN) model
i. In contrast, specialised visiting nurses have more expertise but may be less efficient as they cover a
large geographical area. This is the main model of care in the USA and is generally provided by
private specialised companies. In the UK, this model is available through a few providers, both private
sector and NHS.
Existing evidence on outpatient parenteral antimicrobial therapy
service delivery
There have been evaluations of the staff required to provide OPAT services. However, the conclusions of
such studies vary, with the benefits of a nurse-led service10 and the need for infection specialists11 both
being suggested. There is a striking lack of prospective studies and only one randomised controlled trial
(RCT), which was conducted in New Zealand.12
Although health economics have been addressed in depth overseas (especially in the USA), there is little
detailed analysis in the UK. Most economic evidence comes from studies reporting bed-days saved and
simple analyses of cost savings, which are reported to be significant. A comprehensive pharmacoeconomic
evaluation of OPAT services has yet to be completed, despite the number of published studies.1 Chapman
et al.13 did complete a cost-effectiveness analysis of OPAT in a UK setting but this included only one centre
and was predominantly a comparison of standard hospital inpatient care with daily attendance at a hospital
facility. In addition, owing to a lack of appropriate data, the analysis completed was a cost–consequence
analysis rather than a cost–utility analysis and, thus, did not adhere to National Institute for Health and Care
Excellence (NICE) guidance.14
Little has been published on patients’ preferences for different services, although reports of patient
satisfaction with services have been cited. Only one study was found to evaluate patient preferences directly
in this group, finding that 90% of patients preferred treatment at home to treatment in hospital.15 However,
this study was conducted in Canada, had a small sample (n = 71), compared only two fixed-service models
(in hospital vs. SA at home with weekly hospital visits) and used willingness-to-pay to measure preferences.
National policy and initiatives
Outpatient parenteral antimicrobial therapy services have the potential to generate significant cost
savings for the NHS and to deliver greater patient satisfaction. They may contribute to the delivery of key
health-care strategies and directives such as Equity and Excellence: Liberating the NHS,16 Creating a
Patient-led NHS,17 Your Health, Your Care, Your Say18 and Start Smart then Focus.19 As yet, no national
policy in this area exists, although we understand that there have been meetings between members of the
British Society for Antimicrobial Chemotherapy (BSAC) OPAT steering group and the Department of Health
regarding further service development. Health-care providers mainly use the current system of tariffs
provided through NHS England Payment by Results system, which can be interpreted in a number of
different ways, thus making the commissioning process complex. For more unusual conditions, the
provision of OPAT is part of the recommendations of the NHS England Specialised Services Specifications
for Infectious Diseases and Bone and Joint Infection Services.
Following a conference on OPAT in 2009 hosted by BSAC, a UK database has been set up in which centres
have the option of sharing their data on, for example, service type, patient numbers and outcomes.
A voluntary survey of existing services provided by OPAT group members was carried out at the end of
2011 and presented in summary, focusing largely on clinical issues such as types of infection treated. The
BSAC-sponsored OPAT project is supporting the development of such services throughout the UK without
favouring any particular model of service design. Various resources have been provided to facilitate this,
including the development of practice standards, a preceptorship scheme, regional training days, a model
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business case including a strengths, weaknesses, opportunities, threats (SWOT) analysis of service models,
and software to support a virtual ward round (http://e-opat.com/).
Aims and objectives
The full potential of OPAT has not yet been realised in the UK, as there is patchy implementation and
significant variation in services geographically. There is a paucity of information upon which the NHS can
base decisions regarding the design, supply and commissioning of such services and upon which national
guidance developers can base recommendations for best practice. The proposed research would address
significant gaps in knowledge about the cost-effectiveness of different i.v. antibiotic services and identify
which services patients prefer and which aspects of the services are most important to them. Given that
the services available to patients have different costs, effects and risks, it is essential to understand what
patients consider most important in the care they receive and what trade-offs they are willing to make.
This is especially so assuming that the trend for enhancing patient choice continues in the NHS. The
optimal delivery of OPAT may mean offering patients a choice between several services concurrently,
which has consequences for future planning and resourcing. The evidence generated by the research
would be used to help identify the optimal configuration of services in terms of value for money and
patient preference. The research would also help to identify future research priorities and to design clinical
studies that would generate the evidence necessary to aid decisions over service provision.
The aims of this research project are to establish the types of i.v. antibiotics services available in England
and to identify barriers to the use of each service type; evaluate patients’ preferences for, and the costs
and benefits of, delivering i.v. antibiotics in the community; and make recommendations for the optimal
delivery of the service and for the design of future research including clinical trials. i.v. antibiotic services
have significant potential for cutting NHS costs and for improving patient choice and satisfaction. The
research will help to identify which aspects of services and service types are the most preferred and which
offer the greatest benefits to patients and the NHS in general.
Structure of the project report
This study was funded by the National Institute for Health Research, Health Services and Delivery Research
programme (11/2003/60 CIVAS).
In order to evaluate the existing evidence for different service models for OPAT, we first carried out a
systematic review of the existing literature in the field, focusing on efficacy, safety and cost-effectiveness
(see Chapter 2).
We carried out an assessment of current OPAT provision by the NHS to establish reasons for current service
configuration and to identify barriers to service provision (see Chapter 3). This consisted of an online survey
of current service provision and interviews with health-care professionals currently providing services.
We then used a qualitative approach to determine the preferences of service users for different community
i.v. antibiotic service attributes (see Chapter 4). We started by holding interviews and focus groups with
patients who had received i.v. antibiotics on an outpatient basis to determine the issues or attributes that
were most important to them. From this we developed a pilot discrete choice experiment (DCE) whereby
we constructed a number of questions to explore patients’ views on key attributes. After testing this with a
number of patients, we used this methodology to analyse the preferences of approximately 200 patients,
the results of which are presented in Chapter 5.
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Our quantitative work (see Chapter 6) uses economic modelling of the clinical effectiveness of different
models of service provision using data collected from seven centres in England for both short-term and
long-term infection patient groups.
At the end of our project we held an expert panel event to examine the data collected through the
different project workstreams, in order make recommendations for future service design and further
research. The panel included commissioners with experience in this field, antimicrobial pharmacists,
clinicians (medical and nursing) and experts in health economics and clinical trial design. This event is
described in Chapter 7.
The report concludes with a synthesis of our main findings (see Chapter 8) and a discussion of the
implications for designing and commissioning future NHS OPAT services, with suggestions for
future research.
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Chapter 2 Systematic review of the efficacy,
safety and cost-effectiveness of outpatient parenteral
antimicrobial therapy
Background
The provision of i.v. antibiotics on an outpatient basis is accepted practice in most developed countries but
has been slow to develop in the UK. In the UK, a number of different models of care are in existence, with
variation in the extent of provision geographically.
Research questions
The overall aim of this review was to evaluate the existing evidence in relation to the efficacy, safety and
cost-effectiveness of different community-based i.v. antibiotic services, also known as OPAT. Specific
research questions were:
l What is the most clinically effective model of delivering i.v. antibiotics in the community?
l What is the most cost-effective model of delivering i.v. antibiotics in the community?
l What is the most appropriate model for delivering i.v. antibiotics in the community in terms of
patient safety?
l Is community delivery of i.v. antibiotics acceptable to patients and health-care providers?
Methodology
Identification of studies
The world literature from 1993 to March 2015 was reviewed to identify existing research related to the
safety, efficacy and cost-effectiveness of community i.v. antibiotic delivery services. Separate searches were
run to identify (1) studies of i.v. antibiotics and known models of care and (2) reviews of antibiotic use in
cellulitis or cystic fibrosis (to allow for the identification of models of care that were unknown to us and
subsequently not considered when identifying terms for search 1). We searched MEDLINE via Ovid (1946
to March week 4, 2015), MEDLINE In-Process & Other Non-Indexed Citations (25 March 2015), EMBASE
via Ovid (1947 to 25 March 2015), Cumulative Index to Nursing and Allied Health Literature (CINAHL) via
EBSCOhost (1981 to March 2015), International Pharmaceutical Abstracts via Ovid (1970 to March 2015),
Cochrane Central Register of Controlled Trials, Wiley, Issue 2 of 12 (February 2015), Cochrane Database of
Systematic Reviews, Wiley, Issue 3 of 12 (March 2015), Database of Abstracts of Reviews of Effects, Wiley,
Issue 1 of 4 (January 2015), NHS Economic Evaluation Database 2015, Issue 1 of 4 (January), Health
Technology Assessment Database, Wiley, Issue 1 of 4 (January 2015), Research Papers in Economics
(accessed March 2015), Cost-Effectiveness Analysis (CEA) Registry, Tufts (accessed March 2015), and
Health Business Elite, Healthcare Database Search (HDAS) NHS Evidence (1922 to 25 March 2015).
Supplementary searches of Web of Science Conference Proceedings Citation Index – Science, Thomson
Reuters (1990 to March 2015), the Health Information Management Consortium via Ovid (1983 to
25 March 2015) and the website of the BSAC (accessed March 2015) were conducted to provide relevant
unpublished work. In addition, the reference lists of included studies were reviewed for potentially relevant
papers. A sample search strategy and databases searched is detailed in Appendix 1.
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Selection of studies
Studies were included if the participants were individuals or groups of adult patients or care providers, and
(1) they evaluated the clinical effectiveness or cost-effectiveness of an OPAT model, (2) they described or
evaluated patient safety issues associated with OPAT or (3) they considered the acceptability of OPAT from
the perspective of the patient receiving treatment or the practitioner delivering care. Any form of i.v.
antibiotic drug delivery system (e.g. infusion or bolus) was included. No restrictions on language or study
design were applied.
Studies were excluded if they considered the costs related to a model of delivery but did not consider
patient benefit alongside these, or if they made reference to costs and benefits but did not report specific
cost-effectiveness analysis data [e.g. cost per quality-adjusted life-year (QALY)]. Similarly, studies that made
reference to clinical effectiveness without reporting specific patient outcomes were also excluded. Studies
that included children or that involved multiple routes of antibiotic delivery were reviewed but excluded if
they did not differentiate between outcomes for adult patients or for patients receiving i.v. treatment, and
those of other participants. Studies that focused only on the method or process of delivery or on the
clinical effectiveness of a single treatment or of one class of antibiotic over another were excluded, as were
abstracts only, descriptive or commentary pieces and guidance documents.
Titles and abstracts of all identified studies were screened for eligibility, and full-text versions of papers not
excluded at this stage were obtained for detailed review. All abstracts were reviewed by one researcher
(EDM) with a random selection (20%) independently screened by a second reviewer. Potentially relevant
studies were then independently assessed by two reviewers (EDM with JE, DM, CCM or MT) to determine
if they met the inclusion criteria. Differences of opinion were discussed until a consensus was reached.
Data extraction
Data extraction was carried out by one reviewer (EDM) using a standardised pro forma. Data for a sample of
studies were extracted independently by a second reviewer in order to validate the items being collected.
Extracted data included citation details, study purpose, design, location, duration, population details and
clinical characteristics (e.g. reason for antibiotic treatment), models of care [hospital outpatient (HO), SA,
GN, SN], topic area (clinical effectiveness, cost-effectiveness, safety, acceptability), type of antibiotic, route of
delivery, treatment dose, outcome measures, follow-up and key findings. Assessment of bias was carried out
as part of this process.
Assessment of bias
Quality assessment was carried out by one reviewer (EDM). Where possible, studies were assessed using
previously developed scoring systems. The Cochrane risk-of-bias assessment tool was used for experimental
studies (RCTs, clinical trials, controlled before-and-after studies) and the Newcastle–Ottawa scale was used
for cohort and case–control studies.
A method of assessing the strength of evidence of observational studies – developed as part of a previous
review on the early diagnosis of cancer20 – was modified for this topic area and applied to relevant studies.
The main modification to the assessment system was to account for the fact that, although a study in this
area might not use a power calculation and might include a relatively small sample size, this is actually the
entire population receiving OPAT treatment. As such, it should not be considered automatically to provide
weaker evidence. In this system, papers were evaluated on the basis of ‘population’, ‘ascertainment’ and
‘analysis’ (see Appendix 1). Population relates to the method of determining required levels of participation,
with use of a sample size calculation or inclusion of all possible patients/providers rated more highly than
selective recruitment. Ascertainment relates to methods of obtaining study data, with use of a rigorous
method designed to reduce systematic differences between groups (selection, characteristics, treatment,
etc.) rated more highly than other methods. Finally, analysis relates to the use of analytic techniques, with
reporting of statistically significant differences (or use of appropriate analytic techniques if qualitative) rated
more highly than non-statistical comparisons or descriptive data.
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Studies at risk of bias were not excluded from the review, but an appraisal of the strength of existing
evidence has been reported and findings interpreted in light of this. Many of the papers included in this
review used methodologies that did not lend themselves to the scoring systems outlined above. Many
studies included all patients in receipt of OPAT since its establishment at a particular institution, or all
patients seen over a specified time period, and simply reported conditions treated and therapies used,
along with limited outcomes data. Case series such as these, which were to all intents and purposes audits
of service provision that included little or no analytic content, were not subject to quality assessment.
Data synthesis
The main characteristics of included studies and findings relating to clinical effectiveness, cost-effectiveness,
patient safety and acceptability and study quality have been summarised in narrative and tabular form.
The substantial clinical and methodological heterogeneity precluded pooling of data for meta-analysis.
The majority of studies included a varied case-mix and did not differentiate their results between conditions
treated. In addition, there was variation across studies in relation to what constituted a successful outcome
(cure, improvement, deterioration, etc.) as well as a lack of consistent treatment duration. This meant that it
was not possible to pool the results of individual studies to provide estimates of true effect size when using
OPAT for different patient groups, or even for comparing OPAT as a whole with inpatient treatment.
Substantial clinical [condition treated, duration of treatment and definition of a successful outcome
(cure, improvement, deterioration, etc.)] and methodological heterogeneity precluded pooling of data for
meta-analysis.
Studies included in the review
Overview
The search strategy identified 7214 articles, of which 589 (8.2%) met the inclusion criteria for detailed
review (Figure 1). We retrieved the full text of an additional 17 papers identified from the reference lists of
previous reviews and included studies, giving a total of 606 potentially relevant papers. In a change to the
initial protocol, non-English language papers were not assessed for inclusion owing to the overall volume
of literature identified and timescale of the review (n = 69; see Appendix 1), and we were unable to obtain
one article from the library document service. A total of 128 papers were included in the final analysis.
Reasons for exclusion are shown in Table 1.
Populations
Three-quarters of studies were carried out in Europe (n = 53; 41%) and North America (n = 45; 35%).
Almost two-thirds of the European studies were conducted in the UK. Two studies involved centres in
multiple countries,21,22 whereas another was a systematic review of the world literature (Table 2).23 Most
were relatively small in size (mean 476, median 100, range 6–11,427 participants/episodes of care). It was
not possible to determine participant numbers in one study24 and in another numbers could be identified
only for three of four included groups.25 The period under study ranged from 6 weeks to 15 years. In
general, studies with the largest numbers of subjects (> 1000) either analysed all cases included in an
OPAT registry and/or reviewed cases over a more substantial time period.21,25–34 Most papers were
published in the past 10 years (59%).
The most commonly reported reason for treatment was osteomyelitis, followed by endocarditis, SSTI,
cellulitis and septic arthritis (Table 3). The majority of studies involved multiple conditions (n = 72, 56%),
although six did not specify indications for treatment. These included two qualitative studies and one
survey of patient acceptability,35–37 two surveys of practitioner acceptability,38,39 and one secondary analysis
of data from an OPAT database.40
The total number reported is > 128 studies, as many involved multiple reasons for i.v. therapy.
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Citations identified
from database
searches
(n = 7214)
Inclusion/exclusion
criteria applied
Articles included
(n = 128)
Articles identified
from previous 
studies
(n = 17)
Articles excluded 
after title/abstract
screen
(n = 6625)
Inclusion/exclusion
criteria applied
Articles excluded 
after full-text
screen
(n = 408)
Articles retrieved 
for detailed review
(n = 606)
Non-English
papers set aside
(n = 69)
Unable to 
locate article
(n = 1)
FIGURE 1 Flow of studies into the review.
TABLE 1 Reasons for study exclusion
Reason for exclusion n
Descriptive or commentary piece 118
Non-English language (set aside) 69
Did not consider an OPAT model 50
Abstract only 34
Duplicate paper or study 27
Evidence summarya 26
Focus on efficacy of a specific antibiotic 26
Reported non-i.v. antibiotics 20
No distinction between i.v. antibiotic/other treatments 19
No distinction between adults/children 16
Reported costs only 14
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TABLE 1 Reasons for study exclusion (continued )
Reason for exclusion n
Focus on method or process of delivery 10
Survey but no acceptability data reported 10
Unclear if OPAT model involved i.v. 8
Lacked outcomes data 6
Studied children only 6
Studied other antimicrobial 6
Guidance document 5
Reported non-specific effectiveness 5
Focus on adherence to guidelines 1
Focus on retention of patient training knowledge 1
Unable to locate article 1
a Relates to reviews that included studies already identified or that were outside the time scale or inclusion criteria for this
review. One Cochrane review had no included studies.
TABLE 2 Included papers by country under study
Continent/country n
Continent
Africa 1
Asia 9
Europe 53
America 50
Oceana 21
Country
Argentina 2
Australia 15
Austria 1
Bahrain 1
Canada 11
China 1
Columbia 1
France 4
Greece 1
Ireland 2
Israel 2
Italy 3
New Zealand 6
Pakistan 1
Peru 1
Puerto Rico 1
continued
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Outcomes and outpatient parenteral antimicrobial therapy models studied
Of the five areas evaluated in this review, the most commonly considered were patient safety (n = 109;
85%) and clinical effectiveness (n = 89; 70%). Just over one-quarter of studies involved some aspect
of patient acceptability (n = 37; 29%), but few determined cost-effectiveness (n = 5) or practitioner
acceptability (n = 6). Most reported on multiple areas (70%).
Twenty-two studies (17%) either did not indicate the type of OPAT delivery model used or reported that
home treatment was used without providing any additional detail. In the remainder of studies, the most
frequently reported method across studies was self- (or carer-) administration (n = 66; 52%), followed by
visits from a SN (n = 44; 34%), outpatient attendance (n = 35; 27%) and visits from a GN (n = 14; 11%).
Just over half of these studies evaluated a single model of OPAT delivery (n = 59; 55%). Other, less
common, delivery methods and locations included infusion centres, home infusion or home care
companies, Hospital in the Home Units (HHUs), prison and doctor visits (see Appendix 1, Tables 33–37).
TABLE 2 Included papers by country under study (continued )
Continent/country n
Singapore 4
South Africa 1
Spain 8
Sweden 1
UK 33
USA 34
Worldwide (SR) 1
SR, systematic review.
Two studies involved multiple locations (one in Italy, the UK and the USA; one in Argentina, Colombia, Israel, Peru, South
Africa and Spain) and have been included under each included country.
TABLE 3 Common indications for treatment in included studies
Reason for i.v. therapy n (%)
Osteomyelitis 68 (53.1)
Endocarditis 53 (41.4)
SSTI 41 (32.0)
Cellulitis 32 (25.0)
Septic arthritis 29 (22.7)
Respiratory infection 28 (21.9)
Bacteraemia 27 (21.1)
Abscess 27 (21.1)
Urinary tract infection 25 (19.5)
Prosthetic joint or metalware infection 24 (18.8)
Pneumonia 21 (16.4)
Wound infection 19 (14.8)
Sepsis 18 (14.1)
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Quality assessment
Few studies employed a controlled trial methodology, with two-thirds being case series or observational in
nature (Table 4). Many involved retrospective data collection (n = 57; 45%). Of the 12 included RCTs,
five reported on subgroup analyses from the main study, and all failed to provide details of the original
trial methodology.
Many studies involved a review of medical records and/or the analysis of data from prospectively held
OPAT databases (40%); a small number of other studies carried out secondary analysis of national or
international OPAT registries. Satisfaction surveys, by either questionnaire or telephone completion, were
frequently used, and interviews (face to face, telephone, focus group) and visual analogue scales, although
used less frequently, were also well represented. Less common methods of data collection included clinic
and ward diaries, direct observation and data from previous studies or from the published literature.
It was often unclear who collected data, and few studies reported on how this was done (e.g. using a
standardised pro forma). A significant number provided little or no detail on the methods employed.
Risk of bias within studies
Three of the 14 included trials were assessed as having a low risk of bias,12,41,42 and one was assessed as
having a high risk of bias (a pilot in which patients self-selected hospital or home treatment and were
recruited consecutively to each arm after this decision was made).43 In the remaining nine studies, the level of
potential bias was unclear. In five cases, it was uncertain whether or not randomisation or controlling had
taken place. Four of these studies reported on subgroup analyses from a single open-label trial, and none
provided details of the original study methodology.44–47 The fifth reported on two related trials comparing i.v.
with oral treatment for neutropenia in cancer patients, but reported no methodological details of the parent
studies.22,48–51 In the remaining five trials, details of randomisation, allocation concealment and blinding
(especially in relation to assessment of outcome measures) were poorly reported.52
The five case–control studies (three of which were retrospective) rated low for potential bias (median 8/9;
range 6–9). Those studies scoring lowest did not provide details on the methods used to determine
outcomes. Similarly, four cohort studies (two of which were retrospective) all had low potential for bias
(median 8/9; range 7–9).
TABLE 4 Research designs employed by included studies
Study design n (%)
Before and after 3 (2.3)
Case–control 5 (3.9)
Case series 51 (39.8)
Clinical trial (unspecified) 1 (0.0)
Cohort 4 (3.1)
Controlled trial 1 (0.8)
Cross-sectional 10 (7.8)
DCE 1 (0.8)
Decision tree analysis 3 (2.3)
Literature review (not systematic) 1 (0.8)
Observational 33 (25.8)
Qualitative 3 (2.3)
RCT 12 (9.4)
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In the majority of observational studies, the data analysed were derived from reviews of OPAT databases or
medical records. Many studies also involved questionnaire surveys. Only five studies included a comparator
(inpatient care), with many simply including all OPAT patients over a selected time period. Most studies
reported descriptive results only, with no statistical testing of differences.
Twenty of the 128 studies (16%) received full or partial funding from pharmaceutical companies.
Results
Impact on clinical effectiveness
Only 21 of the 89 studies evaluating the clinical effectiveness of OPAT included a comparator, which, with
few exceptions, was treatment given on an inpatient basis (see Appendix 1, Tables 32 and 33). Five of the
studies did not specify the OPAT model that was being used,29,48,52–54 whereas six others reported combined
results for multiple OPAT models.48,52–55
Synthesis of the findings from these studies indicates that, regardless of the OPAT model used, there is
little impact on the duration of i.v. antibiotic treatment in comparison with inpatient treatment12,22,25,41–43,56–58
(see Appendix 1, Table 32). The effect of OPAT on cure rate, however, is less conclusive. When all models
are considered, OPAT appears to produce superior results compared with inpatient treatment, a finding that
is influenced by the inclusion of positive studies reporting on multiple or unspecified OPAT treatment
models. When these studies are removed and specific models are considered individually, outpatient
attendance appears to have a lower rate of cure or improvement,22 and SA59 or OPAT by a SN has a higher
rate,56,57 whereas OPAT by GN has no impact.12,41 Results from those studies assessing the impact of
treatment via OPAT specifically on lung function in patients with cystic fibrosis were either inconclusive or
found no impact.42,43,58,60
In the remaining studies, which looked at aspects of clinical effectiveness for OPAT only, rates of cure
and/or improvement ranged from 61.1% to 100% (mean 89.6%; median 92.4%). When the various
OPAT models are considered individually, the highest average cure/improvement rate was seen for the SN
model (90.6%), followed by SA (91.3%), the GN model (90.0%) and HO treatment (85.9%). Few studies
reported on bacterial eradication, but those that did saw rates of between 57.1% and 100% (mean
86.2%; median 90.0%) (see Appendix 1, Table 33).
Patient safety and adverse events
Only 24 of the 109 studies evaluating OPAT-related safety included a comparator, which in the majority of
cases was inpatient treatment (see Appendix 1, Tables 32 and 33). Five studies did not specify the OPAT model
that was being used,48,52,55,61,62 and three others reported combined results for multiple models.29,49,63
Synthesis of the findings from these studies indicates that, regardless of the model used, there is little
evidence of impact on either drug-related side effects or number of deaths in OPAT patients in comparison
to patients receiving treatment in hospital10,22,25,41–43,56–59,64 (see Appendix 1, Tables 32 and 34). One study
looking at outpatient attendance22 did find a higher death rate (1 patient vs. 0 patients), but this was a
small study and the overall rate of side effects was lower in OPAT patients (15% vs. 18%). There also
appears to be no conclusive evidence of benefit either in relation to hospital readmissions overall, or in
relation to those who self-administered therapy,42,59 although there were conflicting results for OPAT
provided by nurses, with SNs10,25,57,64 seemingly having superior results to those of GNs.12,41 Perhaps
unsurprisingly, overall there would appear to be more line-related complications in i.v. therapy
administered outside hospital.
Across all studies, the most commonly reported adverse events were rash, fever, nausea/vomiting,
diarrhoea, allergic reaction or anaphylaxis, phlebitis, leucopenia and line complications (including line
infection, occlusion, breakage, and dislodgement).
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Cost-effectiveness of outpatient parenteral antimicrobial therapy
Although many of the identified studies reported on the cost of OPAT, only five considered cost-
effectiveness (see Appendix 1, Table 35). Three studies applied decision tree models to OPAT provided by
SNs, with one also determining the cost-effectiveness of SA. The remaining studies (one literature review,
one retrospective observational study) did not specify the OPAT model(s) used.
In two of the three decision tree analyses, i.v. OPAT was found to be more cost-effective than i.v. inpatient
therapy.24,65 In one case, it was also more cost-effective than early discharge with oral therapy and oral
outpatient therapy,65 while in the other its dominance was maintained only when the i.v. success rate was
> 55%.24 Conversely, in the third study, i.v. OPAT was found to be less cost-effective than both i.v. to oral
switch therapy, and oral treatment both during and after hospitalisation (which was the most cost-effective
option).66 The authors reported the probability estimates used, which were obtained from both published
research and institutional data, to be a limitation of their study.
Studies included in the systematic literature review predominantly concluded that home care i.v.
antibacterial therapy would lead to significant cost reductions from a societal and third-party payer
perspective.23 In 5 of the 11 studies, inpatient therapy was 2–3 times as expensive as home care therapy.
However, there was considerable variation in the ways in which costs were determined and calculated in
the individual studies (e.g. incremental costs, costs for selected components only, etc.), and the review
itself lacked considerable detail on the methodology used and the criteria for study inclusion and exclusion.
The results of the observational study (based on 435 courses of i.v. antibiotic treatment for respiratory
exacerbations in 116 adult patients with cystic fibrosis) indicated that, for both one course and 1 year of
treatment, i.v. antibiotic treatment administered mostly in hospital was more effective but more costly than
treatment administered mostly at home.53 This improved clinical effectiveness could be achieved only with
the input of considerable additional resources (between £46,000 and £73,000 per patient at 2002 prices).
However, when the strictest definition of effectiveness was applied (≤ 0% decline in lung function),
hospital treatment was unlikely ever to be cost-effective.
Patient acceptability
Only 4 of the 36 studies considering patients’ acceptability of OPAT involved a comparison of inpatient and
outpatient therapy (see Appendix 1, Table 36), two of which involved OPAT delivery by GNs12,41 and two of
which involved OPAT delivery by SNs.25,56 In each case, satisfaction was high, with home treatment seen as
being beneficial. One of the two studies involving GN delivery found that only 5% of home group patients
would have preferred hospital treatment, compared with 35% of the hospital group who would have
preferred home treatment at home (p < 0.001),12 while the other found that patients in the home group
were significantly happier with the location of their care than those receiving inpatient therapy (p < 0.001).41
Similarly, in one study for which patients received home care by SNs, almost all (97%) indicated that they
would chose to receive at-home therapy in future and would recommend it to others. The main reasons
given for this were quiet and increased home comfort, familiar environment and free choice of activity.
However, some patients in the study also reported disadvantages to receiving therapy at home, primarily
related to patient and caregiver anxiety.56
Of the remaining studies that considered acceptability in OPAT patients only, most involved multiple OPAT
models (and did not differentiate between them in their findings), or did not specify the model(s) under
study. In general, satisfaction with treatment was very high,2,13,27,36,67–83 including when patients had to have
frequent attendance at hospital.5,84 Commonly perceived advantages of OPAT included the ability to resume
daily activities,2,27,71,73 feelings of improved self-esteem or greater freedom and control,67,71,73,85,86 and not
having to remain in or attend hospital.2,71,82,85,87 The main disadvantages most commonly related to infusion
equipment, and included anxiety about the device and its sterility,35,37,78 the discomfort and limitations
imposed by pump devices,36,37 and issues related to storage.88 Two studies found that younger patients were
better able to use infusion devices, and required less support to do so than older patients.37,89
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Two studies determined patients’ willingness to pay to have treatment in their preferred location, and
although differences did not reach statistical significance, patients reported that they would pay more for
home-based than for hospital-based treatment, including giving up slightly more of their remaining life to
ensure this.15,79
Provider acceptability
Only six studies included some form of assessment of practitioner acceptability, one involving general
practitioners (GPs), one involving nurses and four involving infection specialists (see Appendix 1, Table 37).
In most cases, professionals saw advantages for patients (or a need for) receiving i.v. antibiotic therapy
outside hospital.39,86,90,91 However, there were also negative perceptions of practitioner involvement. Most
GPs saw no advantage to themselves in home treatment, and many thought distance from hospital was an
issue for patients.86 Similarly, nurses perceived that there were challenges in providing this model of care,
mainly around the technical nature of the devices used and dealing with patients’ understanding of the
technology and its related risks.39 Finally, many specialists saw logistical and organisational barriers to the
use of OPAT relating to a lack of funding, the availability of a dedicated OPAT team, the number of
locations involved, leadership, communication and the links between primary and secondary care.38,90–92
In addition, there were concerns regarding who should assume the cost and/or take clinical responsibility
for patients.90,92
Discussion
This review has provided a comprehensive picture of the evidence surrounding the effectiveness, safety
and acceptability of outpatient antibiotic therapy, and, as such, it is a useful addition to the literature in
this area. It has established that there are no systematic differences in relation to the impact of OPAT on
duration of therapy, or on adverse events associated with i.v. antibiotic treatment, and that, on the whole,
OPAT is more cost-effective than inpatient care. However, conclusive evidence of the clinical benefit
(or otherwise) of this mode of therapy compared with traditional inpatient i.v. treatment is lacking.
Acceptability of OPAT appears to be high among patients who appreciate the greater freedom that this
provides, particularly in relation to being able to resume daily activities (such as going to work or school),
having greater control over their illness and not having to attend hospital but being able to stay at home
with family. The most commonly identified disadvantages related to the use of infusion equipment. Few
studies considered practitioner acceptability, but those that did found some concerns related to the
logistics involved in providing an OPAT service, including cost and who would assume clinical responsibility
for patients.
Although many studies were identified and included in this review, its conclusions are limited by the
lack of studies involving a usual care comparison, or comparison with other models of OPAT delivery.
In addition, few studies employed a rigorous study design. Much of the work in this area appears to be
based around service evaluation and, as such, many of the studies provided only basic descriptive findings,
with no estimates of variance and limited data related to patient outcomes. As a result, it is difficult to
grade the quality and robustness of the evidence, even in the few RCTs that have been conducted.
Similarly, the heterogeneous nature of studies in terms of their design and the case-mix of included
patients meant that it was not possible to pool results to provide estimates of effect size for OPAT use.
It is likely that the increased use of OPAT in the UK over the last decade is based, in no small part, on
clinician’s expectations that it should deliver better patient care and better patient experience. However, the
evidence for better care is not strong. In addition, few studies reported on the different levels of service
required to account for the complexity of patient cases encountered, including those with comorbidity,
those requiring ‘one-off’ or longer-term treatment. Many studies provided aggregated results and it was
not possible to disentangle results either for individual OPAT models or for the specific conditions treated.
This, together with the lack detail on the actual delivery model used, makes it difficult for clinicians and
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policy-makers to be able to replicate the practice (and, consequently, the potential outcomes) even from
positive studies. OPAT services have the potential to deliver significant cost savings and increased patient
satisfaction for the NHS, but this information is key and must be reported in future studies if we are to
identify best practice and support decision-making at a local level.
Conclusions
This review provides a comprehensive picture of the current evidence surrounding the effectiveness, safety
and acceptability of outpatient antibiotic therapy. It found no systematic differences related to the impact
of OPAT on duration of therapy or on adverse events associated with i.v. antibiotic treatment. On the
whole, OPAT is more cost-effective than inpatient care, and patient acceptability appears to be high.
However, conclusive evidence as to the clinical benefit (or otherwise) of this mode of therapy compared
with traditional inpatient i.v. treatment is lacking. Few studies considered practitioner acceptability, but
those that did found some concerns relating to the logistics involved in providing an OPAT service,
including cost and who would assume clinical responsibility for patients.
Few studies involved a comparison with inpatient care (or other models of OPAT). Even fewer employed a
rigorous trial design, and much of the work in this area is based around small-scale service evaluations,
with limited outcomes data. Given the cost implications and the potential benefits to patients in receiving
treatment outside hospital, there is still a need for definitive, large-scale studies in this area.
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Chapter 3 Survey and qualitative study examining
current outpatient parenteral antimicrobial therapy
service provision in England
Introduction
Until recently, OPAT in the UK was limited to a small number of specialist centres but over the last
10 years services have begun to expand in an ad hoc manner as the potential of OPAT is recognised.93
In contrast, OPAT has been accepted as the standard of care in the USA and Australia for many years,
although it has been restricted to those with appropriate insurance.1 The 2013 BSAC survey of OPAT in
the UK94 found that 68% of centres have some form of OPAT service (based on a 63% response rate to
an electronic survey). The most commonly reported model of care was a nurse at home, followed by a
hospital attendance, but other models are used. Most respondents to the BSAC survey wanted to extend
their service (85% of responders), and a range of barriers were identified, including a lack of nursing
and clinician resource, lack of buy-in from other departments and the frequency of antibiotics needed.
A small-scale study from the Republic of Ireland found that, although 74% of respondents reported
sending patients home with i.v. antibiotics, 47% did not describe themselves as having a dedicated OPAT
service, but noted that clinicians often simply send patients home on i.v. treatment, sometimes without the
appropriate support.91
In the UK, there are good practice guidelines on the development and delivery of OPAT services93 but
anecdotal evidence suggests that implementation is inconsistent. Although the BSAC survey identified
significant barriers to service development, much less is known about the drivers to service development or
how people have set up services.
The evidence base is poor and unhelpful to commissioners and providers looking for support to develop
such a service. This research aims to explore the current picture of services implemented in the UK and to
identify the barriers to and facilitators of implementation. It forms one work package in a large programme
of exploratory research around outpatient antimicrobial therapies.
Aim
To explore the types of OPAT services that have been commissioned and provided in the UK and to
identify perceived barriers to implementing this type of service.
Although surveys of health-care professionals providing OPAT in the UK were carried out by BSAC in 2011
and 2013, these largely focused on clinical matters such as types of infections treated rather than models
of service provision. We set out to look at the service models provided and the issues influencing their
development.
Objectives
l To undertake a survey of NHS trusts to identify services in England and their configuration.
l To sample from these NHS trusts to identify participants to interview to explore the barriers and levers
to service provision.
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Methods
Health-care professional survey
A brief electronic survey of infectious disease specialists was conducted using the Bristol Online Survey
(BOS) to identify services in England and their configuration.
A letter with a link to the BOS survey was sent to all NHS trusts in England. The letter invited the recipient
to complete the survey and to pass the link on to relevant colleagues. When a microbiologist, infection
specialist or OPAT team could be identified from the NHS trust website, the letter was sent directly to
them. When no details could be obtained, the letter was directed to the hospital main administration
office. E-mails were also sent to all infection specialists and microbiologists, where addresses could be
identified. The survey was distributed in June 2013 and reminders asking people to complete the survey
were sent out in July and August 2013.
The survey was designed to enable us to sample a diverse group of respondents for interview. An initial
corpus of questions was developed, from which 20 were selected by the clinical team to give a picture of
current practice and to enable us to select a diverse sample. The questionnaire was piloted on five local
clinicians to ensure that the questions could be easily understood and that the survey links worked.
The survey asked respondents questions relating to the following.
l Who runs the service and the staffing levels (doctors, nurses, administrators)?
l The involvement of other clinical specialties (e.g. infection specialists, microbiology, pharmacy).
l The size of service and numbers of patients seen per month.
l The involvement of external organisations (e.g. private health-care providers).
l Any future plans (development of service).
l Demographics (where is the service based and what is its coverage), respondent details (job title/
position, years in post, years running OPAT service).
The findings from this initial survey were then used to construct a purposive sample using the following
criteria: NHS trust type [teaching, foundation trust, district general hospital (DGH)]; geographical area
(urban and rural); socioeconomic area [low and high socioeconomic status (SES)]; and diverse ethnicity.
Some selection criteria were nested (e.g. hospital type, geographical area) and participant selection
ensured that a range of view-points were identified.
These results should be considered in the light of the poor response rate, which could be explained by
the timing of this survey. BSAC had just undertaken their survey and there may have been an element of
‘fatigue’ among potential respondents or respondents may have thought that it was the same survey.
Health professional interviews
Sampling
Of the 35 people responding to the BOS survey, 25 agreed to be interviewed. Our original protocol
provided for a purposive sample of up to 30 service leads to be recruited using the sampling frame below
in order to collect a wide range of experiences. It was expected that some selection criteria would be
nested (e.g. hospital type, geographical area):
l NHS trust type (teaching, foundation trust, district general hospital)
l geographical area (urban and rural)
l socioeconomic area (low and high SES)
l diverse ethnicity.
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Interview process
Professional leads were identified from the electronic survey and all who gave permission to be contacted
were invited to take part in a telephone interview. All agreed to be interviewed, but four interviews were
not conducted owing to difficulties organising interviews, and one interview failed to record owing to a
technical failure. For those who agreed to participate, written informed consent was requested along with
permission to record the interview.
The interviewers used a semistructured topic guide, developed by the study team from the available
literature, to explore current service provision and any facilitators of and barriers to implementation. The
interviews were audio-recorded and transcribed verbatim where permission was given. Field notes were
taken where permission to record was refused.
Procedure
Four researchers [one psychologist, two applied health researchers (one with a nursing background) and
one sociologist] carried out the interviews. Recruitment and set up was delayed owing to the limited time
that respondents had available. Interviews were conducted by telephone and recorded with the permission
of the interviewee. One participant refused consent to record the interview and notes were made during
and after the interview and became part of the corpus of data. Interviewees often had limited time, and
interviews varied in length from 30 minutes to 90 minutes. In some cases the interview schedule had to be
adapted to fit the time available, so there are cases where some information is missing. Unfortunately,
owing to changes in personnel at the start of the study, data analysis was not undertaken until all the
interviews were completed, so new emerging themes could not be explored as we would have wished.
Data management and analysis
The data were managed based on principles of information governance at the University of Leeds. The data
from the interviews were analysed using a framework approach allowing a structured exploration of the
participant’s perspectives and a method to compare and contrast different service types.95 Data analysis
comprised five stages: (1) familiarisation with the data; (2) identifying the thematic framework; (3) indexing;
(4) charting; and (5) mapping and interpreting. The process of familiarisation enables the researcher to
identify emerging themes or issues in the data. Little is known about why NHS trusts choose to deliver
specific OPAT models and so the evidence generated from the systematic review and input from our clinical
co-applicants was used to help refine the thematic framework (stage 2). All of the data generated from the
interviews were indexed numerically according to the particular theme to which they corresponded (stage 3).
Data were then lifted from their original text and placed under subheadings derived from the framework
(stage 4). A process of constant comparison was used to examine across themes and cases. This approach
was employed to ensure the collection of a large amount of detailed information about the range of
services, geographical location, barriers and facilitators (personal and attitudinal), resource issues including
staff, budgets and processes for managing and monitoring patients. The interview transcripts were used to
identify key information for each service and key themes about the development and implementation of
OPAT services in the UK. These interview data were considered by the expert panel and informed the
modelling and DCE workstreams.
Results of the Bristol Online Survey
A total of 35 responses were received from 120 potential responses. Of the 35 respondents, 17 were in
the south of England, nine were in the north of England and six were in the Midlands. A further three
were based at tertiary centres covering large parts of England.
Twenty-seven of the 35 respondents (77%) reported that they currently had an outpatient i.v. antibiotic
service. Of these, 15 centres covered the entirety of their NHS trust catchment area, and the remainder
had a more limited service. An additional three respondents indicated they did not have an OPAT service
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but offered an ‘ad hoc’ service, delivering home i.v. therapy from one specialty (e.g. renal) or by the district
nursing team if there was available capacity.
A broad range of health professionals responded to the survey (Table 5); one-third of respondents were
microbiologists and one-quarter were infectious diseases specialists. Five respondents were nurses.
Service organisation
Outpatient parenteral antimicrobial therapy services were based in a range of departments, with 20%
(n = 7) based in acute medicine departments, and 29% (n = 10) based in infectious diseases departments;
however, the majority (54%) were spread across a range of departments including microbiology, surgery,
orthopaedics, accident and emergency (A&E) and respiratory medicine. Other respondents described their
service as ‘informal’ and not located in any specific department. Most services were modest in size, with
48% (n = 13) of services having between one and three whole-time equivalent (WTE) dedicated OPAT
nurses, and only 7% (n = 2) having more than five nursing staff. Five services (18%) had nurses who
worked on the OPAT service in addition to other roles (e.g. ward nurse). About half of services (48%) had
less than one WTE doctor involved in the service, and in most cases the service was consultant led. A small
number of services (n = 2, 7%) were led by a microbiologist and a nurse, and one service was covered by a
hospital-attached GP.
No one had much administrative support, with 74% (n = 20) reporting less than one WTE administrator
working for the service, and 26% reporting that they have no administrative support. Eighteen respondents
(two-thirds) had an infection specialist (microbiologist or infectious disease specialist) involved in the service,
with another 18% having access to a microbiologist. A total of 15% of respondents had no infection
specialist or microbiologist involved.
Eight respondents said that they did not offer an outpatient i.v. service, but went on to provide details of
their service. This finding may be explained by the individual completing the survey not having involvement
in the services offered by their organisation. Some insights into this have emerged from the qualitative
interviews (discussed later). Some of those eight individuals did not class the services provided by their
organisation as conforming to an OPAT model. Some described services provided by outlying community
TABLE 5 Health professionals’ demographics
Job title n %
Consultant in infection/infectious diseases 6 17
Consultant in infectious diseases and microbiology 2 6
Consultant in infectious diseases and general medicine 1 3
Consultant infectious diseases/medical microbiology and virology 1 3
Consultant microbiologist 12 34
Consultant in emergency medicine 1 3
Consultant in respiratory and acute medicine unit 1 3
i.v. therapy team leader 1 3
i.v. nurse/OPAT CNS/i.v. SN 4 11
Advanced nurse practitioner 1 3
Pharmacist 3 9
Specialist registrar microbiology 1 3
Not completed 1 3
CNS, clinical nurse specialist.
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hospitals (part of their trust) which were not overseen by the infectious disease specialists. These were not
described as official OPAT services by those interviewees.
However, the descriptions provided by those eight respondents appeared broadly similar to those provided
by respondents who said that they do offer an OPAT service. Services are based in a range of locations,
with two services based in microbiology, two based in acute medicine, one based in infectious diseases,
one operating as an ad hoc service with no base and two not running a service. Staffing levels are also
similar between services reported by those who said that they ran an outpatient i.v. antibiotic service and
those who said that they did not. Half of respondents who did not run an outpatient i.v. antibiotic service
had less than one doctor involved in their service; one service had five or more and three said ‘other’. In
terms of nurse staffing levels, three respondents had less than one nurse, two had between one and three
nurses, one service had five or more nurses and two said ‘other’. A total of 63% (n = 5) of the eight
respondents said they had less than one member of administrative staff, with the remaining respondents
answering ‘other’ to this question.
Service size
The majority of units that provide an outpatient antibiotic service treated between 1 and 10 short-term
and long-term patients per month (44% and 52%, respectively), with only one unit treating 30 or more
short-term patients per month. Most units offer more than one model of care (Table 6), with > 80%
offering a hospital attendance service and three-quarters offering a district nurse model. Few services use a
‘general nursing’ model for the provision of OPAT.
Of the eight respondents who said they did not offer a defined outpatient i.v. service, four services reported
that they treated long-term patients (between 1 and 20 patients per month), two services treated between 1
and 30 short-term patients per month and one service stated that they treated 30 or more short-term patients
per month. However, half of the services reported that they did not treat long-term patients or did not record
figures. Just over half of respondents said that they either did not treat or did not record the number of
short-term patients.
Half of the respondents who did not report a specialised outpatient service said that their patients visited
the hospital to have treatment. The other half of services offered a district nurse service at home. SNs were
used by three of the eight services, and GN and SA models of care were used by two services. Two
respondents said that they did not use any of the services.
Rationale for model of care offered
Respondents reported that they offered an OPAT service largely because the lead clinician has been an
advocate for change (70%; n = 19). However, there are often several drivers for change, including patient
preference (63%), commissioners’ decisions (26%) and management decision (40%). It seems likely that
the decision to start or continue a service is multifaceted, involving decision-making at several levels.
TABLE 6 Models of care offered
i.v. antibiotic outpatient services offered Number of units offering the service %
Patient visits the hospital to get antibiotics 22 81.5
A GN administers antibiotics at patient’s home 3 11.1
A district nurse administers antibiotics at the patient’s home 20 74.1
A SN administers antibiotics at patient’s home 12 44.4
Patient/carer receives training and self-administers antibiotics at home 14 51.9
Other (including GN and SN options) 12 44.4
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Results of health-care professional interviews
Sample characteristics
Of the health professionals interviewed, four stated that they were from a tertiary service that treated
patients from a range of counties; two served areas in the north of England, one served an area in the
south of England and one service served patients in the north of England and the Midlands.
Some sites serving largely rural populations provided only a service to those living within a few miles of the
hospital (although the distances varied), whereas others offered a limited service (generally a nurse at home
model) across a larger area. Eleven respondents reported working in a teaching hospital, most of which
were also foundation trusts; the remainder were DGHs. Eight respondents worked in areas with high levels
of economic deprivation, and these were also areas of high ethnic diversity. Eight respondents reported that
they did not run an outpatient i.v. antibiotic service. The majority of those who said that they did not run an
OPAT service reported that some clinical specialties had ad hoc services offering some form of community/
hospital-at-home service on a case-by-case basis. One respondent did not elaborate on why there was no
outpatient i.v. antibiotic service and another respondent stated that there was no service because there was
an intention to use a private company to deliver i.v. antibiotics in the community. (A summary of the key
characteristics of each service can be found in Appendix 2, Table 38.) The professions of those interviewed
included nurse specialists (3), microbiologists (6), pharmacists (2) and infection specialists including joint
qualified (9).
This study includes descriptions of 19 OPAT services in the UK (20 interviews), details of which are
provided in Appendix 2, Table 39. Service types are summarised below.
Themes from the analysis
The analysis of the data from interviews with professional leads from OPAT services currently being
delivered has provided an in-depth analysis across a cross-section of services in England.
A priori assumptions and emerging themes:
1. variations in resources needed to deliver OPAT
i. staffing
ii. funding
iii. location and geographical issues influencing delivery
2. facilitators contributing to service delivery
i. core staff and additional staff needed
ii. conditions treated and pathways for doing this
iii. monitoring effectiveness
iv. evaluation, impact and outcomes
3. barriers to delivering a service
i. lack of planning
ii. lack of evidence
iii. lack of resources or facilitators
4. relationships within and between people in organisations (e.g. commissioners, providers, partnerships).
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Emerging themes that were uncovered through the analysis have included:
l the influence of change management in transforming services
l the role of personal and professionals networks to exchange information
l risks to patients through management and monitoring of services.
Service models
Service development
The descriptions of service models reported here cover current service models and future aspirations.
There was a sense that many services had evolved and that they would continue to do so.
Some described services that lacked formal organisational structure, often summed up by participants as
‘ad hoc’, and many were in the process of trying to develop a more coherent service. This was not always
a straightforward process but required the individual clinician to be highly motivated and familiar with
commissioning processes:
I’ve been in post which is about 6 years and I’ve been trying for a long time of that to try and get an
OPAT team in place.
Interview 10
Other interviewees had gone down a more formal route and approached trust management using
business plans to support the case for their OPAT service:
Well we’ve done so many business plans I could talk about them all. For the last [. . .] to keep the
service running I think we’ve done about six business plans.
Interview 8
Location and service type
A range of services were described across urban, semirural and rural locations. Services could be delivered
in hospital by specialist staff and in the community by either SNs, GNs or a mix of both. The core members
of the team were a clinical lead for the service, such as an infectious diseases consultant, a nurse (this was
often not a dedicated post and could be added on to other duties), a pharmacist and microbiologist.
There was a range of service model types. For example, in hospital the service required support from at
least one nurse and from administration/co-ordination services for its day-to-day running. Sometimes there
was a team of people who supported these patients to be discharged from hospital, and in other cases
discharge was down to the consultant in charge of a patient’s care.
Most services could discharge patients to their own homes into the care of community or district nurses.
This was illustrated by a number of responses:
Community nurses know their communities quite well and many of these patients will have
community nurses going in anyway . . . so it’s an efficiency of resources to try and get the same
person going.
Interview 12
It made sense using existing district nurses who were around the area anyway rather than a nurse to
go from one side of the county to another and spend a lot of time travelling.
Interview 10
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The inefficiency of getting a hospital specialist to do it, I think would outweigh any benefits.
Interview 12
In some cases, the delivery of community-based services was commissioned out to a private health-care
provider, as this was considered to be more efficient than setting up their own service. One of the issues
for providers and commissioners was ensuring that staff had sufficient case-loads to maintain competency
in i.v. antibiotic administration:
There was a sense that the ideal model of service would be organised and monitored centrally at the
hospital but delivered locally:
What we have been doing . . . is to organise local services to deliver the antibiotics and then trying to
keep tabs on them in terms of monitoring bloods, etc.
Interview 5
One respondent described a nurse-led service whereby there was a one-step process to set up OPAT.
Someone within the hospital (probably a nurse) would go to assess the patient and that person would also
check the regime with an infectious diseases doctor. The respondent stated:
If they want to discharge a patient to OPAT they have a single telephone number that they ring and
someone goes and assesses that patient’s suitability.
Interview 10
In this service model, patients could be monitored by their own consultant or by the OPAT team. In other
models they would be discharged back to their consultant at the end of the treatment.
Two service leads made it clear that the infectious diseases consultant should be involved to check the
appropriateness of the regime:
It has to be at least discussed with the infection consultant to make sure that the antibiotic
administration is right and the duration is right.
Interview 12
Only one respondent mentioned telemedicine in relation to providing support for patients in
the community:
So we’re just looking into setting up skype™ [Microsoft Corporation, Redmond, WA, USA] and having
skype clinics.
Interview 12
Building the case for support and commissioning the service
Business planning
Twelve services had a business plan in place, some of which were more established than others. Some
business plans were yet to be approved.
Most respondents emphasised the importance of getting the commissioning right and the need to develop
a business case. Demonstrating the need was characterised by one as ‘show me the money’ and another
also noted that there was a need to build a financial case. Reference was also made to user satisfaction,
which was seen as a priority in all aspects of health care.
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Commissioning
Outcomes-based commissioning was alluded to, but examples of this were few. However, other
respondents concentrated on the issue of using the promise of decreased bed-days and numbers of beds
on wards as the driver for change:
[We have looked at] the length of stay for these patients and then looking at what we could do if we
reduce the stay for some of the patients. If we were treating patients, we’d be making more money as
we can get patients back in those beds.
Interview 3
The [GP managers] are the people driving it now which is a big plus in facilitating change as it is
coming from commissioners now, and they have taken ownership and at the stage of looking at, they
have asked us for the financial information whether they need to pump prime for the service, whether
they need to get the money from elsewhere generally.
Interview 3
From our point of view, the CCG [clinical commissioning group] do stand to gain quite a lot financially
and the trust loses because we lose the excess income from these patients. I think it depends what
you put into that bed in its place really whether we then do actually gain or lose.
Interview 10
One respondent said that funding was ‘a bit of a problem’ in relation to getting agreement from the CCGs.
Who will pay for the drugs is central: ‘they won’t go home until funding is agreed by the local CCG.’ Most
services did appear to have funding arrangements in place with their local CCGs. However, those that had
patients from a wide geographical area had more difficulty, with one stating that a national commissioning
framework was needed to support future service development and a more consistent approach. It was felt
that this would circumvent any problems that could arise from an inexperienced team taking on OPAT
delivery. One respondent noted that the CCG had been ‘incredibly supportive’ and that GPs had agreed it
was ‘the way forward’. Another said:
Even within our meeting the commissioners do say that quite clearly, even if it costs money, we can’t
say it costs money, if it’s in the interests of the patients, we have to do it.
Interview 12
Sometimes, decisions to implement changes were based on current pressures in the system and the
availability of short-term funding:
Hospitals are always pushed for bed space in winter [. . .] So the [Trust X] team developed quite a
number of pathways for the service, but again, we were still working with commissioners about what
we would get paid to provide the service, etc. Eventually what happened was around January they
had got some extra funding left over from the end of the financial year that they decided to put
forward some money for support.
Interview 13
Patient pathways
There was little reference to service specifications or processes for managing patients, but some areas had
looked at this in detail and it is possible that there are other examples that were not discussed in the
interviews. A number of services had developed patient pathways or delivery models, with one respondent
stating that they had 10 pathways:
We have pathways and we follow all these pathways on a daily basis.
Interview 12
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Team members and working relationships
Core and additional team members
The core members of the team were generally described as being a microbiologist, an infectious diseases
consultant, a nurse and a pharmacist. There were variations across the services, and the OPAT service
formed only part of the roles of these personnel. Some services referred to a support worker or patient
liaison service, a pharmacy dispenser, someone from the community team and an i.v. access team. In some
cases it was explicit that the hospital team took total responsibility:
The model which we will have is that with a nurse, consultants and pharmacist and administrative staff
as part of a team within the hospital and we will find these patients and get them out of hospital,
and taking total responsibility for the patients once they have left hospital.
Interview 12
Responsibility and teamwork
However, the placing of responsibility was not clear overall and, for example, included shared responsibility
or responsibility lying with the GP in some cases (e.g. for cellulitis) or with the community nurses and
the orthopaedic surgeon in others. Responsibility was implicitly mentioned as one of the reasons for
developing a formalised service, as noted by one respondent:
All the pieces of the jigsaw are there, what we’re trying to do is bring it all together as one and get a
team to take responsibility for this patient.
Interview 3
It was viewed as important that the team should have regular meetings, most likely every week:
We review all the results, prescriptions, side effects and all that side of the stuff for each patient and
we do that, so it’s like a virtual ward round.
Interview 5
The expectation will be on a weekly basis, the whole team with the consultant and all the doctors, registrar,
the microbiologist, the infectious disease consultant and the infectious disease registrar, a pharmacist,
microbiologist, a nurse and admin staff that as necessary and someone from the community team.
Interview 3
One person noted the importance of a good relationship and rapport between team members:
I would say that we have a mutually good relationship, whereas if I rocked up out of the blue and told
them to do something with their patients they may not. So I think you need to build rapport and
relationship with the clinicians that you’re working with quite closely.
Interview 15
Leadership appeared to be important for some:
You need a champion though, someone who takes it into their daily role to do it and to take it on as
their thing.
Interview 15
However, there were examples of services having evolved without a designated clinical lead:
I think the good practice guidelines say we should have a medical lead involved and we don’t at
the moment.
Interview 2
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The background of the interviewee was not always clear, but leadership roles were undertaken by a nurse,
microbiologist and pharmacist in different cases. It was also stated that taking things forward required a
team champion:
Unfortunately people don’t think about it so the service is not used, it’s underutilised because you
need a team championing it.
Interview 3
A degree of friction between primary and secondary care was apparent in some cases; for example, the
district nursing service was described as ‘very patchy’, the practice in primary care was described as ‘quite
variable’ and some resistance to sharing data and information was also mentioned.
Self-administration
Respondents were generally positive about SA:
With the right device and training the patient it works just as well.
Interview 3
Getting people back into work or study or family life and the district nursing model can really take away from
that from them to the tied into being in the house for 6 to 8 hours a day depending on where they are.
Interview 12
Although in many services SA was offered only in rare or exceptional circumstances, it was something that
they would like to increase in the future:
Very occasionally we have [a] patient to self-administer but it’s not the norm.
Interview 10
One respondent noted that if the patient was not able to draw up the antibiotics themselves, prefilled
syringes were supplied, although they were not available in all services.
Patients needed to be on the antibiotics for a period longer than 3–7 days for SA to be appropriate:
So the longer they are going to be on it, the more likely we going to try and discuss with them
self-admin or family admin.
Interview 12
The nurses watch the patient give their first dose at home:
Once they go home the nurses go round and watch them give the first dose of i.v. antibiotics at home
and what they do is they make the environment safe and not every home environment is ideal. They
can’t take them [i.v.] and use them before the nurses appear, the nurses bring them to make sure that
the home is safe.
Interview 15
Monitoring and review, governance and risk
Monitoring
Monitoring or review of patients was mentioned by most respondents, with 12 services having some kind
of formal monitoring system in place. However, seven services had unclear or informal arrangements:
[There isn’t a] single way of capturing all these patients at the moment.
Interview 10
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Another respondent notes that:
. . . we found quite a few patients who had literally been on (OPAT) the 6 months, 12 months,
longer even with no end in sight and no overview.
Interview 6
The common process for monitoring patients was for patients to come back to the clinic every week,
unless this was constrained by distance:
They are coming up every week which is the ideal situation so we assess them and do bloods and
make clinical assessments and give them their medication so there is an opportunity for making sure
that they are taking their treatments and that everything is right and all engaged.
Interview 12
The same person (interviewee 12) mentioned that a formal database modelled on the BSAC
recommendations was planned:
And we set up a database so we can keep track of these patients as well, but only on a day-to-day
basis, but in terms of outcomes type basis as well, which we’re designing.
Interview 12
The database used was based on one elsewhere, which was described as:
. . . very good, because it acts as a virtual ward and it is searchable as well, you can query it when
you’re auditing for outcomes and side effects and that sort of thing.
Interview 12
It is difficult for some services to know how effective they are being owing to a lack of formal monitoring
or evaluation. However, this could have been a result of the lead not choosing to disclose important details
in some services. Some of the clinical leads had limited time for the telephone interviews and so may have
prioritised other types of information.
Governance
Governance was mentioned by most, with its importance emphasised. One example mentioned clinical
governance meetings at which:
We discuss all the adverse outcomes we’ve had, how the service is running; we could have done
differently, is there any trends coming out, then we can do better [. . .] I think it is about trying to drive
a service that is flexible and meeting the needs of operations with something that can have an
appropriate to governance structure.
Interview 13
Some service models were based on monitoring and assessment data routinely collected and governance
systems that focused on improving quality and safety for patients by reviewing the length of treatment and
issues such as toxicity:
We have a very formal governance structure and a very formal pathway and weekly OPAT patient
clinical and governance meeting where we discuss every single patient on OPAT and discuss where the
plans are going. We review all the patients who are on OPAT for more than 5 days in our infectious
diseases clinics so all patients are followed up quite intensively and again that’s not always (been) the
case but we find that this prevents people getting long-term antibiotics that they don’t need.
Interview 12
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Recent reports such as the Francis96 and Keogh97 reports do seem to have acted as levers to improve the
quality and safety of care in some services.
Risk
There were a small number of services operating with informal monitoring systems and at least two
examples of services where patients had been on antibiotics for a prolonged length of time and cases of
patients being readmitted for the same problem. This tended to be where services were understaffed or
did not have dedicated clinical leads. Services without a clear medical lead had some difficulties and delays
in decision-making:
I suppose it’s a bit more difficult trying to get decision-making on a patient, kind of whether you carry
on their i.v. treatment or whether you decide to stop them.
Interview 2
There was a perception of an increased risk to patients in the community when services are commissioned
out to private companies. Whether or not staff in private companies were skilled in knowing when the
patient was at risk or should be referred to a clinician to avoid complications was called into question.
For example, one lead stated:
So what we found initially was that they could do OPAT, but it was very much on an ad hoc basis
done by the private company just doing whatever they were paid for, and there was no one keeping
an overview on the patient, so essentially we found quite a few patients who’d literally been on OPAT
for 6 months, 12 months, longer even with no end in sight and no overview.
Interview 6
Evaluation, outcomes and impact
Outcome-based evaluations were few. Around seven services had evaluation plans in place:
Yes we did our last evaluation about 2 years ago and that was a full evaluation looking at patient
satisfaction and we also have a look at lines from the point of view of thrombosis and infections and
adverse consequences so we have a programme where we review everything on an annual basis so
pretty much we take each one of those each month and assess it and basically about 18 months from
now we do a full evaluation.
Interview 12
One of the key drivers of implementing this type of service was to save bed-days and to reduce the
numbers of patients remaining in hospital for prolonged periods. There are some good cases of services
that have saved excess bed-days. At least one service has been able to translate this into changes by
reducing the number of beds on wards from 18 to 12. One respondent said that there had been:
an absolutely massive difference on the number of patients that are staying in. So we are reconfiguring
wards so there’ll only be 12 beds instead of 18.
Interview 15
In some cases, there was a lack of clarity about how to translate a saving in bed-days into real changes in
the system:
I think it is quite complicated so if the patient has now gone home and that bed is empty, the only
way you’ll save any money on that bed [is] if you [close] that bed and you no longer staff it. [Closing]
random beds scattered throughout the hospital, you’re not really going to make any savings on those,
and you’ll only save if you close half a ward or something like that.
Interview 10
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There is clearly some knowledge in the system about how to do this and a mechanism to share such
learning could be considered.
Most respondents mentioned service evaluation based on feedback from patients, focusing on patient
satisfaction and reporting a positive response:
The feedback has been fantastic. Feedback that has helped us to get more funding to be honest,
patient satisfaction is extremely high so that’s been good.
Interview 15
It’s a no-brainer for a patient really, they get out of hospital.
Interview 5
Some of the leads alluded to improving outcomes such as returning people back to their usual lives and
functioning before they were ill:
The important thing that we found from patients is you know this is not trying to get them out of
hospital and save money and although there’s an element to that, the aim is to get them back to the
life they had.
Interview 12
Change management
Most services proposed some changes to their current system, although some believed that there was no
good reason for change:
It’s primarily configured in the way that it’s configured because no one has decided to configure it in
a different way. There just didn’t seem to be the requirement for the sort of configuration that I’ve
described that, seemed to work well for the disciplines that were delivering it, so we just left it
alone really.
Interview 1
The services with the best levers and agents for change tended to be in urban areas, but there were
problems across the board. Many services took an incremental rather than a transformational change
approach and did not have a vision of the service for the future. There were often tensions in terms of
needing to offer something now (based on a service that evolved over the years) and the need to change
based on knowledge of best practice. A few were currently waiting for plans to be approved.
Only one service lead described how they had visited another successful service and adapted the model to
suit their own local context:
I spent some time with a service [. . .] when I was trying to set up this service [. . .]. and I tweaked it to
kind of suit how we run ours, and that’s how when I set up this service I kind of configured it [based]
on theirs.
Interview 2
This indicated some partnership between services. In some areas it could be beneficial for services to work
together and share best practice and possibly solve problems, which could occur at a regional level. There
is also scope for developing a national commissioning framework that could be adapted at a local level.
There were variations in the perceptions that service leads had about the potential of the organisation to
change. In some cases there were reports that senior managers or commissioners were not convinced by
the evidence or the scale of the impact and benefit for patients. Some felt that they were deliberately
being obstructed.
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I don’t really quite understand what all the difficulty is, but there is always historically huge
managerial resistance.
Interview 20
Relationships within and between people and organisations
Service leads have developed and evolved services based on their informal and formal networks, which
may depend on the size of the trust. Many services developed and evolved based on the motivation and
networking abilities of the leads:
It’s a small trust, and we’re pretty well supported by the consultants that use it, so we’re able to
contact those fairly easily. I think if it was a bigger trust and you couldn’t get hold of your team then
that may be more difficult.
Interview 2
Some service leads did not include a dedicated post such as a pharmacist, but the pharmacy service was
still involved in an informal way and may be involved as part of a wider remit:
[. . .] and we are desperately trying to get a nominated pharmacist but that hasn’t happened yet. There
is one pharmacist normally in charge of infectious diseases not just OPAT and so if there are problems
I ask her but there isn’t regular review or someone to sort of go through the charts and make sure of
all the interactions that is really something that we are lacking.
Interview 5
This could indicate a stretched resource or a small number of patients with infections in that area and may
be linked to geographical context. Some services such as microbiology and pharmacy are implicit as part of
such a service. There were variations in the level of interaction that services had with commissioners, which
could be related to the post held by the service lead and their level of seniority. At least two services were
jointly commissioned with involvement of partners across CCGs, NHS trusts and community organisations.
In some cases, there was tension between providers and commissioners and a lack of trust or engagement
between groups.
Discussion
Service models
Muldoon et al.91 undertook a survey of OPAT in the Republic of Ireland and reported a participation rate
of 10.7%. However, their target participants were slightly different from ours in that they had a broader
professional base which included consultant physicians who made use of OPAT for their patients. They
report similar results to our findings about the most common clinical conditions treated and some of the
problems reported by our respondents. Owing to our modest sample size, our survey results are not
generalisable but they do enable us to draw up a representative sampling frame to undertake the qualitative
interviews.
The OPAT professional leads interviewed delivered services in a range of settings. Most offered some level
of hospital provision, administration and delivery as well as a community delivery option. Community
services were delivered by district nurses or private companies. Service models varied from being well
organised and well planned with regularly updated business plans to those described by leads as being ad
hoc. Many services had evolved and changed incrementally, although there were also examples of
transformational change.
Lane et al.38 suggest from their results that routine infectious disease consultations in an OPAT service can
potentially improve antimicrobial stewardship, citing Sharma et al.11 for their conclusions. Sharma et al.11
found that when the infectious diseases consultant was involved in patient assessment, there was
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optimisation of the treatment regimen and 27% of patients did not require OPAT. Defining leadership
within teams may contribute to improvements in care.
It appears that the further away from the hospital a patient lived, the less likely they were to be offered a
service in which a nurse comes to their home. However, there were some exceptions to this. The logistics
of delivering the service with populations over wide geographical areas did cause some specific issues for
delivering an OPAT service particularly for patients who required more than two i.v. administrations per
day. Lane et al.38 identified the problem of providing care over a large number of locations as a potential
barrier to safe care.
Team members and working relationships
Some services had dedicated OPAT posts, whereas others included OPAT as part of a wider remit; this
could depend on a range of factors such as the evolutionary organisation and planning of the service.
Although good practice recommendations are in place, services did not always manage to meet the criteria
on service structure.93 Responsibility for care was not always explicit and there were examples of clinical
leadership in the form of a designated role being lacking. Leadership was often provided by nursing staff
in those situations. The lead role was often bestowed on an individual, particularly in the unplanned type
of service. This meant that ownership of the service and perceptions of an individual’s ability to improve or
transform the service varied. The additional work could be perceived as an additional management burden
on top of usual roles and be interpreted as resistance to further change. Again, the OPAT good practice
recommendations have specific recommendations regarding leadership of the service, and there were
instances in which these were not met.93
Organisation, funding and commissioning
Business cases were viewed as important to build the case for support based on existing evidence and local
insight. This also may reflect the practice of the hospital senior management team and or relationships
with commissioning partners. Several services had to provide annual reports to governance committees to
maintain funding levels based on the numbers of referrals.
Some services had received short-term funding with no guarantee of continued investment. Services were
often limited by their funding, with expansion being difficult. Funding was a primary reason why services
might adapt or evolve over time. Muldoon et al.91 reported problems obtaining funding to cover the costs
of OPAT in both the public and private health systems.
Patient management, monitoring and evaluation
A number of services have monitoring systems in place. Some referred to national standards (e.g. the
BSAC surveillance system).93 In many cases, this was linked to a greater level of scrutiny in terms of the
clinical governance of the service. Individual patient results were reviewed by multidisciplinary teams
(MDTs) via virtual wards and were then passed on to governance committees and intelligence functions,
often as formal reports. This level of monitoring is considered best practice in the literature;98 however, the
survey work undertaken by Muldoon et al.91 and Lane et al.38 report that responsibility for monitoring
patients is patchy at best. Lane et al.38 noted in their US survey that only 22% of respondents reported
having a system in place to pick up adverse events or ‘near misses’. They also found that a dedicated OPAT
team treating 16 or more patients per month was more likely to have monitoring systems to review and
act on patients’ laboratory results. Conversely, the fewer patients treated, the less likely it was that patients
would be cared for by a dedicated OPAT team, which the authors conclude is a barrier to providing
safe services.38
Outcomes
For those who were able to discuss evaluation of their service, the outcome on which they tended to focus
was reducing bed occupancy, although some did highlight the need to improve patient satisfaction with
care received. There is considerable scope to identify relevant patient outcomes and improve care.
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Strengths and limitations
A weakness of our study was the poor response rate to our survey. We were limited by sending out our survey
shortly after the BSAC sponsored survey, which is likely to have affected response rates. However, our response
rate was similar to other surveys91 and did provide us with a wide sample of respondents for our interviews.
Owing to a change in personnel during the project, we were unable to analyse the interview data until all the
interviews had been completed; therefore, we were unable to explore and expand emerging themes as we
had planned. Time was a limiting factor in some of the interviews, with respondents able to give us only 20 to
30 minutes for the interview, which meant that some of the data for some services are missing.
We did not interview anyone from the commissioning side of OPAT and at the expert panel we realised
that missing this important stakeholder group out from the health professional interviews may mean that
we have missed an opportunity to gain a better understanding of why OPAT is or is not commissioned.
Recommendations emerging from the interviews
Service models
1. A wide range of infections were treated, from cellulitis to bone and joint infections, diabetic foot
infections, respiratory, renal and other infections in a broad range of specialties. This means that OPAT
services within a number of organisation could be somewhat fragmented. Examples of effective patient
pathways could be shared, with the caveat that they be adapted to local circumstances and not just
used as an ‘off the shelf’ solution.
2. Self-administration by patients or family members was uncommon among our participants. In some
areas it was restricted through lack of resources or a perception that there is no need for it. Shared
examples of where this works well and how this has been achieved could support those areas that have
not yet succeeded in providing this for their patients.
Working relationships
3. The role of OPAT champions and of leads appointed to transform the service need some consideration.
Commissioning guidance could focus on the type of partnership and input that is needed from
stakeholders to drive forward and sustain any changes.
4. Some work may be required to establish how formal partnerships succeed or to audit the effectiveness
of existing formal and informal networks. It is possible that this work may have to be prioritised at a
regional rather than a local level depending on the population served and the size of the trusts involved.
5. One respondent listed five key issues that drive commissioners and providers to develop a more
formalised service. These were:
i. clinical governance
ii. individualised care that is currently not patient centred
iii. decreasing costs and getting people out of hospital and creating beds
iv. patients’ preferences to be managed at home
v. meeting national good practice.
Some of the leads expressed an interest in the development of a national commissioning framework to
benchmark consistency in commissioning and providing OPAT services. This could be helpful particularly if
made available from the BSAC website.
6. There are some services that have established evaluation frameworks and it could be helpful if these
were shared.
7. Outcomes for services need to be considered and should include improvements in patient care,
cost-effectiveness, professional and patient satisfaction with the services provided. This could be
informed by national guidance.
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Chapter 4 Qualitative study investigating patient
perceptions of outpatient parenteral antimicrobial
therapy
Context
In this chapter, we present qualitative research that explores patients’ experiences of OPAT services and
the subsequent development of the discrete choice questionnaire. This work, along with the findings of
the systematic review (see Chapter 2), underpins the development of the DCE, the results of which are
presented in Chapter 5.
The systematic review revealed that patients’ acceptability of OPAT is high. The initial review in 2013 identified
34 studies that examined patients’ acceptability of OPAT, but, of these, 21 were quantitative surveys assessing
satisfaction with the service and provided little information about patients’ own perceptions of the benefits
and disadvantages of OPAT.5,12,13,15,25,27,36,41,67,68,70,73,75–78,80–82,86,89 Only six interview-based studies were identified
by the review.35,37,79,85,88,99
The literature indicates that patients generally view OPAT very positively. The main benefits relate to the
comfort of the home environment56,85,86,99 and increased freedom and autonomy.2,56,71,73,86 Some patients
reported that OPAT provides a sense of ownership over their illness and increased involvement in their
treatment.67 Kieran et al.2 found that patients trained to self-administer their treatment were happy with
this and that over three-quarters would be content with telephone follow-up or less frequent outpatient
reviews, providing that the care of their i.v. access could be ensured. Contact with health professionals
may also be qualitatively different when patients are cared for via OPAT as opposed to via inpatient care,
with Dubois and Santos-Eggimann99 reporting that patients found contacts with health-care professionals
delivering OPAT to be less impersonal and more relaxed than contacts with health-care professionals
in hospitals.
However, not all patients view OPAT positively. A small UK study found that, although patients felt that
they would recover more quickly at home, some expressed concerns about safety and, in particular, about
the competence of nursing staff to administer treatment.35 The information needs of patients are not
always sufficiently addressed35 and poor communication between staff and patients may also affect patient
satisfaction.69,99 Some patients and caregivers may find that OPAT causes anxiety,56,99 with concerns about
night-time emergencies and a lack of domestic support within the home, as well as concerns about the
technology increasing stress levels.99 Other barriers to OPAT include accessing patient transport69 and the
expenses incurred by informal carers.99
The findings from the systematic review suggest that patients can have some strong views about the
characteristics of the services they receive, but the data are often poorly reported, as these findings are
often secondary to the main research question. Information on what an attribute should look like is
relatively limited, but ‘it should be important to patients/policy makers, “plausible” and capable of being
traded’100 and the existing data do not provide sufficient breadth or depth of information upon which to
develop the DCE attributes and levels.
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Objectives
The aim of this study was to generate an understanding of patients’ experiences of OPAT and to use these
to inform the development of the DCE.
Key research questions
Our research questions were:
l What are patients’ experiences of receiving i.v. antibiotics for infections?
l What are the benefits of and barriers to OPAT?
l What aspects of the service are important to patients?
l How does receiving OPAT impact on everyday life?
l What would patients change about current OPAT services? What improvements would they make?
Method
This primary qualitative research was part of a mixed-methods approach to developing the DCE alongside
the data from the evidence synthesis (see Chapter 2) and health professionals’ interviews (see Chapter 3).
Qualitative data collection took place between August and October 2013. Our lay co-applicant service user
and patient advisory group (PAG) contributed to the design of the study and data analysis.
Design
Semistructured interviews and focus groups.
Study settings
The study setting for conducting this research was secondary care, and four hospitals were purposively
selected because they offered the following care pathways: HO attendance, nurse at home (GN and SN
models) and SA; the centres provided more than one model of care. Two were large teaching hospitals and
two were DGHs. Each site also offered significant diversity in its sociodemographic characteristics (Table 7).
Participants
A purposive sampling strategy (see Sampling characteristics) was adopted. Two groups of patients were
identified: (1) patients requiring short-term i.v. antimicrobials (n = 15); and (2) patients with deep-seated
infections requiring longer-term i.v. antimicrobials (n = 25). The estimated sample size was based on
previous studies102 and assumes that those on longer-term antimicrobials will be a more diverse population.
It was our intention to capture a detailed and comprehensive range of perspectives. The use of qualitative
data to develop DCE experiments is relatively new, so the final number of participants was dependent on
theoretical saturation.103,104
Sampling characteristics
l Short-term and long-term OPAT.
l OPAT via one of the four care pathways.
l Sex.
l Maximum variation in age (≥ 18 years of age).
l Simple (e.g. cellulitis) and complex infections (e.g. bone infection).
l SES.
l Ethnic background.
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All participants were invited to take part in a focus group or a qualitative interview (face to face or telephone).
Initially, the project intended to conduct five to six focus groups and additional interviews with key informants.
However, it proved difficult to recruit participants to focus groups, as working-age patients did not wish to take
time off work, so the recruitment plan was revised and only one focus group was completed.
Consent
Participants were approached by NHS research nurses and given a copy of the participant information
sheet and given at least 24 hours to decide whether or not to take part. Details of consented participants
were then passed to the research team. Ethics approval was sought and obtained from the National
Research Ethics Service Committee South West – Frenchay (reference 13/SW/0060).
Procedure
At the start of each session participants were informed of their rights as participants (right to withdraw,
confidentiality) and were offered the opportunity to review a copy of the transcript and results. The
purpose of the study was explained, and the interview followed the structure below. Interviews took place
at the patient’s home or the university. Interviews were audio-recorded, with permission, with one
participant refusing to be recorded (notes were taken by the interviewer). Interviews lasted between
30 minutes and 1 hour and 15 minutes.
TABLE 7 Site details
Site Local characteristics
1 Population: 500,000
Urban and rural
25% BME population, predominantly of Pakistani heritage (average across England 11%)
In the 10% most deprived local authority areas outside London (IMD score of 26); OPAT services provided:
HO attendance, visiting GN, SA (well-established service)
2 Population: 798,000
Urban
19% BME population (90 ethnic groups represented); both very high and very low areas of deprivation
(IMD score of 68)
OPAT services provided: HO attendance, SA (both well established) and visiting SN (newly established service)
3 Population: 330,000
Urban and rural
Largely white, working-class population (< 4% non-white)
IMD score of 67
OPAT services provided: visiting SN, HO attendance, SA (well-established services)
4 Population: 385,000
Urban (although hospital draws from rural areas outside the town)
67% white British, 8–12% BME
IMD score of 105
OPAT services provided: visiting GN, HO attendance (newly established service)
BME, black and minority ethnic; IMD, Index of Multiple Deprivation.
Source: Office for National Statistics, 2010.101 Rankings are of the 326 English districts, for which a ranking of 1 is the most
deprived and 326 is the least deprived.
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Topic guide
The interviews and focus group discussions were semistructured and explored patient satisfaction, issues
and preferences. The topic guide covered four main questions:
1. What has been your experience of receiving i.v. antibiotics for infections? What were the good and bad
points of the care/service you received?
2. What are the most important aspects of i.v. antibiotic services for you?
3. If you were designing a service to provide community antibiotic i.v. services what would it look like?
4. How did the i.v. antibiotic treatment course impact on your everyday life (and that of your
friends/family)?
These questions had a list of probes related to each question, to prompt further discussion and gain
further insight into pertinent issues.
Data analysis
Interviews were conducted by four team members [MT and SM (psychology), JE (sociology) and, following
the departure of JE from the study, CCM (nursing)]. MT, CCM and SM contributed to the analysis of the
data. The team met regularly throughout the data collection period to review transcripts to ensure that
they were covering the same topics and to identify issues to explore in later interviews. Owing to the
departure of JE from the project, data collection and analysis became desynchronised, with data analysis
starting after 12 interviews had taken place.
The audio-recordings were transcribed verbatim, anonymised and entered into NVivo version 10 software
(QSR International, Warrington, UK) to facilitate data organisation, coding and retrieval. Data were
analysed thematically for patterns and themes to understand what patients valued about OPAT services
and to explore differences in their experiences using constant comparative methods. Data analysis followed
the standard methodology for thematic content analysis, with close reading of the data to identify words
that capture thoughts or concepts. Labels/codes were attached to these data and became the initial coding
frame. Codes were then sorted into categories based on how they relate to one another and grouped into
meaningful clusters. We also drew from aspects of framework analysis, developing matrices95 to map the
data and aid categorisation.
Initially, two researchers independently read the transcripts and listened to the first three interviews, from
which an initial coding frame was developed. Following this, the wider team examined and agreed the
preliminary codes, and a coding index was agreed and applied in NVivo to the remaining transcripts.
The research team met fortnightly to discuss the analysis and to examine specific cases for disconfirming
perspectives. Before the end of coding it became clear that data saturation had been reached, as no new
ideas relevant to constructing the DCE were identified from the last five interviews.103
Three meetings were held between the qualitative team (MT, CCM, SM), chief investigator (JM), modellers
(DM, SH) and two of the PAG members (HG, CT) to discuss the relevance and suitability of the themes
produced, the ways in which the themes were linked and candidate attributes.
Copies of the interviews were sent to three participants who asked for a copy, but no changes were requested.
Changes from the protocol
We were unable to recruit enough participants to focus groups so we changed our predominant data
collection method to interviews. This provided richer data, but required significantly more resources.
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Results
A total of 41 patients consented, but four did not attend a focus group session and then declined
participation and five subsequently declined to be interviewed. Owing to participants’ preferences and
availability, one focus group (four participants) and 28 interviews took place (Table 8). One interview was
not used in the final analysis, as the participant did not recall having i.v. antibiotics. The demographic details
of participants can be found in Table 8. The results section uses direct quotations from patients to illustrate
the analysis. The following code is used: sex, age < 65 years or > 65 years, OPAT service received.
TABLE 8 Participant demographics
Demographics N= 32
Age (years), mean (range) 53 (21–80)
Sex =male, n 16
Marital status, n
Married 16
Single 7
Divorced/separated/widowed 3
Cohabiting/civil partnership 6
Ethnicity, n
White British 29
White European 2
South Asian 0
Other (not stated) 1
Education, n
University 14
College 9
Secondary 7
Primary (did not complete formal schooling) 2
Employment, n
Full-time (> 30 hours per week) 12
Part-time (< 30 hours per week) 4
Unable to work owing to ill health 5
Retired 10
Carer 1
Infection type, n
Short term 20
Long term 12
Service received, n
HO attendance 14
Nurse at home 13
SA 5
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Theme 1: meeting the needs of a diverse population
For many, the benefit of OPAT was not being admitted to hospital. Most did not see their infection as
warranting this, and those who had previously been treated as an inpatient saw OPAT as an opportunity
to get home earlier. However, being cared for as an outpatient could be challenging:
. . . they [staff] came back and said was I sure this was what I want to do [go home on OPAT], and I
was like ‘Yeah, as long as you put in place that I can have someone come out to me, then I’d like to
go home.’ I didn’t realise how tiring it would be though. It’s still better than hospital, but I never
realised that just making a cuppa could be so tiring!
Female, < 65 years, long term, nurse at home
Older participants, however, often put caveats on when OPAT would be suitable, taking into consideration
the severity of infection, the patient’s general health, family circumstances, number of i.v. infusions per day
and level of mobility:
It depends on the condition you are in, if you couldn’t move about you would have to wait inside
(at home) for somebody to arrive, but only if you have family at home for you, if you could move
about, you would be better off coming to hospital.
Male, > 65 years, short term, A&E
The nurse at home model was viewed as more appropriate for the very old or infirm, especially given the
challenges of travelling to and parking at hospital. A few participants proposed alternative places where
OPAT could be delivered, such as community clinics and GP surgeries and felt that this may be less
intimidating for older people than the hospital:
. . . we have a little centre which is mainly all the elders and a lot of them feel, they feel a little bit
more scared of the hospitals because some of them are single or widowed so they don’t always have
somebody to go with them to the hospital [. . .] a local clinic would be much less stressful for them.
Male, < 65 years, short term, A&E
Many people mentioned that they did not want to be treated in hospital if at all possible, and their
reluctance was unrelated to age, length of infection, frequency of infections or type of OPAT received.
For some, their fear was linked to the perceived risk of contracting an additional infection, often fuelled
by news reports as well as personal experience:
It’s always a worry in hospital, are you going to pick up a staph infection? Things like that.
Female, < 65 years, long term, clinic
Half of participants felt that OPAT services were understaffed, with hospital-based services viewed as
particularly affected. None of the patients interviewed felt that this affected the quality of care they
received and all were sympathetic to the stress that staff were under, suggesting that more staff and
additional facilities were needed to address demand:
I think everyone’s absolutely rushed off their feet in that unit.
Female, < 65 years, short term, A&E
Theme 2: benefits of and barriers to different models of care
A major benefit of OPAT, regardless of the model of care, is the ability to enjoy the comforts of home and
not disrupt things such as diet, sleeping patterns and family life, which people felt was hugely important to
their recovery and well-being.
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Hospital attendance
Younger participants in particular believed that daily attendance at hospital, compared with either
inpatient stay or nurse at home, had the potential to cause the least disruption to daily life. Although they
had quite serious infections, home care and work responsibilities meant that being an inpatient was an
unpalatable option. Indeed, many working-age patients continued to work during their treatment. When
HO appointments ran to time, most found once-daily treatment to have a minimal impact on their lives.
However, many said that attending hospital more than once a day would be as bad as being an inpatient
and none could see any way in which they could attend more than once daily:
I didn’t want to be in hospital at all [. . .] but I really couldn’t imagine having to come back and forth
during the day, with the buses, it just wouldn’t work, it’s a non-starter, I’d no sooner get home than
turn around again.
Female, < 65 years, short term, clinic
Having an appointment time and being seen on time were of particular importance, and so one group of
patients who received OPAT via their A&E department were disappointed to find that all i.v. patients were
given the same appointment time of 10.00 or 14.00:
When you’re sat in A&E, and you thought ‘there’s hardly anybody in’, and it took about initially, about
an hour and a half for even somebody to acknowledge you being there, that was a disappointment.
Male, < 65 years, long term, A&E
In contrast, a different hospital-based clinic offered appointments that could be fitted around the patient’s
lifestyle, and this was valued by patients and improved their overall experience. It allowed them to be able
to balance their treatment with work and family life in a way that was as stress-free as possible:
I think it was really important that the staff were so good, if they’d not been as flexible or if they’d not
been, if they’d been like the staff in my doctors, it would’ve been a horrific experience.
Female, < 65 years, short term, clinic
One perceived benefit of a hospital-based service was that if there was a problem, patients felt that they
were in the best place for prompt access to emergency medical care:
So, personally, for me, I felt like being treated at the hospital was probably the best option because
there’d have been people around who could have come and had a look at me if they’d needed to.
Female, < 65 years, short term, clinic
Geographical barriers
For those living further away from hospital, or relying on public transport, the geographical challenges of
hospital attendance quickly sank in. For those relying on public transport, there was a range of obstacles,
not least having to travel with an i.v. access line, which proved difficult to hide in the height of summer.
Another challenge was managing bus and train delays, which were particularly difficult in inclement
weather. The patients who relied on public transport often found hospital attendance less convenient than
patients with good geographical access or higher social capital:
The distance that I travelled on the bus, you know that’s more inconvenient than sitting and waiting in
the hospital really.
Female, < 65 years, short term, A&E
Even when hospital transport was available, this did not attenuate the travel difficulties. For these patients,
a 30-minute infusion meant leaving home by 9.00 and returning home in the late afternoon. One patient
who had two small children stoically endured this for 8 weeks as the alternative was inpatient care and
seeing little of her family.
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I have to be ready at 7.30 in the morning, they normally get there about 9, so it takes my whole day
to have a half hour drip, but that’s nothing to do with OPAT that’s to do with the way the NHS
driving services run.
Female, < 65 years, long term, clinic
Even for those travelling by car, a lack of parking spaces and high car park fees made daily attendance
frustrating. Some patients suggested that dedicated short-term parking bays, similar to those used by
dialysis patients, would be helpful, as many spent longer finding a parking space than they did receiving
their i.v. treatment.
District or specialist nurse at home
Patients who were treated at home by a nurse perceived their treatment regime to be more convenient
and less stressful than hospital attendance. Many were retired and a few had complex treatment regimes,
often requiring multiple i.v. administrations per day. Even faced with several visits a day, many felt that
OPAT allowed them to carry on with everyday life and compared it favourably to being an inpatient:
. . . they used to come about nine, two and six or seven o’clock, so you’d got them in-between bits to
do things, go to the shops or whatever, and it didn’t impact on my life at all.
Female, < 65 years, long term, SN
In most cases, the nurse arrived at regular times, but missed appointment times were a source of both
frustration and worry, as participants feared they had missed hearing the nurse call. Knowing that the
nurse would call at a particular time made them feel safe; when this implicit contract was broken, the
relationship could be affected. For some, daily attendance at hospital was inconceivable and the prospect
of being discharged home only to come back each day was a worse option than being an inpatient:
. . . for me, I don’t think that [daily attendance at clinic] would have worked, because I was still
extremely weak, and we know the . . .one of the main reasons I wanted to come home was for the
comfort of my own home, and my own bed, and to be able to rest and to build my strength up. Now
to physically have to make a journey each day . . . unnecessarily in my eyes, because if I’d have stayed
in hospital I wouldn’t have had to make the journey, so for me having to physically get up, get
dressed, go out of the house to go to the hospital to have that done would have been exhausting.
Female, < 65 years, short term, SN
A few participants had a team of nurses visiting them and, although participants worried about the lack of
continuity, a greater concern was ensuring that the nurse had been briefed about their infection and
treatment plan, and was competent to deliver the treatment. When on one occasion a replacement nurse
arrived not knowing that she was supposed to administer an i.v. treatment, the patient started to question
the competence of the team:
She had no clue who I was really and arrived not knowing that she was supposed to bring the drugs
with her, it did make me wonder about them.
Female, < 65 years, long term, district nurse
Self-administration
Patients who self-administered had recurrent infections and had been administering their own treatment for
many years. Some felt that they could fit their treatment around their life, with one patient describing how
she had infused in the car on the way to work on occasions. However, two patients felt that they had little
time to fit anything else into their day, as planning the next treatment was always at the back of their mind:
There’s no point really going out much or doing much ‘cos you haven’t got much time when you
aren’t having to think about getting everything sorted.
Male, < 65 years, long term, SA
QUALITATIVE STUDY INVESTIGATING PATIENT PERCEPTIONS OF OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
Although all were experienced with i.v. administration, only two felt confident with the procedure.
Two preferred to have a family member present during their infusion, even if this person was not actively
involved, and felt that they would not be willing to self-administer without this support. Another voiced a
preference for inpatient care, although he said that this was no longer offered to him and he felt that this
was because it was assumed he would self-administer:
If I felt well enough to be at home then I preferred to be at home, because I had lots of back up and
support there. [. . .] Living on my own now I would actually prefer to be in hospital I think.
Male, > 65 years, long term, SA
. . . I think because I’ve done them since I was 13 so 20 years I don’t need anybody to do my drips I
don’t need anybody to see me, I’m very glad I don’t have to come in to do them ‘cos travelling
everyday there and back would be horrendous and very expensive.
Female, < 65 years, long term, SA
Theme 3: effectiveness of treatment
About half of patients believed that i.v. antimicrobials were more effective than oral treatments. Their
apparent effectiveness caused patients to question why they had not been offered i.v. earlier, as their
infections responded quickly to the change of treatment:
I would have like the full dose, not an escalation policy, i.e. you can only take orally up to a certain
level and therefore, when that’s failed, we’ll put the i.v. in. If we know that for many people it’s going
to fail then overprescribe. I don’t know what proportion of people that oral antibiotics would work
you see.
Male, < 65 years, long term, A&E
Some patients experienced a switch from i.v. to oral treatment and a few worried that their treatment had
been changed prematurely, largely because the planned switch was not explained to them. This was noted
only for nurse at home and hospital attendance patients. In the case of cellulitis, the time needed to treat
the infection is shorter than the time required for the skin to heal, leaving patients uncertain about
whether or not the infection was cleared. In these cases, patients commonly said they would have liked to
continue i.v. treatment for longer:
He’d said to me that they were going to review after x amount of days, and it was still a little bit red
and still swollen. Not as swollen and not as red, and I said ‘look, I’m not happy, I know I’m going to
be back here within a fortnight if I don’t have a little bit more’. And he said ‘well go on then!’
Female, < 65 years, short term, clinic
A few patients experienced a subsequent flare-up of their infection, which led them to conclude that their
i.v. had ceased prematurely. Unfortunately, as most short-term infection patients were not seen by a
health-care professional at the end of treatment, this was picked up only when the patients went back to
their GPs, demonstrating an important unmet need of patients:
Well, I went to the GP a week after I finished the i.v. from the hospital, and it (cellulitis) was as bad as
ever, so he sends me back to A&E.
Male, > 65 years, short term, clinic
Theme 4: communication
Information provision
Most patients recalled receiving written information about their treatment. This included information about
managing with the i.v. device once at home (e.g. how to bathe with it in), how infections are treated
using i.v. antimicrobials, description of the OPAT service, risk of infection and what to do/who to contact if
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the patient had any concerns. Patients appreciated this information and in particular being given a named
point of contact, and a few felt empowered to be actively involved in their own care, knowing that
support was there:
I think the important issues are being given information, being told clearly what the problem is, what
is going to happen and so on, and any data that needs to be given to you. It’s far better to be, to
have that clear in your mind, than just let things happen to you, and hope that they’re doing the right
thing. I think that’s the most important thing.
Male, > 65 years, short term, A&E
Someone to talk to
The ability to ask questions, even if the patient had none, was viewed as important.
Patients who were cared for at home enjoyed having the nurse to talk to during their appointment and
felt that they could ask questions as they were not taking up additional nursing time. Some older patients
in particular had concerns about being cared for at home but said that having the nurse to talk to set their
mind at ease and gave them the confidence to manage their own care at home. When only one or two
nurses covered their care, patients appreciated the continuity, as it meant that they got to know the nurse,
which gave them the confidence to ask questions:
. . . I’d got that attention completely for that time, whereas in hospital when the antibiotics are put on,
you know, the nurse would come around and say ‘Hi, how are you?’, just generally passing the time
of day while they were putting it [drip] all together, and then they’d go. I think being at home, having
that person there who’s just, you’ve just got their attention no matter what, then you get to know
them. I found them easy then to open up to, to ask questions.
Female, < 65 years, short term
Few of the patients attending hospital recalled being told much about their infection, but most did feel
able to ask questions. Although most were not overly concerned by the lack of information given to them,
when things went wrong, or recovery was not as they expected, the lack of communication between the
health-care professional and the patient became more significant, and patients felt that they had been left
in the dark:
. . . the doctor said 4 weeks when I saw her, but I’m more than 4 weeks on from seeing the doctor
and it’s still not entirely right so I don’t know, no-one told me anything.
Male, < 65 years, long term, clinic
A lack of communication about treatment became even more significant for patients when accompanied
by perceived health-care errors. Patients tended to blame these on the lack of continuity in who treated
them and a lack of interstaff communication. For one patient, a lack of detailed information in his notes
made it difficult for staff to determine whether or not his infection was responding to treatment, and
another described the errors made at his discharge from hospital:
. . . the final one (staff member) discharged me, not really [having] done an examination of me at all,
in fact I was sat there, with totally bare arms, with a bruise on this wrist where the cannula had been,
and he was saying that he’d have to take the cannula out after they’d given me the shot on Friday,
and I said, ‘it was out yesterday’ and he said ‘Oh, why?’ [. . .] I had to tell him [. . .] so I wasn’t too
happy about that.
Male, > 65 years, short term, A&E
Not unsurprisingly, patients who self-administered were the most knowledgeable about their condition
and most likely to have been told how to manage their i.v. device and how to recognise signs that
indicate possible further infection. All patients knew who to contact if they had any worries. However,
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communication could still break down and damage patient confidence. For one SA patient, the medical
equipment that she needed to treat her condition kept breaking down, so she was unable to self-manage
effectively. Despite ringing for advice, staff did not answer her questions and did not ring her back to
ensure that their proposed solution had worked:
No, I had no phone calls, many from me looking for advice, but none to me.
Female, < 65 years, long term, SA
Theme 5: review and aftercare (follow-up)
Review and follow-up at the end of treatment was important to many but not to all patients and their
experiences differed. Most long-term patients were reviewed regularly, and, although some patients felt
strongly that this review should be undertaken by a doctor, others were happy for the nurse to do this.
What was important was being able to contact the OPAT team between appointments as this provided
reassurance that they were being cared for as well as if they were in hospital. Being followed up at the
end of treatment was particularly important if the patient had not been reviewed face to face during
treatment, and a lack of aftercare was a cause for concern:
I’ve got follow up in a month which is nice so they’re keeping an eye on me, I wouldn’t like it if I
hadn’t been.
Female, < 65 years, long term, clinic
However, few short-term patients were followed up at the end of treatment. Some were advised to come
back to the clinic if they had concerns. Some were content that this was their responsibility, but others
would have preferred an appointment and wanted to know whose responsibility it was to organise this.
This was of particular concern to patients who had been cared for by a nurse at home, as they were
generally not seen again in person by the doctor after the initial diagnosis:
I suppose I was left in the dark as to know what was after the IV, nothing at all. I’d rather if they said
ok, make an appointment to see your doctor.
Male, < 65 years, short term, SN
Self-administration patients were all on longer-term i.v. treatment and valued their mid-term and aftercare
appointments, as they saw these as important to their care:
There’s a liaison nurse who comes down on a pre-arranged date and time and they’ll usually do (tests)
and chat and make sure everything is going ok, that I haven’t got any issues, see how I’m feeling, see
if there’s any improvement or effect.
Male, < 65 years, long term, SA
Theme 6: staff expertise
Patients used the term ‘expertise’ to refer to both a staff member’s level of knowledge of infections, i.v.
antimicrobials and treatments and their practical experience of delivering OPAT, emphasising both equally.
People valued being dealt with by competent staff, and felt that such expertise was built up over time. Ideally,
participants wanted to be cared for by people who understood their infection, were aware of complications
that could arise and knew what to do in those circumstances. Patients were impressed with staff who knew
about their personal circumstances and liked it when they felt that staff ‘went the extra mile’:
The nurses that come out are specialist nurses who are informed about antibiotics and about lots of
illnesses that they are treating, because they obviously need to know [. . .] I felt very comfortable that
they were very knowledgeable about what I was experiencing and this reassured me about coping at
home alone.
Female, < 65 years, short-term, SN
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Some patients wanted their care to be overseen by a doctor, because of their extra training and qualifications.
Although these patients were happy to be treated by a nurse, they wanted the reassurance of a doctor
overseeing their care:
Interviewer: How would you have felt if it had been, for example, a nurse-led service?
Patient: Umm, I would have been worried, I think you need a qualified doctor in charge, to do the
examination, and make a decision on what to do next, what to prescribe, to continue the treatment.
Male, > 65 years, short term, A&E
Theme 7: impact on family and friends
Outpatient parenteral antimicrobial therapy treatment often had a significant effect on the patient’s family
and friends who provided practical and psychological support to the patient. Patients felt that it was
important to consider how their treatment had a wider impact, rather than just how it affected them
individually. For those attending hospital on a daily basis, a reliance on family and friends to get them to
and from the hospital was important, both in terms of time off work and additional travel costs:
I mean it’s a case of them leaving work to take me there [hospital] on a morning because it was at like
10 o’clock my appointment and then to pick me up afterwards. [. . .] the Wednesday, I had to wait
about an hour for treatment, so my dad was hanging around, and he had to leave me because he
was in a meeting at work.
Male, < 65 years, short term, A&E
Some patients were more concerned about the impact their infection had on others than their own
well-being and recovery. Although being at home was viewed as better than being an inpatient, this often
meant that patients tried to carry on as normal, including maintaining family roles, for the sake of their
family. Some expressed a sense of guilt about the impact their treatment had on their children or spouse,
with participants talking about the treats or visits that were missed because they were unwell, or tasks not
completed, as they were their responsibility. Patients expressed guilt that their infection had resulted in
them not being able to care for family members as they usually would do:
I got discharged, I am a carer for my mum and at that point I couldn’t take care of myself so what
they did was, they had to put her in a residential home for about 2 or 3 weeks so until I picked
myself up.
Male, > 65 years, long term (focus group), district nurse
Discussion
This study set out to understand what patients might value about OPAT services, in order to identify
potential attributes for a subsequent DCE.
Patient experiences of outpatient parenteral antimicrobial therapy
Overall, patients appreciate the care that they receive and felt that services were generally well run and of
high quality. While acutely ill, most patients preferred to be cared for in hospital but, once stabilised, most
but not all patients preferred to recover at home, a finding echoed by other studies.2,15,85,105 Not all patients
are suitable for OPAT and are generally selected on the basis of their ability to cope in the community, and
the availability of suitable antimicrobials, and these caveats were echoed by patients.35 In line with other
studies, patients felt that they benefited from being in their own homes,56,85,86 but this also required them
to be more active in their own care, and the willingness of patients to do this needs to be assessed.35,99
Patients identified a range of health-care experiences as important. One important concept related to the
type of staff involved in the service and the skills that they need to deliver good quality care. For some, this
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meant the active involvement of doctors within the service, owing to the perception that doctors were
more knowledgeable or skilled and that health-care decisions should be made by doctors rather than by
nurses or patients. Others focused on the expertise and experience of nursing staff. A good service was
one in which staff were perceived to be competent and highly skilled. Studies have found that a minority
of patients lack the confidence to manage effectively in the community, so understanding what constitutes
good-quality care is important if OPAT provision is to be widened.73,85
Another important concept relates to interpersonal aspects of care, such as respect and empathy. Most
patients were provided with good written information about OPAT, but oral communication between
patients and staff was more variable. Relationships with staff can take time to develop and one way in
which these were achieved was through staff having time to talk patients about their infection and
treatment. Poor communication could leave patients without the knowledge and confidence needed to
be a competent collaborator in their own care and could affect their perceptions of the service. These
findings resonate with the conclusions of a recent review by Entwistle et al.106 that looked at the aspects of
health-care delivery that are most important to patients. The map described by Entwistle et al.106 links
‘health care delivery to what people are enabled (or not) to feel, be or do’ and suggests that both the
structure of health care and social dynamics are important to the patient experience. Our findings lend
support this conclusion.
What are the benefits of and barriers to different service configurations?
Each of the care pathways was viewed as having its own strengths and weaknesses, and the importance
people attached to different attributes seemed to be linked to the age and health of the patient.
A nurse at home model was perceived to be particularly well suited to older patients, those needing longer
courses of i.v. treatment and those with more complex care needs. For many, the one-to-one time with the
nurse was viewed as a key benefit and contrasted strongly with their inpatient experience, a finding also
noted by Dubois and Santos-Eggimann.99 However, this benefit could be quickly eroded if the nursing
team is too large and the continuity of the care relationship is broken.
Hospital attendance was considered to be most suitable for those who were fitter, younger and required
once-daily, short courses (under 1 week) of i.v. treatment, a view also held by those attending clinic with
long-term infections, although several patients were receiving long-term i.v. via the clinic. The availability of
a doctor on duty provided the reassurance some needed ‘in case anything went wrong’, and a qualitative
study by Bamford et al.35 suggests that some patients do not feel confident about being treated by a nurse
at home. However, the evidence is mixed. A large-scale Health Technology Assessment (HTA)-funded
study of doctor-led versus nurse-led care in a bronchiectasis clinic found that patients were happy with a
nurse-led clinic because it provided better continuity of care.107 It is therefore important to understand
what patients value about the different aspects of the service that they receive.
A potential benefit of hospital attendance was its convenience, but this required the use of timed
appointments, and when appointments were not kept this affected the level of patient satisfaction, a
finding reported elsewhere.69 Characteristics of the service (e.g. if understaffed) and the staff themselves
(e.g. not being briefed about the patient) contributed to dissatisfaction. Hospital attendance was the only
care pathway in which transport is a significant issue. Poor public transport links, a reliance on hospital
transport and poor car-parking facilities at hospitals were also key attributes that affected the acceptability
of hospital attendance and have been noted previously.69 One solution that was proposed by patients as
an alternative to hospital-based services was to invest in ‘local clinic services’, perhaps based in local
medical centres.
Self-administration was the model of care least well represented in our sample, and all patients undertaking
this were chronically ill patients who received regular courses of i.v. treatment and thus do not reflect the
views of those who experience a one-off course of antibiotics, for example for a deep-seated infection.
Patients who had no personal experience of SA voiced most concerns about the risks of SA. Although those
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using the service found it convenient, there were residual concerns about the safety of SA, and one patient
did not rule out inpatient care as a favoured alternative. A study of cystic fibrosis patients reported similar
results and recommended that refresher courses be given.88 SA is generally offered only to patients who are
physically and cognitively able to manage its complexity. The findings of our study and the conclusions of
Pilling and Walley88 suggest that when patients are taught to self-administer, treatment choices should be
revisited over time to determine whether or not people’s circumstances have changed.
Strengths and limitations
Our data support and develop the earlier scant qualitative research evaluating OPAT services. OPAT
services can support patients to self-manage in the community, but when services are not configured in a
way that helps patients in this endeavour they can negatively impact on patient satisfaction.
The strengths of this study are that we recruited from four very different sites, including two large teaching
hospitals and two DGHs, which between them offered HO attendance, SN and GN at home and SA OPAT
services. This enabled us to contrast the views and experiences of those who experienced different models
of care and provided contextualised information to unpick the aspects of care that patients valued to
construct our attribute shortlist for the DCE. It should be acknowledged that, although we recruited from
four very different centres, the experiences described cannot be generalised to all services, and further
research is needed to understand patient experiences of OPAT.
We had a broad sampling strategy to obtain views from participants from a diverse range of socioeconomic
backgrounds. However, limitations must be acknowledged in our sampling, as we struggled to recruit the
very elderly (> 85 years of age) and those from local black and minority ethnic (BME) populations. Feedback
from eligible older patients was that they did not feel well enough to be interviewed. We struggled to
recruit from the BME community and only three people consented. Of these, two could not be contacted
after finishing treatment and one decided not to be interviewed. To improve recruitment, we took advice
from researchers with significant experience working with the BME community and from our patient and
public involvement (PPI) group but few eligible patients were identified as receiving OPAT during the
recruitment period, and response to letters inviting those who had previously received OPAT was poor.
We were also able to recruit only five patients with experience of SA, as this was not a model of care
offered as widely as the other two services. For that reason, the findings from the interviews with SA
patients should be interpreted with caution, and more research is needed to understand the experiences of
this population.
We planned to undertake focus groups with relatively few interviews, but recruitment was poor. We
therefore introduced the option of an interview, which was taken up by almost all participants. This
resulted in much richer data, but did put the study behind time as the analysis took longer than
anticipated. This had the knock-on effect of the interviews and analysis becoming desynchronised, so data
saturation was reached before we finished interviewing and no new findings were revealed in the final
five interviews.
Data collection and analysis were undertaken by three researchers with diverse backgrounds, and the team
met regularly to review interview data and to look at the emerging analysis. We view this diversity as a
strength of the study, as it added to the richness of our discussions about the data.
Conclusion
Nationally and internationally, health-care organisations have highlighted the importance of patients’
experiences of the services they receive, and, indeed, the NHS Operating Framework for England108
describes each patient’s experience as ‘the final arbiter of everything the NHS does’. In the current drive to
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have patients cared for in the community, it is important to ensure that services are designed in a way that
meet their needs and improves the quality of people’s experiences of health-care delivery.109 This study
shows that satisfaction with OPAT services was a dynamic process, with both the health-care provider and
the patient contributing to the subjective experience of OPAT. Therefore, understanding which experiences
of health care really matter provides the opportunity to improve services.
The qualitative study identified nine concepts which could be taken forward as possible attributes in the
DCE study. However, two of these (in italics below) were excluded as they did not differentiate between
services, but were specific to one model of care.
1. Personal effort (travel time): an important difference between services but not included as an attribute
in the DCE as relevant only to hospital attendance and as we were not able to vary sufficiently
between services.
2. Number of i.v. administrations per day.
3. Accommodating OPAT within patients’ daily lives (appointment times, waiting for nurse).
4. Expertise of staff: dropped as this attribute did not vary between services.
5. Communication with staff.
6. Communication between staff (quality of handover between team members, staff mix).
7. Doctor- versus nurse-led service: who gives the i.v.?
8. Follow-up or ‘aftercare’.
9. Risk of adverse reaction, side effects and complications.
The interview data also identified a range of attitudes towards hospitals, i.v. antibiotic treatment, OPAT
services and health care more generally which were used to develop the following points to be included in
the DCE.
l People get better more quickly if they are treated at home.
l I do not like hospitals.
l If you are treated in hospital there is an increased risk of contracting a new infection.
l Giving my own i.v. antibiotics would worry me.
l Doctors – not patients – are in the best position to decide where patients should be cared for.
l I would choose to receive i.v. antibiotics in my own home even if this meant waiting several hours for a
nurse to visit.
l I prefer that my recovery is monitored by a doctor rather than by a nurse.
l I want to be responsible for making decisions about my own treatment.
l There is a significant health risk if the i.v. treatment is not given properly.
l Being in hospital would have made things difficult for my family.
l i.v. antibiotics are more effective than oral antibiotics.
l I did not know if my illness was cured when my i.v. treatment finished.
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Chapter 5 Quantitative analysis of patient
preferences
Introduction and background
Ensuring that the views of service users are heard is an important element when designing effective services
and is enshrined in government policy, including the 2011 Health and Social Care Bill.16,108,110,111 This chapter
summarises the work carried out to quantitatively understand patient preferences for OPAT services and to
examine which service characteristics are important to patients. OPAT services have been growing in the UK
for over 10 years, but evidence from the literature112–114 and from our interviews with health professionals
(see Chapter 3) suggest that, despite the reported benefits of OPAT, a key inhibitor to the further
development of these services is a lack of funding, commissioning gaps and not having the evidence to
justify the selection of any particular model of care. Quantifying patient preferences for different types of
care can, therefore, inform changes in service provision and provide information to support the development
of new services so as to obtain the best outcomes within a given budget. An important component in this
work is not just to understand what the overall preferences are (e.g. whether or not hospital treatment is
preferred to home treatment), but how the individual characteristics of a given model of care, such as the
need to travel, influence that preference. Furthermore, there is interest in understanding how these
sensitivities to individual service characteristics and, hence, overall preferences for a given model of care,
vary across patient segments.
This chapter describes a DCE which seeks to understand patient preferences for OPAT services. DCEs (also
known as stated choice) are being increasingly used in health care to elicit preferences for a range of
health-care services,115 for example, smoking cessation in pregnancy116 and communication therapy
following stroke.117 The DCE was developed using the findings from the systematic review and interview
data (see Chapter 4).
The survey data were analysed using advanced discrete choice models belonging to the family of random
utility structure.118 Although initial insights into overall preferences can be obtained by direct questioning
regarding which service a given patient prefers, such approaches fail to recognise that the actual
preferences will be influenced by specific characteristics of the different delivery methods.118 In particular,
they will be the result of trade-offs, whereby a patient selects the option that provides the best overall
combination of characteristics, with good performance of some characteristics compensating for poor
performance of others. In the context of the present study, such trade-offs may, for example, arise where a
patient trades off the fact that i.v. treatment at the hospital gives access to more highly qualified staff than
a nurse at home model against the added risk of hospital-acquired infections.
To understand the trade-off behaviour of patients, which reflects the relative importance they attach to
individual service characteristics (attributes), we developed a questionnaire with a DCE survey component,
the details of which are given below.
The remainder of this chapter is organised as follows. We first discuss the survey design before looking at
data collection. We then provide a summary of the modelling approach and model results before providing
a discussion and conclusions. Appendix 3 includes the full set of stated choice scenarios, details on the
methodology and full results of the modelling work.
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Aim and objectives
The aim of the DCE was to determine how patients react to different community i.v. antibiotic service
attributes and how this drives their overall preference for a given service.
The objectives were:
(a) using qualitative research methods, to identify what aspects of OPAT services are important
to patients
(b) using qualitative research methods, to identify patients’ attitudes to OPAT services and wider aspects
of health-care provision
(c) to design, pilot and conduct a DCE and attitudinal survey with OPAT service users
(d) to conduct modelling of the survey data to identify patients’ relative strength of preference for
different OPAT service attributes
(e) to identify heterogeneity across patients in their attitudes and preferences.
Methods
A DCE was designed to assess preferences for OPAT services.
Questionnaire design
Developing the attributes and levels
The DCE provides data on patient preferences by studying choices across a range of hypothetical scenarios
in which the characteristics of the different models of care vary. The aim is to understand the influence
that these individual characteristics have on the overall preference for a given model of care, where there
will also probably be a baseline preference, all else being equal.
The first phase of DCE development used the systematic literature review data (see Chapter 2) and patient
interviews (see Chapter 4) to identify possible attributes and levels, whereas phase two refined the wording
of items to go into the DCE questionnaire. Throughout this process we were guided by recommendations
by Coast et al.102 on the use of qualitative methods to guide the development of DCEs. Finally, the draft
DCE interview was piloted using a think-aloud technique to identify difficulties with question wording and
interpretation.119 Our PAG was closely involved with this work, meeting with the research team to review
attributes and levels and to comment on draft versions of the questionnaire.
Attribute development
The systematic review revealed that most patients found OPAT to be acceptable and that they believed
that they would recover more quickly at home.56,71 Others, however, were concerned about receiving
treatment in an outpatient setting; particular concerns related to ensuring the sterility of equipment and
the risks of being treated at home,35 the quality of communication between staff,35,69 the lack of
information provided and costs incurred.69 However, owing to the quality of reporting in the literature it
was often difficult to be certain which OPAT models participants had been exposed to, which limited the
usefulness of the existing literature.
To supplement the systematic review findings, qualitative data were collected from 32 patients (see Chapter 4
for sample details). Potential attributes for the DCE were developed on the basis of the findings of the
systematic review and the qualitative interviews in which we asked patients what was important to them
about the service they received, and what difficulties they had experienced during their OPAT treatment. A list
of candidate attributes was constructed and discussed with clinical co-applicants and patient representatives.
Some initially plausible attributes were excluded because they did not distinguish between types of service but
were more representative of OPAT generally (e.g. wanting to be cared for at home) and some of these
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reflected attitudes towards health care or OPAT generally; six attributes were retained for the DCE. The draft
set of items with potential levels was then shared with PPI members (n = 5) and research nurses (n = 8) at two
sites (Leeds and Bradford).
Summary of attributes
Alongside the core type of service (HO, nurse at home, SA), six attributes were chosen to describe the
individual models of care.
Attribute 1: number of treatments per day
The literature suggests that patient satisfaction remains high even when the patient requires regular
attendance at hospital.5,84 In contrast, our patient interviews revealed that many were concerned about the
practicalities of attending hospital more than once daily for treatment and felt this would impact on their
lives significantly. Some younger participants felt that hospital attendance would be more flexible than a
nurse at home model, but older people were more varied in their views, perceiving advantages and
disadvantages to all services. Continuous infusion pumps reduce the need for multiple visits, but the
systematic review suggested that patients may have concerns about the use of pumps, a finding echoed by
our study.37 We therefore chose three levels of treatment (once a day, twice a day and pump to provide
continuous infusion).
Attribute 2: appointments
This attribute varied whether or not patients were given an appointment time to receive their treatment.
Our interviews revealed that almost half of patients attending hospital or being cared for a by a nurse at
home had experienced missed appointment times, a finding echoed by Hitchcock et al.69 The literature
review also revealed that SA is attractive to some as it frees people from appointments.36 Three levels were
selected: daily appointment time given, no appointment time given and no appointment time needed (SA).
Attribute 3: treatment administered by whom?
Participants were split in their opinion about who should deliver i.v. antimicrobials. Some would prefer to
be treated by a doctor, but others preferred to see a nurse, a finding echoed in the literature.35 The patient
interviews also identified that some patients were interested in learning how to self-administer their i.v.
medications, but were concerned about training and the risks involved, a finding also noted by Lehoux.37
It is acknowledged that none of the current OPAT services has doctors directly delivering i.v. treatment, but
it was decided to include this to determine the strength of this preference. Five levels were identified for
this attribute: specialist i.v. nurse, GN, doctor, self with half a day’s training or self with 1-day training.
Attribute 4: communication between patient and health-care professionals
The systematic review and patient interviews show that good communication between patients and staff
was vital. When communications between staff break down and information about the patient is not
passed on correctly this can worry patients, a finding supported by the literature.69 Although not picked up
in the literature, there was also concern from some patients about who they saw and whether or not the
same person cared for them throughout their treatment. Therefore, four levels were selected for this
attribute: see a health-care professional who knows you (continuity of care), see a health-care professional
who does not know you (whoever is on shift), speak on the telephone with a health-care professional who
knows you, speak on the telephone to a health-care professional who does not know you.
Attribute 5: aftercare
The interviews revealed that many patients were concerned about not being followed up at the end of
their treatment and, in many cases, were not sure if they would get an appointment, either from their GP
or from the hospital or if they should instigate that interaction. Where offered, appointments are currently
with a doctor, but as many patients do not receive this, we included an appointment with a nurse or GP as
an option to examine patient willingness to be followed up in this way. We selected four levels for this
attribute: no appointment, appointment at hospital with a nurse, appointment with your GP, telephone
appointment with a nurse.
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Attribute 6: risk of adverse reactions
The systematic review undertaken at the start of the study revealed that only 19 out of 91 studies
evaluating OPAT-related safety included a comparator. The data analysis suggests that there is little impact
on either drug-related side effects or the number of deaths in OPAT compared with hospital treatment.
However, there appear to be more line-related complications in i.v. therapy administered outside the
hospital, and adverse events such as rash, fever, nausea were reported (see Chapter 2 for details).
The following three levels of risk were selected: 1 in 6 chance, 1 in 10 chance, 1 in 25 chance.
Attitude questions
Recent work has shown that when patients are in a situation in which they have to make a decision about
treatments, key influences on this behaviour will be the severity of the condition, past experience, etc., but
also perceptions and attitudes. Klojgaard and Hess120 argue that when clinical evidence is not clear cut, the
perceptions that patients form will play a part in shaping these decisions. Therefore, a measure of patient
attitudes was developed for the survey. In the absence of relevant theory or pre-existing literature, the
items were developed directly from the qualitative data (see Box 1 for questions used). The attitude
questions were phrased as positive or negative statements and scored on a five-point Likert scale.121
The survey
Patients were given eight hypothetical choice scenarios, each time involving the three models of care:
attendance at hospital, nurse at home (which could be further differentiated into GN and SN) and SA.
The characteristics of the models of care were described in the form of the six attributes (e.g. number of
BOX 1 Attitude questions included in the patient survey
Questions (all scored on a five-point scale from strongly agree to strongly disagree)
People get better more quickly if they are treated at home.
I do not like hospitals.
If you are treated in hospital there is an increased risk of contracting a new infection.
Giving my own i.v. antibiotics would worry me.
Doctors, not patients, are in the best position to decide where patients should be cared for.
I would choose to have i.v. antibiotics in my own home even if this meant waiting several hours for a nurse
to visit.
I prefer that my recovery is monitored by a doctor rather than by a nurse.
Being in hospital would have made things difficult for my family.
I want to be responsible for making decisions about my own treatment.
I did not know if my illness was cured when my i.v. treatment finished.
There is a significant health risk if the i.v. treatment is not given properly.
i.v. antibiotics are more effective than oral antibiotics.
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treatments per day) and levels within attributes (e.g. once daily, twice daily) (see Table 9 for description of
attributes and levels). The levels used in these descriptions of services varied across the eight choice tasks,
and patients were asked each time to indicate their most preferred option among the three that were
presented. This allows us to understand how the preferences for a given model can change as a function
of the characteristics of that model of care.
When presenting respondents with hypothetical choices, the analyst needs to decide the values of the
characteristics describing the choices. With the aim of understanding the relative influence that different
characteristics (e.g. risk, treatments per day) have on the choice made, it is important to choose
combinations that do not lead to an overall dominance for one model of care. The specific combinations
of values for the different characteristics to be shown in a given choice task were determined on the basis
of an experimental design. We made use of a D-efficient design,122 in which we relied on zero priors in the
absence of any meaningful evidence in the literature. We decided against using non-zero priors, because
TABLE 9 Attributes and levels of the DCE
Attribute
Nurse gives i.v.
antibiotics in your home
You have your i.v.
antibiotics in hospital
You give i.v. antibiotics
to yourself at home
Number of treatments
each day
One One One
Two
Two Two Three
Pump provides continuous
treatment
Pump provides continuous
treatment
Pump provides continuous
treatment
Appointment times given Daily appointment time
given
Daily appointment time
given
No appointment needed
Daily appointment time not
given
Daily appointment time not
given
Who gives the i.v.
treatment?
Specialist i.v. antibiotic
nurse
Specialist i.v. antibiotic
nurse
You give the i.v. treatment
yourself after half a day of
training
GN
GN Doctor You give the i.v. treatment
yourself after 1 day of
training
Communication between
you and HCPs
See a HCP who knows you See a HCP who knows you Speak on the telephone
with a HCP who knows you
See a HCP who does not
know you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs
after the end of
treatment
None None None
Appointment at hospital
with nurse
Appointment at hospital
with nurse
Appointment at hospital
with nurse
Appointment with your GP Appointment with your GP Appointment with your GP
Telephone appointment
with nurse
Telephone appointment
with nurse
Telephone appointment
with nurse
Risk of a problem such
as another infection or
having to go into
hospital
1 in 6 chance 1 in 6 chance 1 in 6 chance
1 in 10 chance 1 in 10 chance 1 in 10 chance
1 in 25 chance 1 in 25 chance 1 in 25 chance
Please tick which service
you would prefer to have
□ □ □
HCP, health-care professional.
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no appropriate values were available from previous studies and because the sample of respondents
available to us was too limited to develop priors based on a pilot survey. The full design included 24 rows,
and orthogonal blocking was used to split this into three sets of eight choice tasks, with one block used
for each respondent. Each respondent in the survey thus received a set of eight choice tasks, and was each
time asked to indicate his/her preferred model of care under the specific combination of levels for the six
descriptive attributes. A copy of the full set of 24 choices used is included in Appendix 3.
Additional information
In addition to the DCE questions and attitudinal data, we collected information on participants’
educational level, and work history, their infection and its treatment, health-related quality of life, use of
health services and satisfaction with services. The last two sets of questions were asked after participants
had completed the DCE and attitude questions.
Pre-pilot work
The pre-pilot version of the survey, including the DCE questions, was made available to the research team
using an online format provided by ACCENT (a market research company; London). Members of the team,
research nurses and PPI members were invited to complete the questionnaire and make comments.
The wording of four questions was amended on the basis of feedback from 12 people.
Pilot study
We conducted a pilot study with 30 patients to gather their feedback on the survey.
Research objective
To get participant feedback on the survey and DCE choice sets in terms of whether or not the wording
was coherent and made sense to respondents.
Design
Think-aloud study and provisional quantitative analysis of DCE data.
Sample
An opportunity sample of patients aged 18 years and over who were currently or previously on i.v.
antimicrobial treatment for an infection (see Table 10 for sample details). Participants were recruited by
research nurses based at four acute NHS trusts (see Table 7). Data collection took place between May and
June 2014. Thirty people took part, but only 29 sets of data were analysed as one set was not successfully
uploaded and the data could not be recovered.
Procedure
Participants were given an information sheet by research nurses and given at least 24 hours to consider
participation. Interviews were then conducted at a mutually convenient time and place (at hospital or the
patient’s home). The DCE was presented to participants using a laptop or iPad (Apple Inc., Cupertino, CA,
USA). Participants were asked whether or not they understood the information and instructions presented
to them, what they thought they had to do next, and their feedback on the wording of questions was
sought as they were reading or answering so that detailed feedback could be audio-recorded, and written
notes were taken to supplement the analysis.
Main survey
Sampling
Participants were recruited through six NHS acute hospital trusts, representing both teaching hospitals and
DGHs. Both retrospective and prospective recruitment was allowed to provide the best opportunity to recruit to
our sampling frame. Two groups of patients were identified: patients with short-term infections (largely SSTIs)
and patients with deeper infections which generally require longer treatment courses (e.g. joint infections).
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The modelling work, however, identified only small differences between the two groups in terms of
preferences (see Results). We aimed to ensure representation on the basis of age, sex, SES (based on work
status), antibiotic experience and ethnicity.
Data collection
Recruitment took place between September 2014 and May 2015. Eligible patients were approached by a
research nurse and details of consented participants were passed to the research team. The questionnaire
was delivered to patients face to face using a laptop or iPad. Almost all participants completed the
questionnaire in their own homes. A total of 512 people were approached, almost half (n = 254) of whom
consented, and data were collected from 202 participants (20 participants could not be contacted post
recruitment, 15 were too ill to participate, 17 refused post consent). Participants had experience of at least
one model of care (Table 11). After asking participants about their preferences we asked about their past
experiences with OPAT. A total of 94% (n = 191) of participants reported they were quite satisfied or very
satisfied with the service they received.
TABLE 10 Sample characteristics for pilot study
Sample characteristics N= 29, n (%)
Male 13 (45)
Age (years), mean (range) 52 (29–84)
Ethnicity
White British 26 (90)
Asian or Asian British 2 (7)
Other 1 (3)
Education
University or professional 13 (45)
College (post 16 years) 4 (14)
Secondary 12 (41)
Marital status
Married or cohabiting 15 (52)
Single 8 (28)
Divorced 2 (7)
Widowed 4 (14)
Employment status
Working full-time (> 30 hours per week) 8 (28)
Working part-time (< 30 hours per week) 3 (10)
Retired 11 (38)
Unable to work owing to illness or on long-term sick leave 7 (24)
Duration of treatment
Long term 22 (76)
Short term 7 (24)
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Modelling approach
Pilot data
Frequency data were calculated using Microsoft Excel® 2013 (Microsoft Corporation, Redmond, WA, USA)
and Statistical Product and Service Solutions (SPSS; SPSS Inc., Chicago, IL, USA) for analysis. Qualitative
feedback in form of written notes and audio-recordings were used to inform revisions to the survey and
the DCE.
Main study
Our analysis made use of an advanced discrete choice model, which is a mathematical structure used to
explain the influence of explanatory variables (e.g. type of treatment, frequency of treatment, risk) on the
TABLE 11 Main DCE sample characteristics
Characteristics n (%) SD
Age (years), mean (range) 56.78 (20–94) 13.67
Sex (male) 122
Children < 18 years 35 (22)
Ethnicity
White 182 (90)
Asian/black British 16 (8)
Other 4 (2)
Education
University or college 91 (45)
Technical 28 (14)
Secondary 78 (39)
Primary 5 (2)
Working status
Full-time 63 (31)
Part-time 23 (11)
Retired 75 (37)
Unable to work owing to illness 31 (15)
Other 10 (5)
Previous i.v. antibiotic experience
One current/previous infection 171 (85)
Two previous infections 21 (10)
Three previous infections 6 (3)
Four previous infections 3 (1)
Model of care experienced (can be more than one model)
HO attendance 121
Nurse at home 44
SA 18
SD, standard deviation.
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choices that patients make between the different treatment options presented to them. The model is
based on the notion of utility maximisation, with respondents choosing the option that gives them the
greatest utility/smallest disutility. For a detailed overview of choice modelling techniques, see Train.123
The models explain the preference of a patient in a given choice task (i.e. which of the three models of
care is chosen) by estimating the sensitivity that the patient has to the different characteristics of each
model. With the expectation of major differences across patients in these sensitivities (e.g. one patient
cares more about risk than another) and hence in the resulting preferences for a given model of care in a
given choice scenario, our work incorporates three levels of heterogeneity in preferences across patients,
namely:
1. differences that can be linked to the sociodemographic and infection characteristics of the participant
(age, sex, race, education, employment status, past infections and whether they were short-term or
long-term patients)
2. idiosyncratic differences across participants in their preferences that cannot be linked to the
characteristics of the participant
3. differences in preferences that can be linked to underlying attitudes, namely attitudes towards hospitals
and towards health-care responsibility, where we make use of the methods described by (among
others) Abou-Zeid and Ben-Akiva,124 Vij and Walker125 and, with an example of a health application,
Klojgaard and Hess.120
Model estimation produces estimates of the sensitivities/preferences of respondents for the different types of
treatment as well as treatment characteristics and patient characteristics (e.g. sociodemographics) in explaining
these sensitivities and the underlying patient attitudes. These sensitivities in turn drive the preferences that
respondents express between the different services presented in a given choice task. For example, the models
produce parameters for risk and for waiting time, and their relative values allow us to understand the relative
importance of these two characteristics in explaining the choice between the different models of care. These
relative sensitivities vary across individual patients. The actual parameter values are determined in a numerical
process that produces estimates that allow the model to best explain the choices observed in the data. Full
details on the model structure are given in Appendix 3.
Random utility models such as those used in our work recognise the inability of analysts to capture fully the
utility of alternatives and thus acknowledge the presence of a remaining random component of utility.
Although initial insights into overall preferences can be obtained by direct questioning with regard to which
service a given patient prefers, such approaches fail to recognise that the actual preferences will be influenced
by the specific characteristics of the different service delivery methods. In particular, they will be the result of
trade-offs, whereby a patient selects the option that provides the best overall combination of characteristics,
with the good performance of some characteristics compensating for the poor performance of others.
We chose not to segment the analysis by infection type (short term vs. long term) but instead included this
variable as a respondent covariate in the modelling, testing for impacts on the preference for treatment types
as well as the valuation of treatment characteristics. This provides greater sample sizes and acknowledges
that time to infection resolution is on a continuum. In addition, the modelling work showed only small
differences between the two groups in terms of their preferences, and these related solely to appointment
times, training and seeing and speaking to someone that the patient knows, and not to the type of
treatment or key characteristics such as risk.
Full details on the model structure are given in Appendix 3.
Attitudinal data were analysed using principal component analysis with Varimax with Kaiser normalisation to
identify underlying structure within the data (SPSS version 20). Factor loadings > 0.7 were accepted and a
scree plot was used to determine the number of factors to include in the analysis.126 The principal component
analysis indicated that a two-factor solution provided a good fit to the data and accounted for 32% of the
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variance in scores: attitude towards hospitals and attitude towards health care being a doctor’s responsibility.
In both cases a higher value means stronger disagreement. These factors were then used as latent variables
in the analysis, allowing us to understand the role of attitudes in driving preferences (see Appendix 3 for
further information).
Results
Pilot data
Minor revisions were made to the survey questions as a result of the qualitative feedback. In addition,
further instructions were provided for respondents about the structure of the DCE, as it was found that
participants did not understand that the options would change between each choice set. Two attitudinal
items were removed, as all participants agreed with these statements so they did not distinguish between
patients. Missing data were minimal. The data from the survey were analysed using a multinomial logit
model and this yielded significant models whereby the sign and order of the coefficients on service levels
were intuitive and in the expected order (i.e. levels that were worse had higher negative model
coefficients).
Main study
This section gives a high level overview of the estimation results, with full details provided in Appendix 3.
We first look at the two underlying attitudes retrieved from the data, which are an attitude towards
hospitals and an attitude towards health-care responsibility.
l Participants who present a positive attitude towards hospitals are more likely to be female and
non-white, and to live alone, and the impact is stronger the more of these characteristics they have.
As this attitude becomes more positive, we also see an increase in the preference for in-hospital
treatment in the DCE scenarios.
l Participants who see health care as the responsibility of the doctor are likely to be > 65 years old and
non-white. They are also slightly less likely to have a university degree. As this attitude becomes
stronger, these participants have a much greater preference for the attendance at hospital or nurse at
home models of care compared with SA in the DCE scenarios.
We next look at the headline results in terms of utility scores for the different treatment types and
characteristics. The models explain the preference for a given model of care in a given choice scenario as
a function of the sensitivities of the patient and the characteristics of the model of care. Each of these
characteristics has an influence on the utility of the model of care, and the model of care with the highest
utility obtains the highest probability of being chosen. Here, we work with the mean sensitivities at the
sample average in terms of sociodemographic characteristics (which have an influence on preferences both
directly and through the underlying attitudes) and the random variation in preferences (both directly and
through the underlying attitudes).
The results in terms of the impact on utilities (and hence on preferences) are presented in Figure 2 where,
for each attribute, one of the levels is normalised to zero for identification. We observe first of all that
treatment type matters the most of any characteristic, followed by treatment frequency and risk. Looking
in detail at the findings, we note that:
l For treatment type, there is a strong overall preference for the nurse at home model, followed by
hospital treatment.
l Respondents prefer a single treatment per day to two treatments, continuous treatment and three
treatments per day.
l Having an appointment time is preferred to not having an appointment time.
l A SN is preferred to a doctor or a GN.
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l A half-day of training for SA is preferred to a full day of training.
l Patients prefer seeing someone they know.
l Patients prefer speaking to someone they know.
l Patients prefer nurse administered aftercare in hospital to GP aftercare, telephone aftercare and
no aftercare.
l For risk, we obtain clear evidence of non-linearity in sensitivities, leading us away from a continuous
treatment of risk (which would have implied, e.g., that a 1 in 25 risk would have been valued 2.5 times
as highly as a 1 in 10 risk). With only three levels of risk in the data, we then estimated separate
valuations for 1 in 25 and 1 in 10, keeping 1 in 6 as the base. Moving away from a continuous
specification was also justified by our analysis showing a lack of differences between valuations for 1 in
6 and in 10 in several groups.
With the different sociodemographic interactions (discussed in Appendix 3) used in the model (e.g. how
short-term and long-term patients react differently to appointment times), a total of 48 different
sociodemographic groups exist in our model, and we note strong variations in the mean preferences
relative to SA across these groups, as highlighted in Figure 3. What these data show is that the
sociodemographic variables we measured [age, sex, race, education, employment status, number of past
infections, type of current infection (long term vs. short term)] do affect the strength of preferences for a
particular service, but these effects are modest. There is an overall preference for nurse at home treatment
ahead of hospital treatment and ahead of SA, where this ordering applies to 39 out of 48 groups at the
mean sensitivities (i.e. before allowing for random variations in preferences). In addition, nurse at home
treatment is always preferred to SA at the mean preferences, and only white males < 50 years of age and
living alone marginally prefer hospital treatment to nurse at home treatment.
Some groups of patients prefer SA to hospital treatment, namely white respondents aged between 50 and
65 years of age who do not live alone (male or female), or are female and live alone, or are male, live
alone and have a university degree. Importantly, the gaps between preferences for the different treatment
types differ across groups.
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FIGURE 2 Mean preferences (utility scores) at sample average.
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Of course, owing to random heterogeneity, in sensitivities across individual patients, some probability of
reversal of preferences exists. Looking at the largest group (age > 65 years, male, white, not living alone, no
university degree), the mean utilities for hospital treatment and nurse at home (with SA as the base) are:
l hospital treatment utility score: 1.11
l nurse at home utility score: 4.50.
This would mean that the nurse at home model has the highest probability of being chosen, ahead of
hospital treatment and SA. However, the large standard deviations caused by random variations in
preferences give the following 95% confidence intervals (CIs; as used here referring to 95% of values falling
within these intervals, and not suggesting an insignificant estimate, but random variation in preferences):
l HO treatment: 95% CI –12.17 to 14.40
l nurse at home treatment: 95% CI –7.48 to 16.48.
We now see that there is clearly a possibility, even with a small probability, of SA being the most preferred
option for some patients. An important component in our work is the incorporation of underlying
attitudes. As described earlier, participants who present a positive attitude towards hospitals are more
likely to choose hospital treatment, whereas those who see health care as the responsibility of the doctor
have a much greater preference for attendance at hospital or nurse at home models of care, than for SA.
Here, we see that the attitude towards responsibility of health care accounts for 65% of the heterogeneity
for the preference for hospital treatment, and 88% for the preference for nurse at home treatment. The
attitude towards hospitals, however, accounts for only 6.9% of the heterogeneity for the preference for
hospital treatment, and 4.3% for the preference for nurse at home treatment.
For the remaining attributes, we now look only at those in which differences exist across sociodemographic
segments (which is not the case for aftercare and frequency of treatment), given that the overall results are
included in Figure 2.
Figure 4 shows a very large difference between long-term and short-term patients in their preference for
having an appointment time (with no appointment time as the base), with the latter having a much
stronger preference for an appointment time.
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Figure 5 shows that, although patients not living alone have a strong preference for SNs giving the
treatment ahead of GNs and doctors, for those living alone, there is a preference for doctors and SNs
(where the two are not significantly different) over GNs.
More differences arise across groups in terms of the preferences for a half-day of training for self-administration
(with 1 full day as the base). Figure 6 shows that, although long-term patients aged < 50 years who do not live
alone have a very strong preference for a half-day of training, short-term patients > 50 years of age and living
alone have a strong preference for 1 full day of training. Other groups are in between these two extremes.
For communication in person, all patient segments prefer seeing someone they know, but Figure 7 shows
that this is more important to younger patients and long-term patients. More important differences arise
with regard to communication over the telephone, and Figure 8 suggests that, in particular, older patients
living alone have a preference for speaking with someone who they do not know.
Finally, Figure 9 highlights the sensitivity to risk (e.g. of an adverse event). We see that patients aged < 65 years
and not working fail to distinguish between the two higher levels of risk, where the difference in sensitivities
between these two levels is stronger for older patients and for those in employment. The difference between
the two lowest levels of risk (1 in 10 and 1 in 25) is not significant for those aged > 65 years and in
employment, so the positive shift in Figure 9 can be ignored. We chose not to model risk as a continuous
variable, as it appeared to be non-linear. Thus, we were not able to identify the marginal rates of substitution
between this and other attribute levels.
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Discussion
Patient choice is becoming increasingly important in the provision of health care in England. Patients are
being provided with information relating to health conditions and available treatments and are being
empowered to influence the care that they receive. Given this, it is important to factor their preferences
and demand for aspects of care in to the design of new services. This chapter described the application
of a stated choice technique, the DCE, to understand patient preferences for OPAT services.
The use of DCEs to inform the design of health services is a well-established approach.100,127 The models
estimated on such data explain the choices that respondents (in this case, patients) make in individual
choice scenarios through estimating their sensitivities to the different characteristics that describe the
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FIGURE 6 Preference for half-day training (utility score; 1 full day as base).
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alternative options they can choose from, in this case models of care. Although basic models assume that
the sensitivities to individual service characteristics are constant across patients, more advanced models
allow for differences across patients, some of which can be linked to sociodemographic characteristics and
others of which are a function of attitudes; a remaining layer of heterogeneity is purely random.
This research is the first attempt to understand patients’ preferences for OPAT services and one of the most
in-depth explorations of the role of patient attitudes in influencing health-care preferences. The attributes
of the service were selected on the basis of the qualitative interviews and systematic review literature which
showed which of these are important to patients. The choice survey offered three service options (four
including two types of nurse) described by eight attributes (two of these embedded in other attributes).
The attributes mainly comprised process aspects of care, including the number of treatments per day,
whether or not appointments were given, who delivers the treatment and the level of communication and
aftercare provided. However, we did include a health outcome aspect, which was the level of risk of an
adverse event.
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FIGURE 8 Communication over telephone (utility scores; base= unknown).
–1.2
–1.0
–0.8
–0.6
–0.4
U
ti
lit
y 
(v
s.
 b
as
e) –0.2
0.0
0.2
Risk of 1 in 6 Risk of 1 in 10
Aged < 65 years, 
not working
Aged < 65 years, 
working
Aged > 65 years, 
not working
Aged > 65 years, 
working
FIGURE 9 Risk (utility scores; 1 in 25 as base).
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
The results indicate that when we look across respondents and do not take sociodemographic variables
into account, the type of service is the most important factor, with the nurse at home being strongly
preferred to HO treatment and SA. The next strongest sensitivity relates to treatment frequency, with once
per day treatment being strongly preferred to two treatments or continuous treatment. This was closely
followed by the preference for the lowest level of adverse event risk. Although other attribute levels were
significant in determining respondents’ choices, they were less important. People preferred a SN to a
doctor and GN to deliver their intravenous antimicrobials (IVA), preferred an appointment time (to not
having one) and preferred to communicate with someone they know regarding their care. These sources
of process utility are clearly important to patients and this is a consistent finding across stated preference
studies.128 The order of attribute preference was relatively stable across the short- and long-term infection
groups. Indeed, significant differences were not observed for preferences for treatment type or key
characteristics such as risk, with differences only for appointment times, training and seeing or speaking to
someone the patient knows. Generally, the findings (see also the detailed results in Appendix 3) are in line
with the qualitative results, which suggest that no one model is preferred by all patients, with strong
heterogeneity across different patient types, albeit with an overall average preference for the nurse at
home model. The choices that people make about their health care are influenced by a number of patient
characteristics as well as by more general attitudes towards health care.
In this study, younger patients tend to prefer to come to hospital for their care, and older people tend
towards a preference for a nurse at home model, compared with the alternative treatments. Previous studies
have focused on the acceptability of OPAT more generally,36,84 or have compared acceptability of OPAT with
inpatient treatment,12,25,41,56 and have not examined whether or not patients receive a model of care that
fits their needs. However, our qualitative work (see Chapter 4) sheds some light onto these findings, as it
showed that younger people find hospital attendance to be convenient and older people find it less so,
particularly if they do not have their own transport or if their infection leaves them feeling unwell. Given that
older people tend to have more comorbidities than younger people, it is not unsurprising that older people
prefer to be looked after in their own homes. It is also possible that people who need to travel to work
would find it more convenient to visit a hospital for treatment.
Regardless of the model of care preferred, there are some issues that cut across models of care. Overall, there
was a preference for once-daily antimicrobials and for follow-up at the end of treatment, which patients
would prefer to be face to face rather than by telephone. The qualitative interviews found that many patients
did not see a doctor again after they were diagnosed and given their course of i.v. antimicrobials, and this
may go some way to explaining the preferences expressed. The interviews with health-care professionals (see
Chapter 3) found that patients generally do get reviewed while on their i.v. treatment; however, this is often
done as a ‘virtual ward round’, of which the patients are unaware, and, thus, they are left feeling abandoned
at the end of their treatment. The results also revealed that many patients prefer to see, and speak to, a
health-care professional who is known to them, although this preference did not hold for all patient groups.
Similar findings were identified by our systematic review,69 and Talcott et al.87 reported that some patients felt
more isolated at home, than as an inpatient. These feelings may contribute to the desire to be seen at the
end of treatment. These perceptions also accord with the notion of continuity of care, which some consider
to be a ‘cornerstone of care’.129,130 Continuity can be defined in terms of longitudinality, but can also be
characterised as a structural element of care, largely controlled by the care provider, which means that there
are processes and mechanisms in place to ensure that information is passed on efficiently and problems are
adequately followed up from one visit to the next.131 Patients’ wishes to have contact with staff they know
and to be followed up after the end of treatment are therefore something that services should consider
when reviewing or setting up services.
Although wide levels of preference heterogeneity were observed, certain trends were apparent. For example,
age and cohabitation circumstances were consistently important determinants of choices. The finding that
older patients who live alone have a strong preference for longer training sessions, face-to-face contact and
contact with SNs suggests that this group exhibits greater anxiety about IVA and requires greater support.
On average, people preferred less risk, but there were some groups that did not differentiate between the
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risk levels. We were unable to establish the marginal rates of substitution between risk and other service
attributes as risk did not appear to be linear. This may reflect a real non-linear attitude to risk or be a
function of the specific survey design employed here.132 The risks here are higher than those likely to be
faced in reality (see the risks used in the economic models used in Chapter 6).
Strengths and limitations
Despite recruiting in NHS trusts with a significant ethnic minority population (10–20%) we were unable
to recruit as many people from ethnic minorities as we would have liked. However, the proportion of individuals
from ethnic minorities in our sample is in line with the England average. This may be because we did not offer
the DCE in languages other than English, but we have no evidence to support this assertion, as only limited
data are available on non-participants. This means that issues that may be relevant to the non-white population
have perhaps not been sufficiently explored. We are also conscious that all interviewees upon which the DCE is
based were from white British ethnic backgrounds, and so we may have missed issues that are of importance
to the non-white population; this is a potential source of bias in respect of the attributes themselves. However,
the literature that informed the development of the attributes and their levels comes from a range of countries.
Although ethnic mix was not reported in any of these studies, literature from the UK,5,35,69 France,84 New
Zealand,36 Sweden,71 Ireland2 and Canada37 was used, which does provide some evidence to support the
robustness of the attributes.
Some of the options contained in the DCE do not represent current practice. Nurse-led clinics are common in
other health-care situations, but much less so in OPAT, and so we wanted to explore patients’ willingness to
be followed up in this way, given that, currently, many patients are not seen in clinic at the end of treatment.
Likewise, doctors almost never administer i.v. treatment but some patients in our interview study talked in
depth about the importance of the doctor, so we included this to test what patients would be willing to
trade off to receive care in this way.
Patient preconceptions and past experiences may influence the findings, but evidence suggests that past
experience is only a weak predictor of future behaviour,133 and in the present study few patients had
significant OPAT experience to draw upon. Only adults who had previously experienced OPAT were
included; those who would be eligible for OPAT but were not offered the service were not included, and
this population may respond differently. The reason for the sampling used in this study was that the
original protocol included the collection of anonymised data from the DCE participants, so that only those
who had received OPAT were eligible.
Implications
By quantifying patient preferences for attributes of care, commissioners can use the results of this study to
inform changes to service provision so as to obtain the best outcomes within a given budget. The results
indicate that where one model of OPAT care is envisaged, a nurse at home model is likely to be preferred by
patients. However, where possible, a range of options should be available. The most promising model
would be one that offered a SN at home model, utilising one-a-day treatments (where safely available).
The service should have a dedicated team of staff caring for patients and have robust governance processes
in place to ensure that patients receive continuity of care (i.e. good handover and communication between
staff) and are followed up at the end of treatment by a nurse, or where clinically appropriate, a doctor. The
qualitative data (see Chapter 4) triangulate the DCE findings and suggest that patients’ attitudes towards
health care are important and could form a target for future intervention. The preferences across short- and
long-term infection patients were quite stable, suggesting that people in these groups value similar service
attributes. Given this, OPAT services may work across infection types.
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These findings are likely to be useful in determining future service provision in this area, which takes
account of patient preferences. It will help NHS trusts that want to introduce OPAT services by providing a
rationale for service configuration.
Caveats are required, however, in translating the results found here into service commissioning. First, we
must acknowledge that only services that represent value for money should be offered to patients. The
benefits of the services in our DCE were (with exception of risk) based on process utility and not health
outcomes. Although convenience is important, and may offer indirect health benefits (e.g. through better
adherence), we must be cautious in attributing too great a value to it. Second, the DCE provides information
only on stated preferences and may not accurately reflect the choices people would make if faced with the
same options in reality. Additional research is required to understand if and how stated preferences in health
could be calibrated to better reflect revealed preferences to facilitate service design and planning.
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Chapter 6 Cost-effectiveness: report on the
economic modelling of Community IntraVenous
Antibiotic Study services
Introduction
Although there is encouraging evidence relating to the safety and effectiveness of OPAT from observational
and cohort studies, stronger evidence in the form of RCTs is lacking.114,134 Furthermore, although several
observational studies have reported bed-day savings resulting from the introduction of OPAT, robust
economic evaluations of OPAT services are few.134 A recent systematic review of cost-effectiveness analyses
of OPAT services found a number of studies presenting cost analyses but none that would meet the
technology appraisal reference case criteria set out by NICE.135 These studies incorporated a number of
OPAT service models and antimicrobial (both oral and i.v.) service comparators, including inpatient care and
early discharge with oral treatment. The patient populations were varied too, including those with surgical
site infections,66 MRSA-complicated SSTIs,136 cystic fibrosis,53 febrile neutropenia65 and prosthetic joint
infections.24 Of the studies identified in the review, only one presented an incremental cost–utility analysis.65
Using a Canadian health-care provider perspective, the authors in the study found oral antimicrobial
treatment at home to be cheaper and less effective than home i.v. treatment and that home i.v. treatment
dominated (i.e. were cheaper and more effective than) hospital-based services.65
It is possible that the evidence gap in this area has stymied investment from decision-makers and service
commissioners. In the absence of RCT evidence and robust economic evaluations to commend one OPAT
service over another, commissioning in the area is fraught with uncertainty, barriers to the wider adoption
of services remain and geographical variation in service provision pervades. It is clear that further research
is required to inform decision-making. However, given that research resources are scarce and RCTs often
expensive and relatively slow to yield results, it is imperative that they are streamlined to answer the
important questions and include the comparators most likely to be cost-effective. This is especially true in
OPAT i.v. antimicrobial services in which a number of service configurations are possible. As such, formal
characterisations of the value of research137,138 might be beneficial in determining the research agenda in
OPAT. The aim of the research described in this chapter was to conduct a decision-modelling-based
economic evaluation to estimate the cost-effectiveness of different OPAT services and the value of
additional research in order to: (1) provide evidence for decision-making and (2) inform future research by
identifying which services should feature in future RCTs and where the greatest uncertainty lay.
Markov models are the most common type of decision-analytic model employed in economic evaluations.
Although they offer an efficient method of generating estimates of cost-effectiveness and value of
information, there are certain restrictions imposed by their structure. Markov models do not readily provide
information on health-care resource capacity, treatment queuing and delays or required staffing levels
given a patient population size. A patient simulation approach to modelling is required to overcome these
limitations and to provide this information. With this approach it is possible to create mathematical
representations of the process and operation of a system, which enables the analyst to experiment and
test interventions and scenarios, evaluating their consequences in real time.139 Two approaches were
therefore adopted for the evaluation. One approach used a Markov modelling strategy to generate
estimates of cost-effectiveness and value of information and a second approach used patient-level
simulation modelling to provide information on service resourcing.
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Methods
Decision analysis is an explicit, quantitative and systematic approach to decision-making under conditions
of uncertainty.140 Decision-analytic modelling in health is an analytical approach allowing an economic
evaluation of (at least two) alternative courses of action (i.e. treatments or services) that formally
characterises the uncertainty in the decision. The decision model is created to reflect the health-care
process or pathway, capturing the events that occur to the patient or health system during care and
estimating the expected costs and (dis)benefits of the treatment options. Hypothetical patients enter the
model and pass through ‘health states’ that represent the health events. Each health state has costs and
quality-of-life values associated with it, and the route of the patients through the model is determined by
‘transition probabilities’. Decision-analytic models were developed with best practice in mind141 to estimate
the cost-effectiveness of four OPAT service models. The value of information framework142 was employed
to estimate the value of, and priorities for, future research. Both Markov and simulation modelling
approaches were adopted; these are described separately below.
Markov models
Population, interventions, comparator, outcomes and perspective
The population of interest was broadly considered to belong to one of two groups: those with SSTIs
and other short-term infections (short term) and those with longer-term or chronic infections such as
joint and bone infections and cystic fibrosis (long term). For the purpose of the analysis we defined
short-term infections as any SSTI or infection that, on average, would require, at most, 7 days of IVA or
any non-complex SSTI. Infections requiring longer courses of treatment or recurrent infections were
considered long term. These two groups posed distinct decision problems and, therefore, estimates of
cost-effectiveness were generated separately for short- and long-term infection patients.
After discussions with clinicians it was clear that (inpatient) hospital admission should not be a comparator
for the analysis and that the research question should focus on identifying which of the OPAT models was
most cost-effective. Although it is acknowledged that many service configurations exist, the four identified
as most common in a survey of OPAT units conducted in the programme of research were: outpatient
attendance at hospital (HO), treatment provided at home by a GN or district nurse or by a specialist OPAT
nurse and SA following training provision (SA). The HO service involves patients attending a HO clinic to
receive IVA on a daily basis. In the nurse-led services, nurses administer IVA in the patient’s home on a
daily basis. However, the GN administers IVA as part of a range of care provided, whereas the SN is
dedicated to delivering OPAT services. Although it is possible that more than one IVA administration is
required per day, we assumed that all patients received once-daily treatments, as this is common and
increasingly the treatment strategy of choice. Finally, it was assumed that SA patients were given a 2-hour
training session and delivered their own IVA on a daily basis but were followed up by nurses through
face-to-face visits and telephone calls. Patients in the GN, SN and SA services are required to visit the clinic
(one visit assumed in the short term and fortnightly visits in the long term) for a consultation with a doctor
and to review test results. In the long term, these groups also visit the clinic for a final review and check-up
at the end of IVA treatment. It was assumed that each service used the same i.v. antimicrobial. The service
models are outlined in detail in Tables 12 and 13.
Following expert clinical advice it was decided not to include the SA service in the short-term model, as it
was unlikely to be offered to (or demanded by) this patient group. It was also decided to consider HO as
‘standard’ OPAT care in the UK, even though there is geographical variation in service provision. Thus, for
the purpose of modelling, the comparisons for the short-term infection group were: HO versus GN versus
SN; and for the long-term infection group: HO versus GN versus SN versus SA. The primary outcome for
the analysis was cost per QALY. The primary cost perspective chosen was that of the NHS and Health and
Personal Social Services (HPSS). We chose this as the primary perspective in order to conform to the NICE
technology appraisal guidance reference case. A sensitivity analysis considered a combined HPSS and
patient perspective, which incorporated patient out-of-pocket costs.
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Model horizon, structure and assumptions
The model structure (Figure 10) was informed by a rapid review of published infection decision models and
by discussions with patients and clinicians. Cohort Markov models were constructed with daily cycles until
the cohort was healed (or switched to oral antimicrobials) or died. The patient cohort receive one of the
OPAT services and every cycle were either healed (or switched to oral treatment), experienced a severe
adverse reaction to the treatment (e.g. anaphylactic shock), contracted Clostridium difficile infection (CDI)
or contracted a severe secondary-line infection (e.g. Staphylococcus aureus). If patients experienced any of
these negative health events then they were subject to a mortality risk. In addition to the more severe
negative events, those who were not healed were exposed to a daily risk of a mild adverse event (such as
rash, nausea, vomiting, dizziness, fever and minor line events). These events and the associated costs are
incorporated within the ‘not healed’ health state and are not associated with a quality-of-life decrement as
they are both mild and transient in nature. However, a sensitivity analysis did employ a utility decrement
for these events. It was assumed that they do not increase time to heal.
All patients began in the ‘not healed’ state and moved between the health states according to pre-specified
probabilities. The cohort of patients flow through the model pathway accruing costs and quality-of-life
penalties or ‘decrements’ until they are healed or die or until the model has ended. A sensitivity analysis
explored the impact of some patients ‘relapsing’ and needing to receive IVA again after they had been
switched to oral antimicrobials. Even though the costs and benefits of IVA treatments may register after the
infection period (e.g. those who die as a result of an adverse event will lose future QALYs), we decided to
limit the model horizon to the infection period. This was mainly due to the expectation that very few deaths
TABLE 12 Outline of OPAT service models: short term
Service
HO GN SN
Initial consultant-led outpatient
clinic visit
Initial home visit by GN (1.5-hour duration) Initial home visit by SN (1.5-hour duration)
Once daily non-consultant-led
outpatient clinic visit
Daily home visit by GN (1-hour duration) Daily home visit by SN (1-hour duration)
One consultant-led outpatient clinic
review visit
One consultant-led outpatient clinic
review visit
Daily IVA delivery Daily IVA delivery Daily IVA delivery
TABLE 13 Outline of OPAT service models: long term
Service
HO GN SN SA
Initial consultant-led outpatient
clinic visit
Initial home visit by GN
(1.5-hour duration)
Initial home visit by SN
(1.5-hour duration)
2-hour training provided by nurse
and IVA self-administered
Once daily non-consultant-led
outpatient clinic visit
Daily home visit by GN
(1-hour duration)
Daily home visit by SN
(1-hour duration)
Weekly home visit by nurse
(1.5-hour duration)
One consultant-led
outpatient clinic review
visit every 2 weeks
One consultant-led
outpatient clinic review
visit every 2 weeks
One consultant-led outpatient
clinic review visit every 2 weeks
One consultant-led
outpatient clinic visit at
IVA end
One consultant-led
outpatient clinic visit at
IVA end
One consultant-led outpatient
clinic visit at IVA end
Daily IVA delivery Daily IVA delivery Daily IVA delivery Daily IVA delivery
Pump/balloon delivery device used
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would occur and, hence, the additional complexity and computation time required to model a longer time
horizon would not be worthwhile. The time horizons chosen for the short-term (3 months) and long-term
(12 months) models reflected the expectation that a vast majority of infections would have resolved within
these periods. It was assumed that the period of time spent on oral antimicrobials and their effectiveness
was the same across service models and unrelated to their IVA treatment. Given this, it was assumed there
were no differential resource use or quality-of-life effects of oral treatment and that modelling these
outcomes was not warranted.
The transition probabilities, costs and utility parameter values required for the models were taken from a
number of sources including a systematic review134 and expert clinical opinion. In addition, hospital records
of a group of patients (n = 503) who had recently received OPAT care were gathered and used to generate
parameter values (Table 14 provides sample characteristics).
TABLE 14 Hospital record data: sample characteristics
Characteristic Short term (N= 223) Long term (N= 280)
Female, n (%) 90 (40.36) 133 (47.84)
Age (years), mean (SD); range 52.85 (16.36); 18–89 52.59 (18.25); 18–94
Ethnicity, n (%)
White 195 (87.44) 257 (91.79)
Asian 20 (8.97) 16 (5.71)
Black 2 (0.9) 3 (1.07)
Mixed ethnicity 6 (2.69) 4 (1.43)
Type of service received, n (%)
HO 154 (69.37) 63 (22.58)
GN 18 (8.11) 68 (24.37)
SN 36 (16.22) 34 (12.19)
SA 0 (0.00) 68 (24.37)
Combination 14 (6.31) 46 (16.49)
Type of infection, n (%)
Cellulitis/SSTI 196 (87.89) 44 (15.71)
Cystic fibrosis 0 (0.00) 44 (15.71)
Respiratory 8 (3.59) 37 (13.21)
Bone and joint 0 (0.00) 73 (26.07)
Cardiovascular 1 (0.45) 11 (3.93)
Urinary tract 3 (1.35) 7 (2.5)
Intra-abdominal 2 (0.9) 7 (2.5)
Other 13 (5.83) 57 (20.36)
Number with infection in past 6 months 55 (24.66) 154 (55.0)
Number with complex infection 0 (0.00) 75 (26.79)
C-reactive protein level 87.28 (93.01) 80.46 (99.52)
White blood cell count 10.11 (3.55) 10.84 (5.12)
Days to heal, mean (SD); range 5.77 (5.35);1–55 28.54 (20.64); 4–119
continued
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Time to heal was calculated by type of infection and after controlling for a number of factors including
markers of infection severity (e.g. C-reactive protein levels and white cell blood count) and patient
characteristics (e.g. whether or not they had experienced previous infections in the past 6 months). We
applied a negative binomial regression model, as the variable of interest (days to heal) was a non-negative
count variable with a wide dispersion (there were several outlier patients with relatively long heal times).
We used the margins command in Stata (StataCorp LP, College Station, TX, USA) to produce predictions
(and associated standard errors) holding all other covariates at their means. A number of the severity markers
were entered into the model as categories: white blood cells as ‘normal’, ‘mild’, ‘severe’ or ‘not known’;
and C-reactive protein levels as 0–40mg/l (normal or mild), 40–200mg/l (active) and > 200mg/l (severe).
The final model for the adjustments was:
Y^ = α + βCR0…CR2XCR0…CR2 + βWB0…2XWB0…2 + βS0…4XS0…4 + βCXC + βPr XPr, (1)
where Yˆ = time to heal in days; βCR0. . .2 = dummies for C-reactive protein level groups; βWB0. . .2 = dummies for
white blood cell groups; βS0. . .4 = dummies for OPAT service type; βC = complex infection and βPr = previous
infection in past 6 months.
The adjusted time-to-heal figures for the short and long term are included in Table 15 along with their
standard deviations. The cost of resource use was calculated on a daily basis for all services combined
using the same variables and the β on days to heal being the adjusted value employed in the model.
Parameter values
Transition probabilities
The systematic review could only identify effectiveness and risk values presented in observational studies.
These were of limited value, as there was unlikely to be equipoise in service provision; for example, some
departments may have considered only certain patients (e.g. less severe or more independent) for
particular OPAT services. Given this, the patient-level data from records was utilised as it allowed the
possibility of controlling for severity. In the models, ‘not healed’ patients could travel to the CDI state
according to a daily probability based on the time they spent in a hospital environment or in contact with a
GN or SN. It was assumed that HO patients had a greater chance of developing CDI than those patients
treated at home, and the smallest risk was for those in the SA service. The daily mortality rate (0.0004) and
mean time to recover from CDI (16 days) was the same across services. Owing to the constraints of the
Markov model, it was assumed that the original infection of patients with CDI or secondary-line infection
was healed concurrently with the resolution of the adverse event. Severe adverse reactions were assumed
to last for 1 day only and after this the patient returned to the ‘not healed’ state to start their course
TABLE 14 Hospital record data: sample characteristics (continued )
Characteristic Short term (N= 223) Long term (N= 280)
Side effects, n (%)
Rash 3 (1.35) 5 (1.79)
Nausea/vomiting 3 (1.35) 12 (4.29)
Dizziness 1 (0.45) 2 (0.71)
Fever 2 (0.90) 1 (0.36)
Diarrhoea 5 (2.24) 4 (1.43)
Infection of i.v. access device 1 (0.45) 2 (0.71)
Blocked i.v. device 9 (4.04) 13 (4.64)
Other 23 (10.31) 52 (18.57)
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TABLE 15 Parameter values: effectiveness and risks
Parameter Mean SD Distribution Source
Short-term model effectiveness (days to heal)
HO 4.73 0.24 Gamma Adjusted hospital record data
GN 7.36 1.00 Gamma Adjusted hospital record data
SN 6.33 0.65 Gamma Adjusted hospital record data
Long-term model effectiveness (days to heal)
HO 27.21 2.30 Gamma Adjusted hospital record data
GN 31.16 2.65 Gamma Adjusted hospital record data
SN 25.46 3.02 Gamma Adjusted hospital record data
SA 28.20 2.52 Gamma Adjusted hospital record data
Daily risk of an anaphylactic shock 0.00005 0.00099 Beta Matthews et al.29
Anaphylactic shock
Anaphylactic shock mortality risk
HO 0.067 0.04480 Beta Hopf et al.143
GN 0.13 0.04480 Beta Assumed double HO risk
SN 0.13 0.04480 Beta Assumed double HO risk
SA 0.27 0.04480 Beta Assumed double GN/SN risk
Risk of CDI
HO 0.000105 0.000023 Gamma Hourly risk × 4100
GN 0.0000087 0.000004 Gamma Assumed third HO risk and
1-hour contact
SN 0.0000087 0.000004 Gamma Assumed third HO risk and
1-hour contact
Self-administered OPAT 0.00 N/A Fixed Assumed no risk
Time to heal from CDI (days) 16 0.40 Log normal Forster et al.144
Daily CDI mortality risk 0.00040 0.00004 Beta Wiegand et al.145
Risk of a line infection that leads to a S. aureus
infection
0.00052 0.01580 Gamma Barr et al.40
Time to heal from S. aureus 17 0.32 Log normal Forster et al.144
Daily S. aureus mortality risk 0.0092 0.03346 Beta Thwaites et al.146
Short-term model: mild adverse events
HO 0.020 0.006 Gamma Hospital record data
GN 0.046 0.032 Gamma Hospital record data
SN 0.054 0.025 Gamma Hospital record data
Long-term model: mild adverse events
HO 0.008 0.003 Gamma Hospital record data
GN 0.007 0.003 Gamma Hospital record data
SN 0.009 0.004 Gamma Hospital record data
SA 0.033 0.009 Gamma Hospital record data
Probability of infection relapse
HO 0.0 N/A Beta Assumed 5% lower than SN
GN 0.0 N/A Beta Assumed same as SN
SN 0.0 N/A Beta Lillie et al.147
SA 0.0 N/A Beta Assumed same as SN
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of i.v. antimicrobials from the beginning. The same values were assumed across services for the risk of a
secondary infection and associated recovery time and mortality. Hence, the duration of treatment was
considered the main driver for adverse events. The daily risk of a severe adverse reaction was also assumed
to be equivalent for each service type, but the mortality risk associated with this for those being treated by
nurses at home was assumed to be double that of those in the HO service and for those self-administering
was assumed to be double the risk presented by the nurse services.
The ‘effectiveness’ parameter in the model was defined as the number of days of treatment required
before the infection was resolved or the individual was moved on to oral antimicrobials. This value is
somewhat attenuated in OPAT services because patients are often prescribed a fixed number of days of
treatment depending on the underlying infection aetiology; for example, a SSTI may be automatically
prescribed 7 days’ worth of IVA. However, the hospital record data appear to suggest that there are
differential treatment periods by service. We applied adjusted ‘time-to-heal’ values for the base-case
analysis with sensitivity analyses exploring the same heal time across services.
A differential risk of mild adverse events was added for each service based on analysis of the hospital
record data. The base-case analysis assumed that the relapse rate was equivalent between services and zero,
as it was assumed that the heal time used would capture the additional time for those who had relapsed.
However, a scenario analysis was conducted in which heal time was assumed equivalent but a differential
relapse rate was adopted. This relapse value was based on a recent UK study147 for SNs and was used for all
services except for HO. We reduced the HO relapse rate by 5%, as it was thought that frequent observation
of the patient in the hospital setting would allow greater confidence in stopping treatment and better review
decisions. Thus, the model is structured such that the risks, costs and quality-of-life impacts are driven by the
duration of treatment; services that are slower to resolve the infection expose the patient to greater risks of
CDI and secondary infections, incur more visit costs and longer periods with reduced quality of life.
Resource use and costs
The costs for the service models were developed with input from the clinical experts and from the
accounts of resource use from the hospital records and are included in Table 16.
These costs broadly cover: antimicrobial costs, additional expenses required for SA (training and equipment
such as specialist delivery devices), nurse (including paperwork and travel) and hospital visit costs for IVA
delivery and reviews, additional health-care resources used (e.g. GP visits) by the patient and costs associated
with severe adverse events (e.g. hospitalisation following secondary infection). The costs of adverse events
were based on published estimates of the length of stay (or time to recover) per event, multiplied by a
TABLE 16 Parameter values: resource use and costs
Resource usea
Mean
cost (£)b Source
HO
First visit 237.68 NHS Reference Costs 2013–14: consultant-led infectious disease outpatient
visit, first visit148
Subsequent visit 145.23 NHS Reference Costs 2013–14: non-consultant-led infectious disease
outpatient follow-up visit148
GN
GN visit 33.04 PSSRU 2014: community nurse (band 6). Band 5 equivalent estimated using
mid-range salary (£24,063).c Hourly cost. Each visit = 1 hour except first,
which = 1.5 hours149
Paper work per visit 7.30 As above. Assume 10 minutes149
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TABLE 16 Parameter values: resource use and costs (continued )
Resource usea
Mean
cost (£)b Source
SN
SN visit 33.04 PSSRU 2014: community nurse (band 6). Band 5 equivalent estimated using
mid-range salary (£24,063).150 Hourly cost. Each visit = 1 hour except first
which = 1.5 hours149
Paper work per visit 7.30 As above. Assumes 10 minutes149
SA
Training session cost 66.08 £33.04 × 2.149 Assumes delivered by band 5 community nurse over 2 hours
Eclipse balloon/pump device 52.96 Per-patient: based on expert opinion
Check-up nurse visit once a
week (daily cost)
4.72 PSSRU 2014: community nurse (band 5)149
Two telephone calls per week
(daily cost)
0.94 PSSRU 2014: Community nurse (band 5).149 Assumes two telephone calls
lasting 6 minutes
General costs
Cost for use of health-care
services (per day)
12.81 Hospital record data
Antimicrobial treatment
(per day)
24.59 Hospital record data
Resource use costs
GP surgery visit 44.35 PSSRU 2014149
GP home visit 113.45 PSSRU 2014149
District nurse visit 39.62 PSSRU 2014149
Inpatient care cost 208.33 NHS Reference Costs 2013–14148
Outpatient care costs 146.45 NHS Reference Costs 2013–14148
A&E cost 117.58 NHS Reference Costs 2013–14148
Cost of adverse events
Cost of severe line infection
treatment
236.66 NHS Reference Costs 2013–14: assumed equivalent to kidney or urinary
tract infections, with interventions excess bed-day (LA04L)148
Cost of CDI treatment 289.62 NHS Reference Costs 2013–14: assumed equivalent to kidney or urinary
tract infections, with Interventions excess bed-day (LA04L) and isolation
cost148
CDI isolation cost 52.96 Updated guidance of the diagnosis and reporting of CDI. Department of
Health 2012151
Cost of treating anaphylaxis 732.34 NHS Reference Costs 2013–14: shock or anaphylaxis, with CC score of 1
(WA16W) total HRG148
Patient visit costs
Patient travel per day (miles) 6 Assumption
Mileage costs (per mile) 0.67 NHS expense reimbursement rate
Car parking per visit 6.30 £4.20 per hour for 1.5 hours: assumption
CC, compatibility and comorbidity; HRG, Health Resource Group; PSSRU, Personal Social Services Research Unit.
a All costs were inflated to 2015 prices using a health, purchasing power inflator and were fixed (http://eppi.ioe.ac.uk/
costconversion/).
b All resource use and costs assumed to be fixed.
c See www.rcn.org.uk/support/pay_and_conditions/pay-rates-2015-16.
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bed-day cost. The resource use by the patient was based on the hospital record data which reported
secondary and primary care health-care usage during their last infection.
Utility values
Targeted searches of published literature were employed in addition to searches of databases152,153 to identify
utility values. Utility values were similar for short- and long-term infection patients when healed, but during
infection the long-term patients experienced a much larger utility drop, as these infections were believed to
be more severe in nature. Those contracting CDI experience a moderate drop (–0.115) in utility, whereas
those who experience a secondary-line infection are subject to a more substantive utility decrement
associated with being hospitalised (–0.240). No utility loss was assumed following mild events in the main
analysis but one was added for a sensitivity analysis. In addition, we collected EQ-5D (three-level) utility data
from a group of IVA patients who were participating in the discrete choice aspect of the funded research
programme; these base values were included as a sensitivity analysis. Finally, because the mortality risk linked
to adverse events presents a risk of reduced length of life, a lifetime QALY loss value (16.6) was estimated.
This represented the discounted (at 0.035% per annum) total QALYs lost for individuals who died during the
model time horizon using an average starting age of 50 years, survival estimates from life tables and ‘healed’
utility values. This discount rate was used as it conforms to the NICE reference case (Table 17).
Analyses
The model was run separately for each service and yielded expected costs and effects. In line with the
NICE reference case,135 the effects considered were (QALYs and, in the main analysis, a cost–utility analysis
presenting incremental cost-effectiveness ratios (ICERs) where appropriate.158 Services with an ICER
< £20,000 in the incremental analysis were considered cost-effective. Net monetary benefit (NMB) was
also calculated (QALY × £20,000 – cost) for each analysis and cost-effectiveness was assumed for a service
when the incremental NMB over a comparator service was positive (> £0). An analysis of the hospital data
suggested there was insufficient heterogeneity in outcomes or risks based on patient characteristics to
justify subgroup analyses or a need to control for heterogeneity in analyses. With the exception of the
QALY loss estimation following death, all model outcomes were realised by 12 months and, therefore, no
discounting was required. All prices are in presented in 2015 UK pounds sterling. A half-cycle correction
was not employed as the cycles were daily and, therefore, the timing of health state transitions during the
cycle were assumed not to have an impact.
TABLE 17 Parameter values: quality of life/utility
Parameter Mean SD Distribution Source
Utility short term
Not healed 0.4360 0.342 Beta Mason et al.154
Healed 0.7395 0.280 Beta Mason et al.154
Utility long term
Not healed 0.0100 0.400 Normal Bernard et al.155
Healed 0.7200 0.300 Beta Bernard et al.155
Common parameters
Hospital-acquired CDI –0.1150 Fixed Beta Konijeti et al.156
Utility loss per hospital stay owing to line
infection/anaphylaxis
–0.2400 0.0300 Beta Assumed same as for asthma patients157
Death –16.660 Fixed Fixed Life tables UK based on mean age of
50 years and not healed utility value
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Simulation models
Simulation modelling techniques such as discrete event simulation (DES) afford the opportunity to
‘replicate’ an OPAT service in a community and estimate the number of resources (nurses and rooms/beds)
required to cover a specific population. DES is an individual-level modelling technique that originated in
the operational research field but is increasingly being used in a health context. The core concepts of a
DES model are ‘events’, ‘entities’, ‘attributes’, ‘activities’, ‘queues’ and ‘resources’. The ‘entities’ are a
representation of individuals or patients who move through different ‘activities’ in a pre-defined pathway.
The entities possess certain ‘attributes’ (or history) such as whether or not they have experienced a
particular adverse event which can be modified when performing certain ‘activities’ in combination with
different ‘resources’. Those modifications influence the entities’ future movements through the pre-defined
pathway. ‘Queues’ can be formed when entities are about to pass through the different activities and this
is determined by the number of entities, number of resources and time taken to undertake the activity. In
contrast to a Markov model, time is measured as a continuum but evaluated when an events occurs. In the
context of an OPAT service, the DES model not only allows patient history to be considered (via attributes),
but also the operational aspects of an OPAT service as nurses and/or beds can be represented by
‘resources’ and home or outpatient visits as ‘activities’.
Simulation models have been used previously in health to optimise the use of resources and inform
decision-making. The Mayo Clinic’s Centre for Health Care Delivery (Rochester MN, USA) used a DES
model to predict the minimum number of beds needed to meet patient demand and the clinic’s quality
standard of care.159 Elsewhere, Troy and Rosenberg160 estimated the required number of beds for an
intensive care unit in Canada, and Cipriano et al.161 evaluated different strategies to reduce waiting time in
a total joint replacement unit in Canada. The aim of the current analysis was to replicate the operation of
OPAT services to estimate the amount of resources required to run OPAT services in England and Wales
taking into account cost-effectiveness and size and type (e.g. rural vs. urban) of population. As the
DES technique is an individual-level analysis, instead of a cohort of patients, individuals are followed
through a defined pathway in the model. However, the population, model structure and evaluated
services are otherwise the same as that used for the Markov modelling. Any divergence in methods is
described below.
Model horizon, structure, assumptions and perspective
As with the Markov model, patients enter the simulation after being referred to the OPAT service: HO,
GN, SN or SA. Although the simulation model also used daily cycles, it ran for the same period for both
short- and long-term infections (12 months). This was longer than the short-term Markov model as the
simulation model may run for longer as it is better at capturing the real length of health events. The first
step of the simulation assigns patients to one of the four services to commence treatment. The initial
treatment for the patients on the GN service would require a home visit of a GN, whereas for the SN and
SA services a home visit by a SN to commence treatment or training was necessary. The HO service
required a private room in the clinic of the hospital for the service to be delivered.
Although GN and SN service patients ‘wait’ for the nurse visit to deliver their IVA, HO patients wait for an
available bed and SA patients administer their own IVA. The duration of the wait is dependent on the
availability of resources (nurses and rooms). This availability was given by the number of nurses available,
the time required to administer the i.v. service (including travel time) and the working hours (clinic and
nurses). As such, if the availability of nurses is limited owing to lack of personnel or high number of
patients to be treated, the size of the ‘wait’ will increase. We included a sensitivity analysis in which
departments subcontracted a private nurse service to cover any unmet demand (at higher cost) to reduce
or prevent delays in care.
As the resource and safety elements are crucial to the functioning and viability of the services, these
components were explored further by adding a delayed treatment state to the model. Patients who were not
able to be seen within 24 hours for their IVA travelled to this state, as their missed treatment would result in
an outpatient visit and a risk of admission to hospital owing to a worsening of their infection. Modelling this
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eventuality allows us to determine the minimum number of resources needed to avoid delayed cases that
can lead to further costs and hospital admissions. Figure 11 shows the structure of the model.
Two different perspectives were used to estimate the costs of the services. The first refers to the HPSS in
line with the Markov model analysis. These are based on hourly costs and, therefore, nurse visits (general
or specialist) are costed based on the time they spend with the patient. If no patient is seen, the cost of
this resource is zero. There is also no limit to the resources available. The second costing perspective is that
of the commissioner of services. Here, the cost of a nurse is given by their annual salary irrespective of the
number of patients seen in any given time frame. Thus, hiring an additional nurse will represent an
increase in the costs equivalent to their annual salary but increase the resources available to treat patients.
The rest of the costs, such as hospital beds, outpatient service, etc., are costed from the HPSS.
Additional parameter values
The risk and effectiveness parameters were as represented in the Markov model. However, in contrast with
the Markov model, simulation has a ‘memory’; if one of the adverse events occurs, the patients would
receive treatment accordingly and when the event has been resolved they would continue with the
treatment of their infection from the point they experienced the negative outcome (rather than either
starting their IVA from day 1 again or being assumed ‘healed’).
As simulation can capture resources this is where the majority of additional information input to the model
was required. Both GN and SN services require a nurse (general or specialist accordingly) to operate.
Nurses working hours are divided by shifts (morning, afternoon or night shift) and they tend to operate
7 days a week. According to the Unit Cost of Health and Social Care 2014,149 community nurses work on
average 37.5 hours a week and 42 weeks per year. Annual leave was also taken into consideration, with an
average of 260 working days assumed per year on the basis of Unit Cost of Health and Social Care 2014.149
During the first visit it was assumed that they require 1.5 hours to administer the treatment, whereas the
subsequent visits were assumed to take 1 hour. Additional costs were added to allow for the completion
of all the patient-related paperwork, while a sensitivity analysis explored the cost of private nurse cover.
The SA service requires a SN to train and check on the patient. The initial training session takes place in the
patient’s home and was assumed to last for 2 hours on average. A check-up session occurs in the patient’s
home every week, with an average duration of 1 hour, and patients visit the clinic for a fortnightly review.
FIGURE 11 Simulation model structure. Screenshot from Simul8© [Simul8 Corporation (Boston, MA, USA)
www.simul8.com (accessed 8 November 2016)].
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In the HO service the patient would attend the clinic and be assigned to a private room where the i.v.
delivery is administered. It was assumed that the average time for a delivery was 40 minutes and that the
service operated for 4 hours per day.
Information from four OPAT services in the UK about the functioning of their service was collected and
used to populate the model. The information was used to set the initial conditions of the model. The
following variables were collected: number of nurses (district and/or private) and rooms available, shift
patterns, clinic working hours, average number of patients seen in a year and average time per treatment.
This information was used to estimate the actual capacity of the service. The utility values were the same
as those used in the Markov model except for an additional decrement applied when patients experienced
a delay in treatment.
Analyses
The simulation model based on the HPSS resource and cost perspective produced the same outcomes (cost
per QALY and ICERs) as the Markov model and these were compared. Owing to the different characteristics
of the models, they are not directly comparable, but a similar result will provide evidence of the robustness
of the results in both models. More interesting was the simulation model analysis using the commissioner
perspective. This permitted an estimation of the minimum threshold values such as the minimum number of
nurses needed to avoid delays or achieve greatest net benefit. It permitted the exploration of the effects of
reducing the number of staff or switching to private nurses and the impact of the changes in operational
hours. We also explored the commissioner perspective when responsible for a large or small population
(by varying the incidence of infections or patients requiring IVA) and the geographical spread of patients
(e.g. rural vs. urban services) by varying the time required for nurses to complete visits. In addition, a series
of different combinations in terms of the proportion of patients enrolled to each of the available OPAT
services in the community was explored. This aimed to provide information on an optimal combination of
service types within an OPAT unit given the amount of resources available.
Uncertainty
To test the sensitivity of the modelling results to the inherent assumptions and parameter values, a number
of deterministic one-way and scenario sensitivity analyses were conducted. A probabilistic sensitivity analysis
(PSA) was conducted (10,000 Monte Carlo simulation runs) to allow for random changes in all parameter
values at the same time based on pre-specified value distributions. These simulated analyses were plotted on
a cost-effectiveness plane and the probability that services were cost-effective given a range of QALY
willingness-to-pay thresholds was represented on the cost-effectiveness acceptability curve (CEAC).162
Distribution plots of incremental net monetary benefit (INMB) were also produced.
Value of information analysis
Given that the PSA characterises the level of uncertainty in the analysis, it is possible to cost this formally
based on the probability of making a ‘wrong’ decision regarding service provision choice using the value of
information framework.142 We estimated the expected value of perfect information (EVPI) for the population
based on the Monte Carlo simulated NMB, identifying in each case the net benefit loss by basing the
decision on the average net benefit rather than that based on perfect knowledge (each simulation). This
represents the individual value of perfect information and is multiplied by the population of interest over the
relevant decision period to gain the population EVPI. The higher the population EVPI, the greater the cost of
uncertainty and the greater the value of additional research. Should the EVPI exceed the expected research
cost for reducing uncertainty then investment in research is recommended.163
We assumed that the population that could benefit from the services to be 21,000 patients with short-term
infections. This figure is based on the assumption that 70,000 patients per year are hospitalised with SSTIs164
and approximately one-third of these could be eligible for IVA.137 Although not all of these would be
suitable for OPAT (e.g. owing to impaired functioning), this figure is likely to be an underestimate, as it does
not include other types of infection such as respiratory and urinary tract infections. To explore this issue we
have run the analysis assuming 100% could receive OPAT (n = 21,000) and a scenario in which only 50%
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are eligible for OPAT (n = 10,500). The long-term infection population group was estimated based on the
assumption of 1% prevalence of infections at elective orthopaedic surgical sites.130 This translates to 2000
joint-related infections in addition to 5000 osteomyelitis-related infections. The total of 7000 was scaled up
to include other long-term infections such as endocarditis using the proportions from a UK cohort study.29
The expected value of partial perfect information (EVPPI) was calculated using a recently developed
non-parametric regression method tool.165 Using the simulated parameter values and associated NMB
estimates from the Monte Carlo simulation, the EVPPI represents the monetary value of uncertainty
emanating from each of the parameters used. This is particularly useful in identifying which parameters are
driving the EVPI and which might be the target of efforts to reduce uncertainty in the decision and future
research investments, for example whether it relates to effectiveness, risks or quality-of-life estimates. The
expected value of sample information (EVSI) represents the expected value of increased research sample
size. EVSI helps determine the optimal sample size for a study based on the marginal benefit from an
additional study participant compared with the marginal cost of enrolling them. The optimal point occurs
when the marginal benefit is equal to the marginal cost.12 This analysis was conducted if there was
sufficient value of additional research and information was required on the research design.
Results
Markov model: short-term infections
Base case
Table 18 includes the model heal time, adverse event and cost predictions in the short term. The low event
rates and costs reflect the low risk rates included in the model and the short period of risk (< 1 week on
average during treatment).
Table 19 includes the base-case cost-effectiveness results. For an average short-term infection, HO is the
most expensive service, at £146 and £219 more expensive than GN and SN services, respectively. However,
HO provides (negligible) QALY gains over both of the nurse-led services. Both GN and SN are cost-effective
compared with HO. SN is the most cost-effective service overall, yielding a saving of £76,506 for every
QALY lost (vs. HO) and a £162 NMB gain over HO.
TABLE 18 Short term: model predictions
Parameters
Service
HO GN SN
Time to heal (mean days) 4.72 6.84 6.00
CDI person-days (per 1000 people) 7.80 0.94 0.83
Secondary infection person-days (per 1000 people) 35.87 51.98 45.62
Severe adverse reactions (per 1000 people) 0.22 0.30 0.26
Number of relapses (per 1000 initial infections) 0.00 0.00 0.00
Days in hospital (per 1000 people) 43.88 53.22 46.71
Deaths (per 1000) 0.35 0.52 0.46
Costs, £ (per 1000 people)
CDI 2258.10 272.67 239.32
Secondary infections 8488.15 12,300.48 10,795.85
Severe adverse reactions 162.29 220.52 193.53
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Sensitivity analyses: deterministic
For the deterministic sensitivity analyses for short-term infections where risks, effectiveness, cost and utility
model parameter inputs are varied and impact on cost-effectiveness observed, see Appendix 4, Table 43.
It also includes a number of scenario analyses. In most cases, GN is more cost-effective than HO, and SN
is more cost-effective than both HO and GN and, hence, represents the best value for money in the short
term. Again, the results are largely driven by costs as the risks of adverse events are low and QALY gains
are similar. SN is more cost-effective than HO even if a band 6 nurse is used (instead of a band 5 nurse)
or if an additional outpatient review is included at the end of treatment in the nurse services. Changes
in utility values do not appear to influence results. HO attendance becomes cost-effective only when
scenarios weighted in the service’s favour are employed. Table 20 incorporates threshold analyses where
the threshold values are sought, at which point HO become cost-effective (against SN, as this was the most
cost-effective service). Holding all else equal, HO would require 2.48 fewer heal days than SN or the cost of
nurse visits would have to increase from £33.04 to £58.31 before HO becomes the optimal strategy.
Sensitivity analyses: probabilistic
Table 21 includes the probabilistic mean estimates from the Monte Carlo simulation. These, and the
cost-effectiveness plane which plots the simulated ICERs, corroborate the deterministic results (Figures 12
and 13). These indicate that, even with uncertainty introduced into the results, GN is more cost-effective
TABLE 19 Short term: base-case deterministic cost-effectiveness
Mean
Service
Comparison ICER INMB InterpretationHO GN SN
Costs (£) 998 852 779 HO vs. GN £31,600 –£54 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN £76,506 –£162 SN cost-effective
GN vs. SN SN dominates –£108 SN cost-effective
TABLE 20 Threshold analyses: short-term infections
Values required for HO to be cost-effective vs. SNa Threshold value
HO days to heal 3.85 (or 2.48 days fewer)
Cost of nurse visit (£) 58.31 (or 25.27 more)
Cost of outpatient follow-up visit (£) 100.93
Relapse rate in SN (%) 45
a Where INMB = 1.
TABLE 21 Base-case probabilistic cost-effectiveness: short-term infections
Mean
Service
Comparison ICER INMB InterpretationHO GN SN
Costs (£) 998 851 778 HO vs. GN £32,634 –£57 GN cost-effective
QALYs 0.174 0.169 0.171 HO vs. SN £80,351 –£166 SN cost-effective
GN vs. SN SN dominates –£109 SN cost-effective
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than HO, and SN is more cost-effective than both. The CEAC (Figure 14) indicates that SN would be the
cost-effective option for all values of willingness-to-pay thresholds and at £20,000 has a 78% chance of
being cost-effective. The INMB distribution plot shows that, compared with the optimal strategy (SN),
there is some overlap in the simulated INMB results with GN, but very few of the HO simulations exceed 0.
Value of information
The population EVPI is shown in Figure 15. The EVPI is low (£302,353, where λ = £20,000) even with the
assumption that 100% of patients requiring IVA would be eligible for OPAT. This reflects the low decision
uncertainty in short-term infections given that, in the base-case model, SN clearly offers the best value for
money. The EVPPI for individual parameters shown in Figure 16 suggest that the greatest proportion of EVPI
is driven by the respective effectiveness parameters (days to heal) in the GN and SN services. Other risks and
utility values did register a positive value but their EVPI was small. Over the course of 1 year (and even up to
5 years) it is unlikely that the cost of decision uncertainty characterised here would warrant significant
further research investment in the form of a clinical trial. Given the low EVPI values, EVSI was not calculated.
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Markov model: long-term infections
Base case
Table 22 includes the model heal time, adverse event and cost predictions for long-term infections. As with
the short-term infection model, event rates and per person adverse event costs are low. Table 23 includes
the base-case cost-effectiveness results. SA appears to be the cheapest service followed by SN, GN and
finally HO. The QALY differential between services was minimal, with SN being the most effective option,
followed by HO, SA and GN. Despite providing 0.012 fewer QALYs than HO, GN is still preferred owing to
the significant cost savings (£1553). Owing to the relatively large cost-savings and only slightly inferior
QALY gain, SA was the most cost-effective service, providing an INMB of £255 per infection over SN.
Sensitivity analyses: deterministic
For the deterministic sensitivity analyses and scenario analyses for long-term infections. In most cases, SA
continues to be the most cost-effective service regardless of parameter value changes and the order of value
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for money changes rarely with SA > SN > GN > HO, see Appendix 4, Table 44. In many cases SN and SA
dominate (are cheaper and more effective than) GN and, in some instances, SN dominates HO, although the
incremental QALY remains very small. SA remains cost-effective even when the additional equipment costs
required for the service are tripled (from £50 to £150). However, SN does become cost-effective compared
with SA when the risks of a severe line infection (S. aureus) are doubled for the latter (making the risk four
times that in SN and GN). This is also the case in scenarios in which the heal time for SA is assumed to be
30 days (4.54 days longer than SN) and the SA training costs are doubled (from £66.08 to £132.16).
However, in these cases, SA is still preferred to GN and HO. Table 24 incorporates threshold analyses where
the threshold values are sought, at which point SN become cost-effective against SA. These services were
compared, as they offered the greatest NMB. All else remaining equal, SN would require 4.31 fewer heal
days than SA or the cost of nurse visits would have to fall from £33.04 to £17.10 before SN would become
the most cost-effective service. The daily probability of anaphylactic shock would have to increase from
0.00005 to 0.00031 (640% increase) before SN becomes better value for money.
Sensitivity analyses: probabilistic
Table 25 includes the probabilistic mean estimates from the Monte Carlo simulation. This mirrors the
deterministic values and decision, with SA being the most cost-effective service. Figures 17 and 18 are
TABLE 22 Long term: model predictions
Variables
Service
HO GN SN SA
Time to heal (mean days) 23.65 27.06 22.13 24.50
CDI person-days (per 1000 people) 39.19 3.74 3.06 0.00
Secondary infection person-days (per 1000 people) 180.05 206.38 168.72 186.82
Severe adverse reactions (per 1000 people) 1.11 1.19 0.98 0.96
Number of relapses (per 100 initial infections) 0.00 0.00 0.00 0.00
Days in hospital (per 1000 people) 220.34 211.32 172.75 187.78
Deaths (per 1000) 1.75 2.06 1.68 1.98
Costs, £ (per 1000 people)
CDI 11,349.43 1084.18 886.33 0.00
Secondary infections 42,610.03 48,842.67 39,929.53 44,213.75
Severe adverse reactions 813.00 873.68 714.24 703.00
TABLE 23 Long term: base-case deterministic cost-effectiveness
Mean
Service
Comparison ICER INMB InterpretationHO GN SN SA
Costs (£) 4631 3078 2563 2114 HO vs. GN £128,354 –£1310 GN cost-effective
QALYs 0.644 0.631 0.648 0.638 HO vs. SN SN dominates –£2149 SN cost-effective
HO vs. SA £448,254 –£2404 SA cost-effective
GN vs. SN SN dominates –£839 SN cost-effective
GN vs. SA SA dominates –£1094 SA cost-effective
SN vs. SA £46,393 –£255 SA cost-effective
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TABLE 24 Threshold analyses: long-term infections
Values required for SN to be cost-effective vs. SAa Threshold value
Days to heal in SN 23.83 (or 4.31 fewer)
Cost of nurse visit (£) 17.10
Cost of SA training (£) 305.02
Risk of anaphylactic shock 0.00031
a Where INMB = 1.
TABLE 25 Long term: base-case probabilistic cost-effectiveness
Mean
Service
Comparison ICER INMB InterpretationHO GN SN SA
Costs (£) 4635 3081 2564 2112 HO vs. GN £130,359 –£1315 GN cost-effective
QALYs 0.646 0.634 0.650 0.641 HO vs. SN SN dominates –£2152 SN cost-effective
HO vs. SA £482,422 –£2419 SA cost-effective
GN vs. SN SN dominates –£836 SN cost-effective
GN vs. SA SA dominates –£1103 SA cost-effective
SN vs. SA £48,845 –£267 SA cost-effective
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the cost-effectiveness planes for all services versus HO and for SA versus SN, respectively. Figure 19 is the
CEAC for long-term infections and indicates slightly more decisional uncertainty than the short-term
infection model. Where the ceiling ratio is £20,000, SA has a 70% chance of being cost-effective versus a
30% chance for SN. At £30,000 this becomes 62% and 37%, respectively, and when the ceiling ratio
increases to £61,000, SN becomes more likely to be cost-effective. GN and HO do not become the optimal
strategy at any point across the ceiling ratio range used (up to £100,000). This is further illustrated by the
distribution plot of INMB in Figure 20 where only the tail of the distributions for GN and HM cross the
INMB = 0 line (vs. SA).
Value of information
The population EVPI is illustrated across the range of ceiling ratios in Figure 21. Over 1 year and where
λ = £20,000, the EVPI is £1,078,204. Figure 22 indicates that a large majority of this value is associated
with the time to heal values from the SN and SA parameters. There is little value in reducing the
uncertainty around the GN effectiveness parameter. The only other factor to register a positive EVPI figure
was the probability of S. aureus infection. The value here is higher than that in the short term but still
relatively low and, given this, EVSI was not calculated.
Simulation model
Health and Personal Social Services perspective: comparison with Markov
Tables 26 and 27 include the expected costs and benefits of the OPAT services generated by the
simulation model for short- and long-term infections, respectively. These allow a comparison with the
Markov model results which are largely in agreement. The decision in the short- and long-term infection
groups is unchanged, with SN and SA, respectively, being clearly optimal.
The results of the simulation corroborate what the Markov model estimated, providing certainty to the
model results. The CEAC (Figure 23) shows that the probability of SN and SA being cost-effective is
> 65%, which is similar to that estimated by the Markov model (> 70%).
Service combinations (Table 28) introduce combined services into the cost-effectiveness analyses. None of
the combined services was cost-effective.
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TABLE 26 Simulation model cost-effectiveness: short-term infections
Interventiona Costs (£) QALYs ICER (vs. SN) INMB (vs. SN) Result
SN 709.74 0.7228 – Cost-effective
GN 787.75 0.7193 Dominated –£148.25 Not cost-effective
HO 972.64 0.7239 £233,034 –£240.30 Not cost-effective
a Ordered in terms of least costly.
TABLE 27 Simulation model cost-effectiveness: long-term infections
Interventiona Costs (£) QALYs ICER (vs. SA) INMB (vs. SA) Result
SA 1883.47 0.6660 – Cost-effective
SN 2378.92 0.6767 £46,060 –£280.32 Not cost-effective
GN 2956.77 0.6552 Dominated –£1288.99 Not cost-effective
HO 5135.02 0.6670 Dominated –£3174.34 Not cost-effective
a Ordered in terms of least costly.
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Commissioning perspective
There was a clear, positive relationship between the number of delays in treatment experienced, costs
and time to heal (Figure 24). This is corroborated by Figure 25, which plots the relationship between costs,
delays in patient IVA administrations and NMB when different levels of resources (nurse numbers) are
available in the long-term SN service. This is presented in two scenarios: (1) an urban setting in which
we might expect nurse visit times to be shorter owing to reduced travel times; and (2) a rural setting in
which patients may be more dispersed and nurse travel and visit times are increased. For a given patient
population (in this case, n = 304), there appears to be a non-trivial number of treatment delays.
In the urban setting adding further nurses reduces the number of delays significantly without adding
significantly to the costs. However, NMB is relatively unchanged. In the rural setting the delays are much
higher and the benefit (reduced costs and increased NMB) of additional nurses is marked.
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FIGURE 23 Cost-effectiveness acceptability curve: (a) short- and (b) long-term infection simulation model.
TABLE 28A Service combination: short-term infections – 50% SN, 50% HO
Interventiona Costs (£) QALYs ICER (vs. SN) INMB (vs. SN) Result
SN 709.74 0.7228 Cost-effective
SN 50%, HO 50% 841.26 0.7235 £182,493 –£117.10 Not cost-effective
HO 972.64 0.7239 £233,034 –£23.24 Not cost-effective
a Ordered in terms of least costly.
TABLE 28B Service combination: long-term infections – 50% SA, 50% SN
Interventiona Costs (£) QALYs ICER (vs. SA) INMB (vs. SA) Interpretation
SA 1883.47 0.6660 Cost-effective
SA 50%, SN 50% 2127.99 0.6721 £39,819 –£127.70 Not cost-effective
SN 2378.92 0.6767 £54,364 –£158.61 Not cost-effective
a Ordered in terms of least costly.
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Tables 29 and 30 include the cost-effectiveness results from the commissioning perspective. Here, the costs
of resource use are not calculated on an hourly basis but as sunken costs relating to the employment of
nurses on a salaried annual basis. In short-term infections, fewer nurses lead to more treatment delays, but
this does not translate into greater costs and reduced QALYs. This is the case when the patient population
is 304 and 150. In long-term infections the nursing resources do have an impact on costs and QALYs
when nurses drop from 4 to 2. Furthermore, when the visits require 2 hours rather than 1 hour, there is a
noticeable drop in patient QALYs as a result of treatment delays.
An estimation of the number of patients that can be seen per nurse was made assuming a long-term
infection in an urban setting (1 hour’s treatment including travel time) using the SN service. As shown in
Figure 26, 92.50 patients can be treated per nurse in a year before reaching saturation. At this point costs
will start to increase, while QALYs will decrease.
Discussion
The aim of the economic evaluation was to produce estimates of the cost-effectiveness of OPAT services.
After consultation with clinicians it was decided that two decision problems were pertinent, one for short-
term infections (HO vs. GN vs. SN) and one for long-term infections (HO vs. GN vs. SN vs. SA). The models
estimated the costs and effects of OPAT services, taking into account treatment time and risks of
anaphylactic shock, CDI, severe S. aureus line infections and death.
The estimates of cost-effectiveness were generated using decision-analytic modelling techniques and,
where possible, adhered to NICE’s reference case for health technology appraisals. We generated versions
of the Markov model for short-term and long-term infections. We also used these to estimate the value
TABLE 29 Short-term infections: commissioning perspective
Intervention Costs (£) QALYs Delays
304 patients
SN, four nurses, 2 hours 1129.69 0.7204 5.95
SN, two nurses, 1 hour 1127.10 0.7204 2.30
150 patients
SN, two nurses, 2 hours 1150.23 0.7208 12.84
SN, two nurses, 1 hour 1136.42 0.7209 4.85
TABLE 30 Long-term infections: commissioning perspective
Intervention Costs (£) QALYs Delays
304 patients
SN, four nurse, 2 hours 4336.02 0.61556 2588
SN, two nurses, 1 hour 2395.17 0.68557 125
150 patients
SN, two nurses, 2 hours 4088.57 0.62339 1109
SN, two nurses, 1 hour 2536.37 0.68604 120
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of additional research based on the level of uncertainty around the estimates of cost-effectiveness.
Although Markov models can provide these estimates relatively easily, there are limits to the level of
information they can provide. For example, they cannot readily provide data on required staffing levels, the
impact of combinations of treatments or the impact of delays on patients. In view of this, we also chose to
conduct DES modelling of the decision problem. These types of models provide information over and
above that yielded from Markov models, as well as providing standard estimates of cost-effectiveness.
The systematic review of the literature reported in Chapter 2 identified previous economic evaluations in
the area and parameter values to inform the decision models. Only two randomised trials were identified
but they were non-UK based and the comparator was inpatient treatment.12,166 Additional targeted
literature searches were conducted for certain key parameters. Comparative data on the safety and
effectiveness of the OPAT service types were limited and a majority of studies reporting these were
observational cohorts rather than randomised studies and, thus, provided potentially biased values and
negated attempts at synthesising results. To illustrate, elderly patients or those with comorbidities may not
be asked to attend clinics daily as they may find it difficult to travel. There are also differences in the
underlying condition that cohort patients have and variations in the way outcomes are defined (e.g. heal
vs. switch to oral). Furthermore, different centres may have alternative protocols relating to switching
patients to oral treatment. As a result, for our main effectiveness parameter, we relied on a data set
generated from hospital records of previous OPAT patients; this allowed us to control for heterogeneity in
the patients receiving each service.
In both short- and long-term infection Markov models, the difference in expected effectiveness (QALYs)
across service models was negligible. The explanation for this is that the time horizon employed (3 and
12 months for short-term and long-term infections, respectively) is relatively short and, for many, the
health event of interest is transient in nature with a very low risk of mortality. Furthermore, the risk of
adverse events was very low across all services. In contrast, there were significant cost differentials
between the services that drove the cost-effectiveness results.
The SN service was the optimal service in the short term, being only marginally less effective than HO visits
but £220 cheaper and being both more effective and cheaper than GN. These results were relatively
insensitive to alternative analyses and did not change with modest changes in the risks, costs or utility
parameter values. HO would have to be 2.48 days quicker to ‘heal’ patients than SN or nurse costs
almost doubled (to £58.31) before HO became cost-effective. At a willingness-to-pay (per QALY gain)
threshold of £20,000, SN had a 78% chance of being cost-effective. For long-term infections, the order of
cost-effectiveness was maintained with GN preferred to HO, SN preferred to GN and SA preferred to SN;
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this also reflected the order of costs, with SA proving to be cheapest. SA was £452, £969 and £2523
cheaper than SN, GN and HO, respectively. The QALY gain differential was largely attributable to the
greater time horizon and treatment period but still very small. As in the short-term infection model, it
appears that costs drives the results. Again, results were relatively insensitive to parameter changes.
The results changed in favour of SN when the risk of S. aureus in SA was doubled. The heal time in SA
had to be 4.31 days longer than that in SN or the training cost had to be increased to £305.02 before SN
became the optimal strategy. At a threshold of £20,000 SA had a 70% chance of being cost-effective
versus a 30% chance for SN.
The results from the simulation modelling corroborated the Markov models results. As in the Markov model,
SN and SA were the most cost-effective strategies for the short- and long-term models, respectively.
The probability of these strategies being cost-effective was also similar to the Markov model estimations
(≥ 65% vs. ≥ 70% in the Markov model).
The simulation yielded several additional useful pieces of information. It showed that NMB was inversely
related to the number of treatment delays and that when resources are exhausted, delays and costs increase
and QALYs decrease (especially in the long term). The analysis found that for high density population areas
where nurse visits might be conducted in 1 hour, each nurse can safely handle just over 90 infections per
year. This number clearly would be fewer if travel time or complexity of cases is increased. The results also
suggested that long-term infections may best be served by a combination of SA and SN services.
The addition of the simulation model to the evaluation is relatively novel. Many technology appraisals assume
that resources (e.g. staff and hospital beds) are infinite and are costed on a per-use basis. However, this
clearly neglects key considerations for decision-making in the real world. We conducted a ‘commissioning’
perspective here that also allowed us to specify a set of fixed resources that could be exhausted and to
determine the impact on the costs of purchasing additional resources and on patients who may be denied or
receive delayed health care. Although not inconsistent with the usual HTA perspective of the health and
social care system, it facilitates decision-making at a local level. Here, factors such as the number of patients
in a given area, number of available staff and hospital beds, the geography of the local catchment area and
patient preferences can be accounted for in the estimates of cost-effectiveness and decision-making.
The results from both Markov and simulation models suggest that SN is the optimal service in the short
term. In the long term SA appears optimal, although SN provides slightly higher benefits but at higher
cost. The optimal service provision and staffing level strategy from the commissioner’s perspective will be
dependent on local factors, local priorities and any external quality standards. For example, providing
nursing levels that optimise net benefit (cost-effectiveness) may be less of a priority than avoiding
treatments delays.
Patient involvement
The research team met three times with members of the PAG during the development of both the Markov
and simulation models. At these meetings we presented the graphics for the preliminary models to the
group and provided an oral overview of them and what we were aiming to do. Their input and that of the
clinical experts informed the development of the patient pathway described in the models. The patients
also provided key insights into the important health events that might occur, on the health-care services
that might be used and into the impact on their quality of life that infections had.
Limitations
Decision-analytic modelling is useful when the information required to make a decision is not available or
requires synthesis; it can also help to inform research priorities. Notwithstanding this, the usefulness of
modelling is a function of the quality of data available to populate the models that are constructed. In this
economic evaluation we were constrained to some extent by the available data. There was a paucity of
useful comparative UK data on the effectiveness and safety of the OPAT services. Furthermore, the concept
of effectiveness in OPAT services is attenuated, as, quite often, fixed treatment courses are prescribed.
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We used a hospital record data set to derive our measure of ‘effectiveness’ (time to heal). The data set
permitted adjustment for patient heterogeneity between services and did indicate differences in time to
heal (or switch to oral antimicrobials). The differential between services on this factor may reflect
effectiveness or the impact of adverse events and compliance, which may indirectly affect treatment time.
Although there are non-trivial chances of experiencing mild adverse events in the course of IVA receipt,
these are often self-limiting, transient and have minimal cost implications or impact on patient quality of
life. The more severe events that are possible (e.g. severe line infection, anaphylactic shock or CDI) are
relatively rare and, in the case of CDI, becoming rarer; thus, their impact at a cohort level is relatively
minor. Given these issues, it is debatable whether or not better-quality data would have influenced the
results to a great degree.
Antimicrobial stewardship is currently a key concern but we chose not to model antimicrobial resistance.
We believe that the differential rate of resistance between the service models would have been negligible
and did not warrant the additional modelling resources required or additional layer of complexity in the
models. We also acknowledge that other variations on OPAT service models are available, for example
delivery by a GP at the local clinic. However, it was not practicable to evaluate all of these. Outcomes data
for all possible service configurations would be scarce and we chose to focus on the most commonly used
in current practice.
Further research
The value of additional research was formally assessed using the outputs from simulations of the Markov
decision models. These values (EVPI) represent in monetary terms the level of uncertainty in the estimates
of cost-effectiveness; if these exceed costs we might expect to incur undertaking activities to reduce the
uncertainty (e.g. conducting a large RCT) then we may proceed to invest in further research. If they are
lower than the research investment then we should make the decision with the current available evidence.
In the short-term model the EVPI was relatively small, given the low levels of uncertainty around the
decision (SN had a 78% chance of being optimal). The EVPI figure over 1 year is £302,353 and, assuming
that a clinical trial to reduce uncertainty would cost in the order of £1M–£3M, is outweighed by the
research costs. Given this, additional research of this nature does not appear to be warranted.
The EVPI for long-term infections was higher (£1,078,204), mainly because there was greater uncertainty
(present in the decision between SN and SA), and approached the cost of a trial. If we consider that the
decision problem may be over the next 5 years then the EVPI increases significantly (although not
sufficiently in the short-term group) to a value that exceeds the research costs. However, in reality, further
trial-based research may take at least a further 4 or 5 years to report. By this time it is debatable whether
or not the research question would still be relevant, as new treatments and modalities become available or
current practice is challenged.167 To illustrate this, the Oral Versus Intravenous Antibiotics for bone and
joint infection (OVIVA) trial currently being conducted in Oxford is comparing IVA with oral antimicrobials
in bone and joint infections. Should this research find that oral treatments are a suitable alternative to IVA,
research investment in establishing evidence for OPAT services in this group will potentially be obsolete.
Should future trials of OPAT be considered, it is likely that they will be based on equivalence and safety.
However, it is debatable whether or not the sample sizes sufficient to capture risks of the more severe
events would be achievable. This is further complicated by the fact that departments often need to offer
more than one type of service because some OPAT services are not suitable for all. Although SA is the
most cost-effective option for long-term infections, it would not be possible to provide only this service
because it would not be appropriate for those who were not able to self-administer (for cognitive or
functional reasons). Furthermore, the expert panel also appeared to agree that a clinical trial may not be
the most useful avenue for further research but that the establishment and analysis of large cohort data
may be more fruitful. We are aware that BSAC are currently undertaking such an initiative but that, to
date, the results have been mixed with variable uptake. Given the results and opinion of the consensus
panel, the value of information analysis did not extend to include the EVSI that could inform trial design.
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In terms of future methodological pursuits, the current research has highlighted the disconnect between
macro- and micro-level decision-making. The real world usefulness of cohort-model-based estimates of
cost-effectiveness conducted from the perspective of the health system is questionable when local-level
factors are brought to bear. The conclusion we might make from the short-term infection modelling is that
SN should be adopted wholesale. However, if combinations of services are required (to include HO),
patient preferences are considered important and local resources accounted for, decisions made based on
this information may not be optimal. Future research is required to explore the impact of local decision-
making factors on estimates of cost-effectiveness and ways in which to consolidate local and wider NHS
perspectives. Further analyses might also explore the whole commissioning picture whereby both
short- and long-term service decisions are made concurrently.
Changes to protocol
Recruitment to the DCE was initially very slow so rather than risk getting insufficient participants for the
health economic evaluation we continued to sample after the initial 200 data sets. As the profile of
the DCE patients would then mean oversampling on some models (e.g. hospital attendance), a decision
was taken to continue recruiting patients to provide anonymised data. We chose not to conduct the EVSI
as the EVPI figures suggested that further research was not warranted.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99

Chapter 7 Expert panel review of the data
Aims and objectives of the meeting
The role of the expert panel was to consider the evidence generated from the systematic review,
qualitative research, economic modelling, DCE and survey of current service provision. The following four
questions were constructed to help the expert panel consider the findings of the four workstreams:
1. What is likely to represent an optimal service model for delivery of antimicrobial therapy for the two
patient groups (long- and short-term i.v. antibiotic patients)?
2. Where does patient choice fit?
3. Are we ready for a clinical trial?
4. What are the future research priorities?
Method
The expert panel was convened on 28 September 2015 at the Doubletree at Hilton Hotel, Leeds. All panel
members were asked to undertake preparatory reading (systematic review and summaries of the patient
interviews, health professional interviews, DCE and economic modelling). The reports each contained an
executive summary, method section with key results (see Appendix 5). All panel members were advised of the
group discussions and provided with the questions prior to the meeting. The meeting was audio-recorded,
with consent from attendees (to aid data analysis).
The expert panel meeting was structured as follows: (1) PowerPoint (Microsoft Corporation, Redmond, WA,
USA) presentations by the workstream leads; (2) a question-and-answer session to ensure that expert panel
members understood the material presented, and to generate discussion about the research findings.
Delegates were provided with a 1-page summary of each workstream to use as an aide-memoire during
the subsequent discussions (see Appendix 5). The expert panel was asked to address four questions
(detailed above). To facilitate discussions the panel was split into two groups: group 1 discussed questions
1 and 3, and group 2 discussed questions 2 and 4. Each group discussion was facilitated by two members
of the research team (JM and MT; CCM and DM).
Panel members were briefed as follows: ‘You should use the data provided to discuss the following questions.
You should brainstorm your ideas and nominate a note-taker to record your views on the flipchart provided,
and agree a person to feedback to the group’. Facilitators then left the group for 15 minutes to discuss the
issues, returning to provide further information and facilitate the discussion.
Panel composition
The panel comprised an independent chair (pharmacist), a CCG representative, an OPAT nurse, a
microbiologist, two pharmacists, an infection specialist clinician, a patient, a statistician, a clinical triallist
and a health economist. Three members of the panel sit on the BSAC committee. Three patients from our
PAG were invited to attend. Two were unable to attend on the day owing to illness and the third attended
the first half of the event but was unwell and could not stay for the discussion group. In addition to the
independent panel members, six members of the research team were present and were available to
answer questions during the group discussions.
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Summary of discussion
Question 1: What is likely to represent an optimal service model for delivery of
antimicrobial therapy for the two patient groups (long- and short-term i.v.
antibiotic patients)?
Members of the expert panel drew on their own clinical expertise and experience as well as the evidence
presented from CIVAS when considering these questions. To facilitate their discussion, three inter-related
questions were posed.
Are different models needed for long- and short-term infections?
The group discussed what was meant by ‘different models’ and concluded that both long- and short-term
infections should be covered by one ‘service’. Expert panel members had experience of different care
pathways and this resulted in a long discussion about the merits of these; there was some disagreement
between panel members as to the best model of care as there are advantages to all. There was agreement
that OPAT services could be located in the NHS trust or be community based and that they should offer
different care pathways (e.g. SA, hospital attendance, nurse at home). The group agreed that there needs
to be flexibility to accommodate patients with different needs and that within any one OPAT service there
should be several care pathways (rather than only one care pathway).
Although the health economics evidence presented suggested that, as costs drive the models, a SN service
was optimal for short- and long-term infections, with SA marginally less expensive for long-term infections.
However, there was reluctance by the panel to accept these findings.
Should services focus on once-daily antimicrobials (balancing antimicrobial
resistance against costs)?
The overwhelming view was that OPAT services should focus on antimicrobials which could be administered
once a day, provided that the treatment selected is clinically appropriate. It was felt that once-daily
treatment provided the greatest potential for services to treat more patients (freeing up staff who would
otherwise be involved in repeat administrations). Twice-daily administrations should be accommodated
when the infection dictated (i.e. when no once-daily treatment is available). The group thought that this
might be achievable if smaller hospitals that do not currently have infection-specialist input on site could
access this input via telemedicine to ensure that the most appropriate antimicrobial was offered. It was
agreed that the involvement of an infection specialist/microbiologist at diagnosis and review stages would
be appropriate.
How do we ensure equality of access to services and equivalent standards of
service across England?
Panel members described situations in which patients could not be sent home because they lived in the
‘wrong’ CCG area, or lived too far from the hospital to receive OPAT. It was thought that in more rural
areas a hub and spoke model (network) might be appropriate, similar to the model used in cancer, with
tertiary (specialist), DGH and medical centres (CCG level) working together to provide care.
This would require a more ‘joined up’ approach with national-level commissioning and all agreed that a
nationally commissioned service is needed, rather than local negotiation with CCGs. There were examples
given of how, when one CCG commissions a service and a neighbouring one commissions a different model,
secondary care has to try to run two (or more) services, and neither is likely to be cost-effective. National
commissioning could also improve the care, as it would make it easier for patients to be seen in tertiary
centres and then referred back to local DGHs, which are often out of the area; a nationally commissioned
service would be able to accommodate this in a way that locally commissioned services cannot.
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Question 2: where does patient choice fit?
How important is patient choice?
The group focussed their discussion on whether or not it is possible to implement patient choice. From a
commissioning perspective, patient choice was viewed as essential, although it was acknowledged that this
would still be within the confines of what is financially viable. From a clinical perspective patient choice
was also viewed as important, but it was acknowledged that the choice may be about whether or not the
patient wants to have OPAT or inpatient care, and would not necessarily include a choice about the form
of OPAT they receive.
The group discussed the fact that the patient interview data had revealed information which panel
members had not previously considered about what people take into account when making choices about
their care, such as not wanting to be in hospital because they were worried about the impact on their
family. Other challenges such as access to treatment, car parking, etc., were more obvious challenges that
would influence the willingness of patients to receive OPAT and their preferences for care.
It was therefore agreed that patient choice is important, but there was the view that any service should
also offer good value for money to the NHS. Examples were given about the desire to offer OPAT to those
living in rural communities, but the feasibility of offering services in such circumstances is challenging.
Although an individual patient may prefer to be cared for at home, patient characteristics (e.g. age, health)
and nature of the infection may influence whether or not a model of care is available to the patient
(e.g. multiple administrations of i.v. antibiotics in a rural area).
If we think choice is important, how do we translate patient preferences into
service commissioning decisions?
It was acknowledged that sometimes the most cost-effective model of care may not be the one which
patients would prefer, and the group discussed whether or not the NHS can afford ‘choice’. They
concluded that the NHS already takes patient choice into account when commissioning service, via data
from patient surveys. However, it was acknowledged that, although there is a desire to ensure that the
patients’ voice is heard, final commissioning decisions may not always accord with patient preferences
(e.g. decommissioning of services, hospital closures).
It was acknowledge that owing to the geography of the UK it may be difficult in some areas to
commission an OPAT service which is sufficiently flexible to include different care pathways and, therefore,
meet patient preferences, and any OPAT service must also be able to offer what the NHS acute trust needs
to facilitate early discharge (non-admission) of patients requiring i.v. antimicrobials.
There was a desire that patient preferences should be examined at the local health economy level and there
were concerns about whether or not the findings of the DCE study, which collected data from across
Yorkshire and the Humber, could be translated to other localities, although no definitive reasons why they
should differ were identified. There was a discussion about the importance of ensuring that local services
support the needs of the local community, for example, through accommodating local geography (rural/
metropolitan) or population size. There was strong interest from the commissioner and clinicians to replicate
the DCE in other areas and to use these data to make comparisons across the country to test the robustness
of the original findings, but to also use the new ‘local’ findings to ensure that local OPAT services meet local
needs and preferences, especially in relation to local ethnic diversity. As some CCGs co-commission with
other commissioning groups, factors other than patient preferences influence commissioning decisions.
Although patient preferences influence what is included in the service tender, the skill set of those tendering
to deliver the service may not meet these needs, which may limit the services that can be offered locally.
In conclusion, patient preferences were viewed as important but these must be balanced against what is
feasible for that community.
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How do we balance choice and cost?
It was agreed that different patient characteristics might result in different care preferences, which was
borne out (to some extent) by the DCE data, which showed that younger men had a preference for
attending hospital, compared with the general population. It was also agreed that scale of the service and
demand for treatment may affect the choices available to patients (so their ability to receive the model of
care they prefer) and subsequent costs.
There was some debate about whether or not patients are able to make an informed choice about the
care they receive. Offering individual patients a choice about the care they receive means educating them
to enable them to make an informed/aided decision. It was agreed that patients are unlikely to understand
the implications, for example of SA, unless this was clearly explained to them. Therefore, the additional
cost of explaining to patients what going home will entail needs consideration.
Attitudes were found by the DCE study to be important predictors of patient preferences, and the group
discussed the implications of patient attitudes when considering the push to move to community-based
care. It was agreed that the findings of the study indicate that there may be a need for an attitudinal/
behavioural shift by both NHS staff and patients to accept these new ways of delivering health care, not just
i.v. services. If we can manage this change within OPAT then this could provide a model for other services.
Finally, there was a debate about the nature of choice and preference. It was acknowledged that,
although someone may prefer one option, they may choose another owing to other factors. The difference
between choice and preference is one that is picked up by the DCE, and the finding that preferences can
be influenced by attitudes may also be a good target for intervention. By changing people’s attitudes,
might we change their preferences?
Question 3: Is there sufficient evidence upon which to base a clinical trial
comparing service models?
Following a long discussion, it was agreed that NIHR would not fund a randomised clinical trial comparing
two or more models of care. The rationale for this view was:
l There is no obvious comparator group.
l It was difficult to decide what the outcome measure would look like. Quality of life and readmission to
hospital seemed the most plausible, but readmission is not common, which would lead to an unfeasibly
large trial.
l The OPAT population is too heterogeneous (e.g. cellulitis vs. bone infection), and a complex cellulitis
may also require longer treatment than a simple cellulitis.
l We do not have a clear picture of what current service provision in England looks like. This makes it
impossible to determine whether or not there are sufficient ‘clean’ sites to introduce a new model to
test in any future trial. It was suggested that BSAC data should be used to help answer this question.
Another source of information would be local commissioners in each CCG.
l It was agreed that it is unlikely that any CCG would pay for the set up costs of any new services to test the
effectiveness of ‘pure’ models (e.g. pure nurse-led community service vs. doctor-run, hospital-led service).
l There was a discussion about whether or not a hub and spoke model could be used (cluster trial) so
that an area could offer both services, but areas would be large and it was agreed that this was
unlikely to be feasible.
A final but important stumbling block to any trial was that if the premise from the first discussion holds
true, namely that any service should be accessible to as many people as possible, then comparing HO with
community-based treatment becomes an invalid comparison. The data presented by the research team
indicate that there is heterogeneity in patient preferences, and the group felt that offering choice is
important. It was agreed that it is more important to offer forward-thinking models of care that meet the
needs of patients, which is why such different models of care have developed across the country.
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Finally, there is an acknowledged lack of equipoise in the community (most services are developed and run
by enthusiasts, who set up what they believe to be the best model). The group discussed the possibility of
other study designs.
What should such a trial (study) look like?
The group concluded that a prospective, observational study might be useful. The likely outcomes to
consider would be value for money, safety (patient harm), admission avoidance and early discharge.
How useful are patient preference data (discrete choice experiment): should we be
encouraging its use in other health-care settings?
The group found the results of the DCE to be very interesting, and they helped them to understand the
impact of attitudes on preferences. The group felt that we should be encouraging the use of DCEs in other
areas. The group thought that collecting data on patient attitudes would be of interest for commissioning
decisions and commissioners.
Question 4: what should the future research priorities for outpatient parenteral
antimicrobial therapy be?
l It was agreed that replicating the DCE study in other areas would be useful. There were some concerns
within the expert panel members around the lack of ethnic diversity in the development of the
questionnaire. If the robustness of the measure could be determined by input from further work with
patients from a range of ethnic groups, this would be beneficial.
l The inclusion of attitudinal data questions in the DCE was of particular interest to commissioners and
there was a desire to have this included in a commissioning toolkit to inform commissioning decisions
and also to use for quality monitoring, along with other measures.
l It might be useful to consider the cost-effectiveness of OPAT services, but also to consider the costs of
‘injectables’ (e.g. blood products) more widely.
l One possible area of research would be to consider patients’ willingness to pay. It was proposed that
repeating the DCE with a question about willingness to pay would be interesting. However, this may
dominate the model, so it would be important to have a split sample to test what impact this has on
the data. However, from a commissioning perspective it was viewed as unlikely that patients would be
asked to pay for OPAT as it saves the NHS money. We could look at willingness to pay (patient) to
travel to a health-care setting to receive care versus care at home. For example, having a service at
hospital versus at a general practice/medical centre. Would paying for transport influence patient
choices? Would being able to park (e.g. at GP surgery) overcome any reluctance that patients have?
l Is there a role for a GP-facilitated model of OPAT (not involving GPs, but using their venue with a
district nurse/SN model of care)?
l Is there a role for the third sector (voluntary services) and private companies?
l Who has overall responsibility for patients’ infections? It was agreed that the governance of OPAT
services was an important issue. Although the referring specialist could maintain control, is this clinically
effective? Would it be better for the patient to be ‘managed’ by an infection specialist?
Summary and recommendations
Following a long discussion there was general agreement that we do not need different models of care for
short- and long-term infections. The health economics evidence presented from this study suggests that
a SN at home model was optimal, with SA being marginally less expensive for long-term infections.
However, the panel felt that OPAT services (whether based in acute care or in the community) should offer
different care pathways depending on local needs (e.g. SA, hospital attendance, nurse at home).
Patient preferences were viewed as having an important role in the commissioning of NHS services, and
the data from the current study were welcomed as informing that process. However, panel members were
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keen to replicate the study in other geographical areas to test the ‘generalisability’ of the model. For
example, would the same findings be obtained in very urban areas with good hospital access or in areas
with poor access? It was recognised that those commissioning NHS services had to balance the wishes of
different patient groups when making commissioning decisions in the current NHS climate. It was also
noted that assessing preferences might overstate people’s likelihood of selecting one particular model of
care, as there may be other factors that influence behaviour. It is recommended that the DCE study be
replicated in other UK sites to test the robustness of the model, preferably with some more qualitative
work with ethnic minority groups to ensure the DCE choices meet their needs.
It was agreed that the attitudinal questionnaire developed as part of the DCE would be useful to
commissioners for service monitoring within local contracts and would make a welcome addition to their
commissioner’s toolkit.
Understanding patient attitudes was also viewed as having an important role in helping the NHS in a
practical way. It was felt that if we understand patient attitudes towards different service models then
we may be able to use this knowledge to influence behaviour, possibly drawing on ‘nudge theory’ to
encourage patients to accept more cost-effective approaches168,169 although this approach has also been
criticised.170 However, it was also acknowledged that we need research into how best to influence health
professionals’ behaviour as many are risk averse, so may not discharge patients on OPAT.
It was agreed that introducing patient choice also means ensuring that patients understand that
implications of those choices and that there was a need for more research to ensure patients have
information to make an informed/aided choice.
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Chapter 8 Discussion and conclusions
Introduction
Outpatient parenteral antimicrobial therapy services were initially provided in the UK by a few specialised
units with strong leadership to champion such services.3,13,75 Over the past 10 years, OPAT services have
become more common in response to pressure for health care to be delivered in the community rather
than hospital, as well as opportunities for cost savings by reducing bed occupancy.94 However, OPAT
coverage has remained patchy, with marked heterogeneity in providers, models of care and clinical
services. During the period of this research project, the Five Year Forward View was published171 setting
out key challenges and plans for the future NHS, including new care systems relevant to OPAT services.
These include closer working between primary and secondary care and the expansion of care provision out
of hospital. It is also proposed that patients gain much more control of their own health care, reiterating
the longstanding NHS pledge of giving patients choice in how and where they receive care. Better
understanding of factors affecting choice and decision-making is needed for the NHS to be able to
achieve this.
The aims of this project were to examine current OPAT provision across England and to gain an
understanding of patient preferences and cost-effectiveness, which could inform future service provision.
Specific objectives were to: carry out a systematic review of the relevant literature; establish the types of
OPAT services available in England and identify barriers to the use of each service type; evaluate patients’
preferences for, and the costs and benefits of, delivering i.v. antibiotics in the community; and make
recommendations for the optimal delivery of the service and for future research including the design of
future clinical trials. The project included an examination of patient preferences and attitudes using a DCE,
as well as both traditional health economic and simulation modelling techniques to inform health
service planning.
Principal findings
Our systematic review has provided a comprehensive picture of the current evidence surrounding the
effectiveness, safety and acceptability of outpatient antibiotic therapy. We concluded that there are no
systematic differences in relation to the impact of OPAT on duration of therapy, or on adverse events
associated with i.v. antibiotic treatment, and that, on the whole, OPAT is more cost-effective than
inpatient care. However, conclusive evidence as to the clinical benefit (or otherwise) of this mode of
therapy compared with traditional inpatient i.v. treatment is lacking. Patient acceptability of OPAT appears
to be high, with patients particularly appreciating being able to resume their daily activities (such as going
to work or school), having greater freedom and control over their illness, and not having to attend hospital
but being able to stay at home with family. The disadvantages identified by patients were most commonly
related to the use of infusion equipment. Few studies considered practitioner acceptability, but those that
did found some concerns related to the logistics involved in providing an OPAT service, including cost and
a lack of clarity about who would assume clinical responsibility for patients. Although many studies were
identified and included in this review, few involved a comparison with inpatient care (or other models of
OPAT), and even fewer employed a rigorous trial design. Much of the work in this area is based around
‘audits’ of services provided with limited data relating to outcomes. In addition, many of the studies
involved small numbers of patients.
We sought the views of health-care professionals involved in OPAT through an online survey and in-depth
interviews. Unfortunately, the response rate to the survey was low, although a wide range of staff and
settings were covered. Much more information was obtained from the interviews with OPAT professional
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leads who delivered services in a range of settings. Most offered some level of hospital provision, as well
as a community delivery option, but SA by patient or carer was relatively rare. They treated a wide range
of infections across a broad range of specialties. Service models varied from being well organised with
regularly updated business plans to those described by leads as being ad hoc. A number of problems with
service delivery were highlighted. Although good practice recommendations are in place,93 services did not
always manage to meet these criteria. Responsibility for care was not always explicit and there were
examples of clinical leadership being lacking. Some services had received short-term funding with no
guarantee of continued investment. Services were often limited by their funding, with expansion being
difficult. Interviewees made a number of suggestions on how OPAT service provision might be improved.
In particular, there was felt to be a need for guidance on commissioning to ensure consistency of service
provision as well as providing information on how to provide appropriate service models according to local
population needs, taking into account local resources. Clinical governance was thought to be important
and clinical outcomes should be measured as well as cost-effectiveness and professional and patient
satisfaction with the services provided. This could be informed by national guidance. Networks at local,
regional and national levels could facilitate both governance and service development.
Antimicrobial stewardship is currently a key concern, after the issue of increasing antimicrobial resistance
was high-lighted by the Chief Medical Officer and placed on the National Risk Register.172 The once-daily
antibiotics favoured in OPAT may be broader spectrum [ertapenem (Invanz, Merck Sharp & Dohme
Limited)8], but some are narrow but of concern for resistance [teicoplanin (Targocid, Sanofi)173] and so
research is required on appropriate antibiotic choice by OPAT services and surveillance for the development
of antimicrobial resistance following OPAT.174
Our qualitative study of patients’ perceptions of OPAT was designed to explore the attributes of such
services in detail and to compare different models of service delivery. We recruited patients representing a
range of socioeconomic backgrounds who between them experienced all four main OPAT service models.
Overall, patients appreciated the care they receive and felt that services were generally well run and of
high quality. Most acutely ill patients preferred to be cared for in hospital, but once stabilised most
preferred to recover at home. Some aspects of the service were identified which were not specific to a
particular service model; for example, patients preferred to have a definite appointment for their treatment
rather than to be kept waiting. They also were keen to have follow-up after their treatment had finished.
Patients identified a range of health-care experiences as being important. A good service was one in which
staff were perceived to be competent and highly skilled. For some this meant the active involvement of
doctors within the service but others focused on the expertise and experience of nursing staff. OPAT
services can support patients to self-manage in the community but when services are not configured in a
way that helps patients, this can negatively impact on patient satisfaction. Poor communication could leave
patients without the knowledge and confidence needed to be a competent collaborator in their own care
and affect their perceptions of the service. These findings suggest that both the organisation of health care
and the personal interactions or social dynamics are important to the patient experience, as noted by
Entwistle et al.106
Each of the care pathways was viewed as having its own strengths and weaknesses, and the importance
people attached to different attributes seemed to be linked to the age and health of the patient. A nurse
at home model was perceived to be particularly well suited for older patients, those needing longer
courses of i.v. treatment and those with more complex care needs. For many, the one-to-one time with the
nurse was viewed as a key benefit, but this could be quickly eroded if the nursing team is large and the
continuity of the care relationship is broken. Hospital attendance was considered to be most suitable
for those who were fitter, younger and who required once-daily, short courses (under 1 week) of i.v.
treatment, a view also held by those attending clinic with long-term infections. The availability of a doctor
in the clinic provided the reassurance some needed ‘in case anything went wrong’; other qualitative
studies such as that by Bamford et al.35 have suggested that some patients do not feel confident about
being treated by a nurse at home.
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A potential benefit of hospital attendance was its convenience for hospital staff, but this required the use of
timed appointments and when appointments were not kept, this affected the level of patient satisfaction,
a finding reported elsewhere.69 Characteristics of the service (e.g. if understaffed) and the staff themselves
(e.g. not briefed about the patient) contributed to dissatisfaction. Hospital attendance was the only care
pathway in which transport is a significant issue. Poor public transport links, a reliance on hospital transport
and poor car-parking facilities at hospitals were also key attributes that affected the acceptability of hospital
attendance and have been noted previously.69
Self-administration was the model of care least well represented in our sample, and all patients receiving
this were chronically ill patients who received regular courses of i.v. treatment, so do not reflect the views
of those who experience a one-off course of antibiotics, for example for a deep-seated infection. Patients
who had no personal experience of SA voiced most concerns about the risks of this service model.
Although those using the service found it convenient, there were residual concerns about the safety of SA,
and there was a suggestion that some would prefer inpatient care. SA was offered only to patients who
were physically and cognitively able to manage the complexity of delivering the therapy themselves.
Through these interviews and the focus group we were able to identify a number of attributes of such
services, which were used to develop our survey of patient preferences through the DCE. In addition, a
number of questions to determine patients’ attitudes to OPAT and health care in general were identified.
The DCE was designed to explore the aspects of the different service models that matter most to patients
and the aspects that they might be prepared to ‘trade off’. Six key attributes were developed through the
systematic review and interviews with health-care professionals and patients:
1. number of treatments per day
2. the importance of a timed appointment
3. who administers the treatment
4. communication with health-care professionals
5. follow-up arrangements
6. risk of adverse reactions.
The DCE was piloted in a small number of patients and after minor adjustments was then administered to
just over 200 participants. These were recruited from six centres providing OPAT services across Yorkshire
and included those patients with complex infections requiring long-term treatment, as well as those
requiring short courses of antibiotics, who between them experienced all the service models. Anonymised
clinical and demographic background information was collected, as well as a survey on patients’ attitudes
to health care in general and OPAT in particular. In summary, the attitudinal data showed a tendency for
non-white females living alone to prefer inpatient treatment. Older, non-white patients were more likely to
perceive health care as the responsibility of the doctor.
The DCE showed that, overall, the visiting nurse at home model of care is preferred to attendance at
hospital. However, this was influenced by sociodemographic factors; for example, younger males preferred
to attend hospital rather than receive treatment at home. The next strongest preference was for once-daily
treatment over two or continuous treatments, closely followed by the preference for the lowest level of
adverse event risk. Although other attribute levels were significant in determining respondent’s choices,
they were less important. People preferred a SN to a doctor and GN to deliver their treatment, preferred
having an appointment time (to not having one) and preferred to communicate with someone they have
met before regarding their care.
Our health economics workstream examined the value for money of different OPAT service models using
two different approaches: a Markov model to generate estimates of cost-effectiveness and a simulation
model. In both short- and long-term infection Markov models, the difference in expected effectiveness
(QALYs) across service models was negligible. The explanation for this is that the period of observation
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(3 and 12 months for short-term and long-term infections, respectively) is relatively short and, for many,
the infection being treated is transient in nature with a very low risk of mortality. Furthermore, the risk
of adverse events was very low across all services. In contrast, there were significant cost differentials
between the services which drove the cost-effectiveness results.
The SN service was the optimal service for short-term infections, being only marginally less effective than
HO visits and being more cost-effective than a GN. SA was very rare for the treatment of short-term
infections, so we did not include this model in the analysis. These results were relatively insensitive to
alternative analyses and did not change with modest changes in the risks, costs or utility parameter values.
For long-term infections, the order of cost-effectiveness was maintained, with GN preferred to HO, SN
preferred to GN and SA preferred to SN; this also reflected the order of costs, with SA proving cheapest.
The QALY gain differential was largely attributable to the greater time horizon and treatment period but
was still very small. As in the short-term infection model, it appears that costs drives the results. Again,
results were relatively insensitive to parameter changes; for example, the results changed in favour of SN
only when the risk of line infection in SA was doubled. The results from the simulation modelling largely
corroborated the Markov models results, although SN was found to be optimal for long-term treatment,
in contrast to SA which was optimal in the Markov model. However, the ordering in terms of costs and
QALYs across treatments was the same and the actual difference in NMB between the models was
minimal. The results from both Markov and simulation models suggest that SN is the optimal service in the
short term. In the long term, SA appears optimal, although SN provides slightly higher benefits but at
higher cost. Not all patients will be able to self-administer their treatment, so an alternative model of care
needs to be available.
The simulation yielded several additional useful pieces of information. It showed that net benefit was
inversely related to the number of treatment delays and that when resources (e.g. availability of nurses to
provide treatment) are exhausted, delays and costs increase and QALYs decrease (especially in the long
term). The analysis found that for high-density population areas where nurse visits might be conducted in
1 hour, each nurse can safely handle just over 90 infections per year. This clearly would be fewer if travel
time or the complexity of cases is increased. The results also suggested that long-term infections may best
be served by a combination of SA and SN services.
Once we had completed the project workstreams described above, we presented the results to a panel of
expert researchers and health-care professionals in the field. We asked them to review the findings and
give their opinions on a number of questions.
There was broad agreement that OPAT services could be based either in an acute hospital trust or in the
community. The panel agreed that there needs to be flexibility to accommodate patients with different
needs and, therefore, that within any one OPAT service there should be more than one care pathway
(e.g. SA, HO attendance, nurse at home).
The health economics evidence suggested that a SN service was the most cost-effective for short- and
long-term infections, with SA being less expensive for long-term infections. However, there was some
reluctance to accept these findings by some panel members who favoured their current care pathways for
their patient populations. However, there was agreement that OPAT services should focus on antimicrobials
which could be administered once a day, provided that the treatment selected is clinically appropriate,
as this provided the greatest potential for services to treat more patients (by freeing up staff who would
otherwise be involved in repeat administrations).
The expert panel agreed that a nationally commissioned service is needed, rather than local negotiation with
CCGs. It was thought that in more rural areas a hub and spoke model (network) might be appropriate,
similar to the model used in cancer, with tertiary (specialist), DGH and medical centres (CCG level) working
together to provide care. Technological advances such as telemedicine could be employed in more
remote areas.
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It was agreed that patient choice is important, but that any service should also offer good value for money
to the NHS and be appropriate for the individual patient’s clinical needs. Service users need to be provided
with appropriate information to inform their decision-making. Local services must both support the needs
of the whole community and take into account the skill set of the available providers. The group discussed
the implications of patient attitudes when considering the push to move to community-based care. It was
agreed that the findings of the study indicate that there may be a need for an attitudinal/behavioural shift
by both NHS staff and patients to accept these new ways of delivering health care in the community in
general, not just i.v. services. It was suggested that the attitudinal questionnaire developed as part of the
DCE would be useful to commissioners for service monitoring within local contracts and would make a
welcome component of a commissioner’s toolkit.
Strengths and limitations
Our systematic review, revised just before submission of this report, provides the most comprehensive
review of the research published on OPAT in recent years. This helped us to plan our subsequent research
focusing on areas in which little was known, such as patient preferences. Our interviews with health-care
professionals across England working in a range of services provide insight into the challenges of setting
up and running such services.
Our data support and develop the earlier limited qualitative research evaluating OPAT services. The strengths
of this part of the study are that we recruited from four sites, including two large teaching hospitals and
two DGHs, which between them offered HO attendance, SN and GN nurse at home and SA OPAT services.
We had a broad sampling strategy to obtain views from participants from a diverse range of socioeconomic
backgrounds. This enabled us to contrast the views and experiences of those who experienced different
models of care and provided relevant information to examine the aspects of care that patients valued to
construct our attribute shortlist for the DCE.
The use of DCEs to inform the design of health services is a well-established approach.100,127 This research
is the first attempt to understand patients’ preferences for OPAT services and one of the most in-depth
explorations of the role of patient attitudes in influencing health-care preferences. The DCE provided
useful information on not only the type of services that individuals prefer but also on which aspects of
those services were important to them. This is crucial for designing new services and, should more patient
choice be offered, understanding demand. The DCE also highlighted the high degree of heterogeneity in
preferences which would be useful for tailoring services.
The cost-effectiveness modelling and extensive sensitivity analyses represent the most in-depth economic
evaluation of OPAT services to date. The addition of the simulation model to the evaluation is relatively
novel. Many technology appraisals assume that resources (i.e. staff and hospital beds) are infinite and are
costed on a per use basis. However, this clearly neglects key considerations for decision-making in the real
world. We conducted a ‘commissioning’ perspective here that also allowed us to specify a set of fixed
resources that could be exhausted and determine the impact on the costs of purchasing additional
resources and on patients who may be denied or receive delayed health care. Although not inconsistent
with the usual HTA perspective of the health and social care system, it facilitates decision-making at a local
level. Here, factors such as the number of patients in a given area, number of available staff and hospital
beds, the geography of the local catchment area and patient preferences can be accounted for in the
estimates of cost-effectiveness and decision-making.
The expert panel event allowed us to obtain feedback on our findings and to formulate further research
questions from specialists in the field who were independent of the project. This included individuals
involved in commissioning and formulating policy for NHS England on antimicrobial stewardship and
representatives of BSAC, the professional society championing OPAT.
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Our survey of health-care providers was hampered by a low response rate, which was probably due to
‘survey fatigue’ and the pressure of work – such problems have been noted elsewhere.91 Owing to delays
in gaining ethics approval, we had only 3 months in which to recruit to the interview study. We planned to
undertake focus groups with relatively few interviews, but recruitment was poor. We therefore switched
to interviews only, which resulted in much richer data, but did put the study behind time as the analysis
took longer than anticipated. This had the knock-on effect of the interviews and analysis becoming
desynchronised, so some data saturation was reached before we finished interviewing and no new
findings were revealed in the final five interviews.
Overall recruitment of patients to the study was initially behind target, so we increased our number of sites
to include two more sites. However, we still lacked patients with experience of SA for single infections rather
than recurrent infections, so we then opened a further site where this model of care is commonly used.
We struggled to recruit the very elderly (> 85 years of age) and those from local BME populations. Feedback
from eligible older patients was that they did not feel well enough to be interviewed. We struggled to
recruit from the BME community despite advice from researchers with significant experience working with
the BME community and our PPI group. We may therefore have missed issues that are of importance to the
non-white population and this is a potential source of bias in respect of the DCE attributes themselves.
However, the systematic review evidence that informed the development of the attributes and their levels
comes from a range of countries.
Caveats are required in translating the results found here into service commissioning. First, we must
acknowledge that only services that represent value for money should be offered to patients.175 The benefits
of the services in our DCE were (with the exception of risk) based on process utility and not health
outcomes. Although convenience is important and may offer indirect health benefits (e.g. through better
adherence), we must be cautious in attributing too great a value to it. Second, the DCE provides information
only on stated preferences and may not accurately reflect the choices that people would make if faced with
the same options in reality.
Some of the options contained in the DCE do not represent current practice. For example, doctors rarely
administer i.v. treatment but some patients in our interview study talked in depth about the importance of
the doctor, so we included this to test what patients would be willing to trade to receive this level of care.
Patient preconceptions and past experiences may influence the findings. Only adults who had previously
experienced OPAT were included; those who would be eligible for OPAT but were not offered the service
were not included, and this population may respond differently. The reason for the sampling used in this
study was that the original protocol included the collection of anonymised data from the DCE participants,
so only those who had received OPAT were eligible.
Decision-analytic modelling is useful when the information required to make a decision is not available or
requires synthesis; it can also help to inform research priorities.127 Notwithstanding this, the usefulness of
modelling is a function of the quality of data available to populate the models that are constructed. In this
economic evaluation we were constrained to some extent by the available data. There was a paucity of
useful comparative UK data on the effectiveness and safety of the OPAT services. The more severe events
that are possible (e.g. severe line infection, anaphylactic shock or CDI) are relatively rare and, in the case of
CDI, becoming rarer;176 thus, their impact at a cohort level is relatively minor. Given these issues, it is
debatable if better quality data would have influenced the results to a great degree. We also acknowledge
that other variations on OPAT service models are available, for example, delivery by a GP at the local clinic.
However, it was not practical to evaluate all of these. Outcomes data for all possible service configurations
would be scarce and we chose to focus on the most commonly used in current practice. Although topical,172
we chose not to model the development of antimicrobial resistance. We believe the differential rate of
resistance between the service models would have been negligible and did not warrant the additional
modelling resources required or the additional layer of complexity in the models. However, with antimicrobial
stewardship being a key concern in light of increasing antimicrobial resistance,172 some of the once-daily
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antibiotics favoured in OPAT (e.g. teicoplanin173) may be of concern for resistance; thus, research is required
on appropriate antibiotic choice by OPAT services and surveillance for the development of antimicrobial
resistance following OPAT.174
Conclusions
It has been long established in the UK and many other countries that OPAT is generally preferred by
patients, is safe and is cost-effective in comparison to inpatient admission for i.v. antibiotic treatment.
Through the systematic review, this project has highlighted the lack of previous research into the cost-
effectiveness of different models of service provision and patient choice in this area. In addition, conclusive
evidence as to the clinical benefit (or otherwise) of this mode of therapy compared with traditional
inpatient i.v. treatment is lacking. Because OPAT services are now established in many areas of the UK, in
response to general policy initiatives to treat patients in the community rather than in hospital, and to save
on hospital admission costs it would be now very difficult to conduct such a study.
Our survey of OPAT provision and interviews with health-care providers in England makes it clear that
there is a great variation both in the extent of services provided and models of care in existence. In
addition, some respondents were struggling to maintain or even set up OPAT services because of the lack
of clear commissioning directives and/or engagement by senior managers.
Our qualitative studies, although confirming that most patients prefer to receive treatment through OPAT
services, did highlight some organisational shortcomings, for example where patients were kept waiting for
long periods to receive treatments or where aftercare expectations were not met. This suggests that the
governance of such services needs to be improved to meet both specific and general clinical standards.
Our DCE modelling data collected on patient preferences showed that most patients preferred to be treated
at home, although certain sociodemographic groups would rather attend a hospital clinic. The health
economics workstream similarly showed that visiting nurse model was the most cost-effective overall. NMB
values for HO, GN and SN services were £2493, £2547 and £2655, respectively, for short-term services. SA
is also cost-effective for patients willing and competent to be trained to do this; in practice this is useful only
for those patients requiring longer or repeated courses of treatment. NMB values for HO, GN, SN and SA
services were £8240, £9550, £10,388 and £10,644, respectively. The simulation model provides a useful
method of calculating the capacity of services according to the number of staff employed.
Implications for future service planning and commissioning
Commissioning of health-care services in England is increasingly complex and has been subject to frequent
change in recent years,177 including through the introduction of commercial and non-NHS providers of
services. The Five Year Forward View171 accepts that one size does not fit all and recommends an emphasis
on ‘diverse solutions and local leadership’ supported by ‘meaningful local flexibility in the way payment
rules, regulatory requirements and other mechanisms are applied’. Currently, most common conditions are
commissioned locally by CCGs, whereas rarer diseases are commissioned at national level by NHS England.
At present there is no clear commissioning mechanism for OPAT services. There is much variation in how
the cost of treating cellulitis, the most common condition requiring OPAT, is reimbursed to providers
(see Jones et al.178). The NHS England service specification requires that infectious diseases services include
a requirement to provide OPAT services; however, infectious diseases units are largely based in tertiary
referral hospitals so areas of the country remote from large centres of population do not have such
services. In general, commissioning decisions appear to be based on a variety of factors including local
knowledge, advice from clinicians, informal contacts and, less frequently, traditionally published academic
research. It has been proposed that research evidence should be communicated in ways that are more
accessible to commissioners.177
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Patient preferences
Patient choice has become an important factor in decision-making on health-care services, but formal
research into how those views can be quantified is limited. It is known that direct questioning may provide
information on which type of service is preferred overall but does not give information on the relative
importance of the multiple attributes patients consider when making their decision. Commissioners
are increasingly sensitive to patient views in supporting service developments, particularly qualitative
research.109,179 Therefore, our study of patient preferences for particular services models will help to inform
decision-making on provision of OPAT services. Commissioners can also use the results of this study to
influence service provision so as to obtain the best outcomes within a given budget. The results indicate
that where one model of OPAT care is envisaged, a visiting nurse at home model is likely to be preferred
by patients. However, where possible, a range of options should be available. One solution that was
proposed by patients as an alternative to hospital-based services was to invest in ‘local clinic services’,
perhaps based in local medical centres. This might fit within the ‘Multi-Specialty Community Provider’
model proposed in the Five Year Forward View by NHS England.171 Patients valued good communication
between staff members, and robust governance processes should be in place to ensure patients receive
continuity of care. Aftercare, such as follow-up by a nurse at the end of treatment for short-term infections
such as cellulitis,10 is expected by patients. The qualitative data (see Chapter 4) support the DCE findings
and suggest that patients’ attitudes towards health care are important and could form a target for future
intervention. The preferences across short- and long-term infection patients were quite stable, suggesting
that people in these groups value similar service attributes. These findings are likely to be useful in
determining future service provision in this area, which takes account of patient preferences. It will help
NHS trusts who want to introduce OPAT services by providing a rationale for service configuration.
Recommendations for future research
Together with the expert panel we concluded that a RCT of different models of care is not feasible because
of the problems of centres being not able to provide all the necessary comparator services for randomisation,
difficulties in deciding on the outcome measure and the heterogeneous nature of the patient population.
However, other, more pragmatic, study designs could be considered, such as prospective observational
multicentre studies to collect information of outcomes, adverse events, and costs. For example, the use of
the proposed multi-specialty community provider facilities for OPAT could be evaluated in this way. Other
specific research topics include the development of a patient-reported outcome measure which could be
used to standardise research in the OPAT, and the evaluation of mixed models of care, including provision of
other i.v. therapies (such as diuretics for patients with heart failure).
The expert panel suggested that replicating the DCE study in other areas of the country would be useful to
further validate our findings. There were some concerns among the expert panel members around the lack of
ethnic diversity in the development of the questionnaire. If the robustness of the measure could be determined
by input from further work with patients from a range of ethnic groups, this would be beneficial.
There are a number of potential topics for research which could develop our patient preference evaluation.
Additional research is required to understand if and how stated preferences in health could be calibrated
to better reflect revealed preferences to facilitate service design and planning. One possible area of
research would be to consider patients’ willingness to pay for aspects of care using the DCE, for example
the extent of the influence of costs of transport to or parking at a health-care setting on patient choices.
Our methodology is transferable to other health service evaluations. The economic models are tools that
could be used to evaluate other (related) interventions, including oral therapy as an alternative to i.v.
antibiotics.66 The simulation model could be used to aid commissioning decisions. For example, with
knowledge of patient numbers and local geography, the models can inform the optimal configuration of
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services and staffing levels. The DCE methods could be applied to inform the development of other local
services to ensure that they meet local preferences.
In summary, our specific recommendations for further research in order of priority are:
l prospective observational multicentre studies to collect information of outcomes, adverse events and
costs of OPAT, including mixed models of care
l the development of a patient-reported outcome measure which could be used to standardise research
in OPAT
l an assessment of how stated preferences in health could be calibrated to better reflect revealed
preferences to facilitate service design and planning, in particular, direct costs to the patient
l an evaluation of simulation model as a tool to plan OPAT services in different areas.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115

Acknowledgements
Contributions of authors
Jane Minton (Consultant in Infectious Diseases and Honorary Clinical Associate Professor) contributed
clinical expertise and wrote the introduction and discussion chapters of the report.
Carolyn Czoski Murray (Senior Research Fellow in Applied Health) led the survey and interviews with
health-care professionals and wrote Chapter 3 of the report. She also contributed to the systematic review
and analysis of patient interviews.
David Meads (Associate Professor of Health Economics) led the economic modelling work and prepared
the results for publication. He also contributed to the development of the DCE survey and the
interpretation of the health economics literature.
Stephane Hess (Professor of Choice Modelling) led the choice modelling workstream and analysed
the DCE.
Armando Vargas-Palacios (Research Fellow) conducted the health economics analysis, in particular the
simulation modelling, and prepared the results for publication.
Elizabeth Mitchell (Senior Research Fellow) carried out the systematic review and wrote Chapter 2 of
the report.
Judy Wright (Senior Information Specialist) carried out the literature searches for the systematic review.
Claire Hulme (Professor of Health Economics) advised on the health economic work and the preparation
of the final report.
David K Raynor (Professor of Pharmacy Practice) advised on community pharmacy aspects of the project,
contributed to the analysis of the health professional interviews and the expert panel review.
Angela Gregson (Clinical Pathway Lead for Community i.v. Antibiotics Service) advised on community
nursing aspects of the project, including costs and patient pathways for the economic evaluation.
Philip Stanley (Consultant in Infectious Diseases) contributed clinical expertise in OPAT, in particular to
the economic modelling and development of the DCE and contributed to Chapters 1 and 8 of the report.
Kate McLintock (Clinical Lecturer in Primary Care) contributed clinical expertise from a community
perspective and took part in the Expert panel review.
Rachel Vincent (Lead Pharmacist in Infectious Diseases, OPAT and HIV) contributed expertise on
antimicrobials and devices used for OPAT and costs for the economic evaluation.
Maureen Twiddy (Senior Research Fellow in Applied Health) led the qualitative workstream (patient
interviews) and wrote up Chapter 4 for publication. She contributed to the development of the DCE survey
and DCE choice modelling report, wrote the expert panel chapter and acted as PPI lead and project manager.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117
Other key contributors to the research
Miss Samantha Mason and Mrs Janine Heeley (DCE data collection).
Dr Jill Edwards and Dr Janine Bestall (health professionals study).
Research nurses at all seven sites.
Patient advisory group
Mrs Heather Gent, Mrs Andrea McGowan, Mr Paul Parmenter and Mr Christopher Townsley.
Independent Steering Committee Members
Professor Jenny Hewison (chairperson), Dr Ann Chapman, Dr Philip Howard, Dr Claire McKenna,
Dr Sue Pavitt, Dr Jonathan Sandoe and Dr Barbara Summers.
Publications
Czoski Murray CJ, Mitchell ED, Twiddy M, Wright J, Meads D, Minton J. Outpatient Parenteral Antimicrobial
Therapy (OPAT): A Systematic Review of Models of Care. Paper presented at the Federation of Infection
Societies 2014, Harrogate, 24–26 November 2014.
Czoski-Murray CJ, Mitchell ED, Twiddy M, Wright J, Meads D, Minton J. Outpatient Parenteral
Antimicrobial Therapy (OPAT): A Systematic Review of Models of Care. Poster presented at the OPAT 2015
National Conference, London, 13 April 2015.
Czoski Murray C, Twiddy M, Meads D, Hess S, Wright J, Mitchell ED, et al. Community intravenous
Antibiotic Study (CIVAS): a protocol for an evaluation of patient preferences for and cost-effectiveness of
community intravenous antibiotic services. BMJ Open 2015;5:e008965.
Data sharing statement
All data can be obtained from Dr Maureen Twiddy. Data will be archived at the University of Leeds for
15 years.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
References
1. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis
2010;51(Suppl. 2):198–208. http://dx.doi.org/10.1086/653520
2. Kieran J, O’Reilly A, Parker J, Clarke S, Bergin C. Self-administered outpatient parenteral antimicrobial
therapy: a report of three years experience in the Irish healthcare setting. Eur J Clin Microbiol Infect
Dis 2009;28:1369–74. http://dx.doi.org/10.1007/s10096-009-0794-5
3. Mackintosh C, White H, Seaton R. Outpatient parenteral antibiotic therapy (OPAT) for bone and
joint infections: experience from a UK teaching hospital-based service. J Antimicrob Chemother
2011;66:408–15. http://dx.doi.org/10.1093/jac/dkq445
4. Nazarko L. Providing outpatient antibiotic therapy for cellulitis in primary care. Br J Community
Nurs 2008;13:520–4. http://dx.doi.org/10.12968/bjcn.2008.13.11.31524
5. Yan YM, Singh M, Tonks K, Kavi J, Langford NJ. Delivering outpatient antibiotic therapy (OPAT) in
an Acute Medical Unit. Acute Med 2011;10:22–5.
6. Gilchrist M, Franklin BD, Patel JP. An outpatient parenteral antibiotic therapy (OPAT) map to identify
risks associated with an OPAT service. J Antimicrob Chemother 2008;62:177–83. http://dx.doi.org/
10.1093/jac/dkn152
7. Török ME, Chapman AL, Lessing MP, Sanderson F, Seaton RA. Outpatient parenteral antimicrobial
therapy: recent developments and future prospects. Curr Opin Investig Drugs 2010;11:929–39.
8. Bazaz R, Chapman A, Winstanley T. Ertapenem administered as outpatient parenteral antibiotic
therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing
Gram-negative organisms. J Antimicrob Chemother 2010;65:1510–13. http://dx.doi.org/10.1093/
jac/dkq152
9. Tice AD, Rehm SJ. Meeting the challenges of methicillin-resistant Staphylococcus aureus with
outpatient parenteral antimicrobial therapy. Clin Infect Dis 2010;51(Suppl. 2):171–5.
http://dx.doi.org/10.1086/653517
10. Seaton RA, Bell E, Gourlay Y, Semple L. Nurse-led management of uncomplicated cellulitis in the
community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob
Chemother 2005;55:764–7. http://dx.doi.org/10.1093/jac/dki092
11. Sharma R, Loomis W, Brown RB. Impact of mandatory inpatient infectious disease consultation on
outpatient parenteral antibiotic therapy. Am J Med Sci 2005;330:60–4. http://dx.doi.org/10.1097/
00000441-200508000-00002
12. Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE, et al. Randomised controlled
trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ
2005;330:129. http://dx.doi.org/10.1136/bmj.38309.447975.EB
13. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy and
cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.
J Antimicrob Chemother 2009;64:1316–24. http://dx.doi.org/10.1093/jac/dkp343
14. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Health
Technology Appraisal. London: NICE; 2013.
15. Marra CA, Frighetto L, Goodfellow AF, Wai AO, Chase ML, Nicol RE, et al. Willingness to pay to
assess patient preferences for therapy in a Canadian setting. BMC Health Serv Res 2005;5:43.
http://dx.doi.org/10.1186/1472-6963-5-43
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
16. Department of Health (DH). Equity and Excellence: Liberating the NHS. London: DH; 2010.
17. Department of Health (DH). Creating a Patient-Led NHS. London: DH; 2005.
18. Department of Health (DH). Your Health, Your Care, Your Say. London: DH; 2006.
19. Ashiru-Oredope D, Sharland M, Charani E, McNulty C, Cooke J, ARHAI Antimicrobial Stewardship
Group. Improving the quality of antibiotic prescribing in the NHS by developing a new
Antimicrobial Stewardship Programme: Start Smart – Then Focus. J Antimicrob Chemother
2012;67(Suppl. 1):i51–63. http://dx.doi.org/10.1093/jac/dks202
20. Mitchell E, Macdonald S, Campbell NC, Weller D, Macleod U. Influences on pre-hospital
delay in the diagnosis of colorectal cancer: a systematic review. Br J Cancer 2008;98:60–70.
http://dx.doi.org/10.1038/sj.bjc.6604096
21. Esposito S, Noviello S, Leone S, Tice A, Seibold G, Nathwani D, Scaglione F, International OPAT
Registry. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison.
Int J Antimicrob Agents 2004;24:473–8. http://dx.doi.org/10.1016/j.ijantimicag.2004.06.004
22. Rapoport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, et al. Ceftriaxone plus
once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital
discharge vs. Standard In-patient care. Chemotherapy 1999;45:466–76. http://dx.doi.org/
10.1159/000007240
23. Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for
the economic evaluation of potential therapies. PharmacoEconomics 2003;21:1001–24.
http://dx.doi.org/10.2165/00019053-200321140-00002
24. You JH, Lee GC, So RK, Cheung KW, Hui M. Linezolid versus vancomycin for prosthetic joint
infections: a cost analysis. Infection 2007;35:265–70. http://dx.doi.org/10.1007/s15010-007-6304-8
25. Dall L, Peddicord T, Peterson S, Simmons T, Dall T. Hospitalist treatment of CAP and cellulitis
using objective criteria to select patients. Infect Med 2003;20:379–99.
26. Duncan CJ, Barr DA, Seaton RA. Outpatient parenteral antimicrobial therapy with ceftriaxone,
a review. Int J Clin Pharm 2012;34:410–7. http://dx.doi.org/10.1007/s11096-012-9637-z
27. Goodwin DD, Hanson JC, Berry CP. The changing face of Canadian home parenteral therapy.
J Infus Nurs 2002;25:372–8. http://dx.doi.org/10.1097/00129804-200211000-00005
28. Laupland KB, Gill MJ, Schenk L, Goodwin D, Davies HD. Outpatient parenteral antibiotic therapy:
evolution of the Calgary adult home parenteral therapy program. Clin Invest Med 2002;25:185–90.
29. Matthews P, Conlon C, Berendt A, Kayley J, Jefferies L, Atkins B, et al. Outpatient parenteral
antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A
retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother 2007;60:356–62.
http://dx.doi.org/10.1093/jac/dkm210
30. Montalto M, Lui B, Mullins A, Woodmason K. Medically-managed Hospital in the Home: 7 year
study of mortality and unplanned interruption. Aust Health Rev 2010;34:269–75. http://dx.doi.org/
10.1071/AH09771
31. Williams DN. Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial
agents. Int J Antimicrob Agents 1995;5:3–8. http://dx.doi.org/10.1016/0924-8579(94)00046-W
32. Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient
parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus.
South Med J 2005;98:590–5. http://dx.doi.org/10.1097/01.SMJ.0000145300.28736.BB
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
33. Seetoh T, Lye DC, Cook AR, Archuleta S, Chan M, Sulaiman Z, et al. An outcomes analysis of
outpatient parenteral antibiotic therapy (OPAT) in a large Asian cohort. Int J Antimicrob Ag
2013;41:569–73. http://dx.doi.org/10.1016/j.ijantimicag.2013.01.015
34. Barr DA, Semple L, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching
hospital-based practice: a retrospective cohort study describing experience and evolution over
10 years. Int J Antimicrob Agents 2012;39:407–13. http://dx.doi.org/10.1016/j.ijantimicag.
2012.01.016
35. Bamford KB, Desai M, Aruede MJ, Lawson W, Jacklin A, Franklin BD. Patients’ views and experience
of intravenous and oral antimicrobial therapy: room for change. Injury 2011;42(Suppl. 5):24–7.
http://dx.doi.org/10.1016/S0020-1383(11)70129-2
36. Chambers S, Gallagher K, Pithie A. Patient acceptability of home intravenous antibiotic therapy.
N Z Med J 2004;117:U865.
37. Lehoux P. Patients’ perspectives on high-tech home care: a qualitative inquiry into the user-friendliness
of four technologies. BMC Health Serv Res 2004;4:28. http://dx.doi.org/10.1186/1472-6963-4-28
38. Lane MA, Marschall J, Beekmann SE, Polgreen PM, Banerjee R, Hersh AL, Babcock HM.
Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians.
Infect Control Hosp Epidemiol 2014;35:839–44. http://dx.doi.org/10.1086/676859
39. Lehoux P, Richard L, Pineault R, Saint-Arnaud J. Delivery of high-tech home care by hospital-based
nursing units in Quebec: clinical and technical challenges. Nurs Leadersh (Tor Ont) 2006;19:44–55.
http://dx.doi.org/10.12927/cjnl.2006.18048
40. Barr DA, Semple L, Seaton RA. Self-administration of outpatient parenteral antibiotic therapy and
risk of catheter-related adverse events: a retrospective cohort study. Eur J Clin Microbiol Infect Dis
2012;31:2611–19. http://dx.doi.org/10.1007/s10096-012-1604-z
41. Richards DA, Toop LJ, Epton MJ, McGeoch GR, Town GI, Wynn-Thomas SM, et al. Home
management of mild to moderately severe community-acquired pneumonia: a randomised
controlled trial. Med J Aust 2005;183:235–8.
42. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis:
a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J
1997;10:896–900.
43. Esmond G, Butler M, McCormack AM. Comparison of hospital and home intravenous antibiotic
therapy in adults with cystic fibrosis. J Clin Nurs 2006;15:52–60. http://dx.doi.org/10.1111/
j.1365-2702.2005.01236.x
44. Angel JV. Outpatient antibiotic therapy for elderly patients. HIAT Study Group. Am J Med
1994;97:43–9.
45. Mauceri AA. Treatment of bone and joint infections utilizing a third-generation cephalosporin
with an outpatient drug delivery device. HIAT Study Group. Am J Med 1994;97:14–22.
46. Poretz DM. Treatment of serious infections with cefotaxime utilizing an outpatient drug delivery
device: global analysis of a large-scale, multicenter trial. HIAT Study Group. Am J Med 1994;97:34–42.
http://dx.doi.org/10.1016/0002-9343(94)90286-0
47. Poretz DM. Treatment of skin and soft-tissue infections utilizing an outpatient parenteral drug
delivery device: a multicenter trial. HIAT Study Group. Am J Med 1994;97:23–7. http://dx.doi.org/
10.1016/0002-9343(94)90284-4
48. Wolter JM, Cagney RA, McCormack JG. A randomized trial of home vs hospital intravenous
antibiotic therapy in adults with infectious diseases. J Infect 2004;48:263–8. http://dx.doi.org/
10.1016/S0163-4453(03)00135-X
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
49. Rehm S, Campion M, Katz DE, Russo R, Boucher HW. Community-based outpatient parenteral
antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective
endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.
J Antimicrob Chemother 2009;63:1034–42. http://dx.doi.org/10.1093/jac/dkp051
50. Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, et al. Oral moxifloxacin
or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients
suitable for early hospital discharge. Support Care Cancer 2008;16:1017–23.
51. Stein GE, Schooley SL, Havlichek DH, Nix DE. Outpatient intravenous antibiotic therapy compared
with oral linezolid in patients with skin and soft tissue infections: a pharmacoeconomic analysis.
Infect Dis Clin Pract 2008;16:235–39.
52. Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in
low-risk neutropenic patients with cancer. Cancer Invest 1997;15:237–42. http://dx.doi.org/
10.3109/07357909709039721
53. Thornton J, Elliott RA, Tully MP, Dodd M, Webb AK. Clinical and economic choices in the treatment
of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros
2005;4:239–47. http://dx.doi.org/10.1016/j.jcf.2005.08.003
54. Duncan CJ, Barr DA, Ho A, Sharp E, Semple L, Seaton RA. Risk factors for failure of outpatient
parenteral antibiotic therapy (OPAT) in infective endocarditis. J Antimicrob Chemother
2013;68:1650–4. http://dx.doi.org/10.1093/jac/dkt046
55. Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin:
insights from a patient registry. Int J Clin Pract 2008;62:1183–7. http://dx.doi.org/10.1111/
j.1742-1241.2008.01824.x
56. Fernández-Avilés F, Carreras E, Urbano-Ispizua A, Rovira M, Martínez C, Gaya A, et al. Case-control
comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic
malignancies. J Clin Oncol 2006;24:4855–61. http://dx.doi.org/10.1200/JCO.2006.06.4238
57. Montalto M, Dunt D. Home and hospital intravenous therapy for two acute infections: an early
study. Aust N Z J Med 1997;27:19–23. http://dx.doi.org/10.1111/j.1445-5994.1997.tb00908.x
58. Pond MN, Newport M, Joanes D, Conway SP. Home versus hospital intravenous antibiotic therapy
in the treatment of young adults with cystic fibrosis. Eur Respir J 1994;7:1640–4. http://dx.doi.org/
10.1183/09031936.94.07091640
59. Bedi P, Sidhu MK, Donaldson LS, Chalmers JD, Smith MP, Turnbull K, et al. A prospective cohort
study of the use of domiciliary intravenous antibiotics in bronchiectasis. NPJ Prim Care Respir Med
2014;24:14090. http://dx.doi.org/10.1038/npjpcrm.2014.90
60. Bradley JM, Wallace ES, Elborn JS, Howard JL, McCoy MP. An audit of the effect of intravenous
antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis. Ir J Med Sci
1999;168:25–8. http://dx.doi.org/10.1007/BF02939576
61. Yang A, Fung R, Brunton J, Dresser L. Outpatient parenteral antimicrobial therapy for surgery patients:
A comparison with previous standard of care. Can J Infect Dis Med Microbiol 2013;24:74–8.
62. Lacroix A, Revest M, Patrat-Delon S, Lemaître F, Donal E, Lorléac’h A, et al. Outpatient parenteral
antimicrobial therapy for infective endocarditis: a cost-effective strategy. Med Mal Infect
2014;44:327–30. http://dx.doi.org/10.1016/j.medmal.2014.05.001
63. Yong C, Fisher DA, Sklar GE, Li SC. A cost analysis of Outpatient Parenteral Antibiotic Therapy
(OPAT): an Asian perspective. Int J Antimicrob Agents 2009;33:46–51. http://dx.doi.org/10.1016/
j.ijantimicag.2008.07.016
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
122
64. Mazo S, Emparan C, Vallejo M, Soriano P. Hospital-in-the-home treatment of surgical infectious
diseases: an economic analysis. Surg Infect 2007;8:567–74. http://dx.doi.org/10.1089/sur.2006.047
65. Teuffel O, Amir E, Alibhai S, Beyene J, Sung L. Cost effectiveness of outpatient treatment for
febrile neutropaenia in adult cancer patients. Br J Cancer 2011;104:1377–83. http://dx.doi.org/
10.1038/bjc.2011.101
66. Patanwala AE, Erstad BL, Nix DE. Cost-effectiveness of linezolid and vancomycin in the treatment
of surgical site infections. Curr Med Res Opin 2007;23:185–93. http://dx.doi.org/10.1185/
030079906X162700
67. Grayson ML, Silvers J, Turnidge J. Home intravenous antibiotic therapy. A safe and effective
alternative to inpatient care. Med J Aust 1995;162:249–53.
68. Hindes R, Winkler C, Kane P, Kunkel M, Poretz DM. Outpatient intravenous antibiotic therapy in
Medicare patients: Cost-savings analysis. Infec Dis Clin Pract 1995;4:211–8. http://dx.doi.org/
10.1097/00019048-199505000-00016
69. Hitchcock J, Jepson AP, Main J, Wickens HJ. Establishment of an outpatient and home parenteral
antimicrobial therapy service at a London teaching hospital: a case series. J Antimicrob Chemother
2009;64:630–4. http://dx.doi.org/10.1093/jac/dkp212
70. Huminer D, Bishara J, Pitlik S. Home intravenous antibiotic therapy for patients with infective
endocarditis. Eur J Clin Microbiol 1999;18:330–4. http://dx.doi.org/10.1007/PL00015014
71. Johansson E, Bjorkholm M, Wredling R, Kalin M, Engervall P. Outpatient parenteral antibiotic
therapy in patients with haematological malignancies. A pilot study of an early discharge strategy.
Support Care Cancer 2001;9:619–24. http://dx.doi.org/10.1007/s005200100247
72. Kayley J, Berendt AR, Snelling MJ, Moore H, Hamilton HC, Peto TE, et al. Safe intravenous
antibiotic therapy at home: experience of a UK based programme. J Antimicrob Chemother
1996;37:1023–9. http://dx.doi.org/10.1093/jac/37.5.1023
73. Martel A. Home intravenous self-injection of antibiotic therapy. Can J Infect Dis Med Microbiol
1994;5:51C–55C. http://dx.doi.org/10.1155/1994/673183
74. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic
therapy in the United Kingdom. Chemotherapy 2001;47(Suppl. 1):17–23. http://dx.doi.org/
10.1159/000048564
75. Nathwani D, Morrison J, Seaton RA, France AJ, Davey P, Gray K. Out-patient and home-parenteral
antibiotic therapy (OHPAT): evaluation of the impact of one year’s experience in Tayside. Health Bull
1999;57:332–7.
76. Rodríguez-Cerrillo M, Poza-Montoro A, Fernandez-Diaz E, Romero AI. Patients with uncomplicated
diverticulitis and comorbidity can be treated at home. Eur J Intern Med 2010;21:553–4.
http://dx.doi.org/10.1016/j.ejim.2010.09.002
77. Rodríguez-Cerrillo M, Poza-Montoro A, Fernandez-Diaz E, Iñurrieta-Romero A, Matesanz-David M.
Home treatment of patients with acute cholecystitis. Eur J Intern Med 2012;23:e10–13.
http://dx.doi.org/10.1016/j.ejim.2011.07.012
78. Seaton RA, Nathwani D, Williams FL, Boyter AC. Feasibility of an outpatient and home parenteral
antibiotic therapy (OHPAT) programme in Tayside, Scotland. J Infect 1999;39:129–33.
http://dx.doi.org/10.1016/S0163-4453(99)90004-X
79. Teuffel O, Cheng S, Ethier MC, Diorio C, Martino J, Mayo C, et al. Health-related quality of life
anticipated with different management strategies for febrile neutropenia in adult cancer patients.
Support Care Cancer 2012;20:2755–64. http://dx.doi.org/10.1007/s00520-012-1397-8
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
80. Tice A. The use of outpatient parenteral antimicrobial therapy in the management of
osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries.
Chemotherapy 2001;47(Suppl. 1):5–16. http://dx.doi.org/10.1159/000048563
81. Tice AD. Experience with a physician-directed, clinic-based program for outpatient parenteral
antibiotic therapy in the USA. Eur J Clin Microbiol Infect Dis 1995;14:655–61. http://dx.doi.org/
10.1007/BF01690748
82. Al Ansari A, Al Alawi S, Al Qahtani M, Darwish A. Outpatient parenteral antimicrobial therapy
(OPAT) in the Kingdom of Bahrain: efficacy, patient satisfaction and cost effectiveness. Open
Infect Dis J 2013;7:90–5. http://dx.doi.org/10.2174/1874279301307010090
83. Esposito S, Leone S, Noviello S, Ianniello F, Fiore M, Russo M, et al. Outpatient parenteral antibiotic
therapy for bone and joint infections: an Italian multicenter study. J Chemother 2007;19:417–22.
http://dx.doi.org/10.1179/joc.2007.19.4.417
84. Bernard L, El-Hajj, Pron B, Lotthé A, Gleizes V, Signoret F, et al. Outpatient parenteral antimicrobial
therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost.
J Clin Pharm Ther 2001;26:445–51. http://dx.doi.org/10.1046/j.1365-2710.2001.00380.x
85. Montalto M. Patients’ and carers’ satisfaction with hospital-in-the-home care. Int J Qual Health
Care 1996;8:243–51. http://dx.doi.org/10.1016/1353-4505(96)00029-4
86. Parker SE, Nathwani D, O’Reilly D, Parkinson S, Davey PG. Evaluation of the impact of non-inpatient
i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient.
J Antimicrob Chemother 1998;42:373–80. http://dx.doi.org/10.1093/jac/42.3.373
87. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer
patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction
rule. J Clin Oncol 1994;12:107–14.
88. Pilling M, Walley T. Parenteral antibiotics at home in cystic fibrosis: experiences and attitudes of
recipients. Health Soc Care Community 1997;5:209–12.
89. Cox AM, Malani PN, Wiseman SW, Kauffman CA. Home intravenous antimicrobial infusion
therapy: a viable option in older adults. J Am Geriatr Soc 2007;55:645–50. http://dx.doi.org/
10.1111/j.1532-5415.2007.01133.x
90. Seaton RA, Nathwani D. Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK:
survey of infection specialists’ experience and views. Clin Microbiol Infect 2000;6:387–90.
http://dx.doi.org/10.1046/j.1469-0691.2000.00112.x
91. Muldoon EG, Allison GM, Gallagher D, Snydman DR, Bergin C. Outpatient parenteral
antimicrobial therapy (OPAT) in the Republic of Ireland: results of a national survey. Eur J Clin
Microbiol Infect Dis 2013;32:1465–70. http://dx.doi.org/10.1007/s10096-013-1899-4
92. Muldoon EG, Switkowski K, Tice A, Snydman DR, Allison GM. A national survey of infectious
disease practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT). Infect Dis
2015;47:39–45. http://dx.doi.org/10.3109/00365548.2014.967290
93. Chapman AL, Seaton RA, Cooper MA, Hedderwick S, Goodall V, Reed C, et al. Good practice
recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK:
a consensus statement. J Antimicrob Chemother 2012;67:1053–62. http://dx.doi.org/10.1093/
jac/dks003
94. Seaton A. The UK OPAT Initiative – Then, Now & in the Future, Overview of 2013 Audit. 2013.
URL: https://s3-eu-west-1.amazonaws.com/opat-national-conference-2013/Dr-Andrew-Seaton-
The-UK-OPAT-Initiative.pdf (accessed 14 September 2016).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
124
95. Ritchie J, Lewis J. Qualitative Research Practice: A Guide for Social Science Students and Researchers.
London: Sage; 2003.
96. Francis R. Report of the Mid Staffordshire NHS Foundation Trust Public Enquiry. London:
The Stationery Office; 2013.
97. Keogh B. Review into the Quality of Care and Treatment Provided by 14 Hospital Trusts in
England: Overview Report. London: NHS England; 2013.
98. Halilovic J, Christensen CL, Nguyen HH. Managing an outpatient parenteral antibiotic therapy
team: challenges and solutions. Ther Clin Risk Manag 2014;10:459–65. http://dx.doi.org/10.2147/
TCRM.S48906
99. Dubois A, Santos-Eggimann B. Evaluation of patients’ satisfaction with hospital-at-home care.
Eval Health Prof 2001;24:84–98. http://dx.doi.org/10.1177/01632780122034812
100. Ryan M. Using Consumer Preferencs in Health Care Decision Making. The Application of Conjoint
Analysis. London: Office of Health Economics; 1996.
101. Department for Communities and Local Government. Index of Multiple Deprivation 2010, Local
Authority District Rank of Average Rank. URL: http://opendatacommunities.org/data/societal-
wellbeing/deprivation/imd-rank-la-2010 (accessed 19 October 2015).
102. Coast J, Al-Janabi H, Sutton E, Horrocks S, Vosper A, Swancutt D, et al. Using qualitative
methods for attribute development for discrete choice experiments: issues and recommendations.
Health Econ 2011;6:730–41.
103. Strauss A, Corbin J. Basics of Qualitative Research: Grounded Theory Procedures and Techniques.
London: Sage; 1990.
104. Green J, Thorogood N. Qualitative Methods for Health Research. London: Sage; 2013.
105. Baldie DJ, Entwistle VA, Davey PG. The information and support needs of patients discharged
after a short hospital stay for treatment of low-risk community acquired pneumonia: implications
for treatment without admission. BMC Pulm Med 2008;8:11. http://dx.doi.org/10.1186/
1471-2466-8-11
106. Entwistle V, Firnigl D, Ryan M, Francis J, Kinghorn P. Which experiences of health care delivery
matter to service users and why? A critical interpretive synthesis and conceptual map. J Health
Serv Res Policy 2012;17:70–8. http://dx.doi.org/10.1258/jhsrp.2011.011029
107. Caine N, Sharples LD, Hollingworth W, French J, Keogan M, Exley A, et al. A randomised
controlled crossover trial of nurse practitioner versus doctor-led outpatient care in a bronchiectasis
clinic. Health Technol Assess 2002;6(27). http://dx.doi.org/10.3310/hta6270
108. Department of Health (DH). Operational Guidance to the NHS – Extending Patient Choice of
Provider. London: DH; 2011.
109. Ziebland S, Hunt K. Using secondary analysis of qualitative data of patient experiences of health
care to inform health services research and policy. J Health Serv Res Policy 2014;19:177–82.
http://dx.doi.org/10.1177/1355819614524187
110. NHS Confederation. Patient and Public Engagement in the New Commissioning System:
Discussion Paper. London: NHS Confederation; 2011.
111. Department of Health. Health and Social Care Bill. London: The Stationery Office; 2011.
112. Jones G, Cumming D, Gilchrist M, Seaton R. Outpatient antimicrobial therapy (response). BMJ
2013;346:f1585.
113. Davey P, Wilcox M, Irving W, Thwaites G. Antimicrobial Chemotherapy. Oxford: Oxford University
Press; 2005.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
114. Chapman AL. Outpatient parenteral antimicrobial therapy. BMJ 2013;346:f1585. http://dx.doi.org/
10.1136/bmj.f1585
115. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review
of the literature. Health Econ 2012;21:145–72. http://dx.doi.org/10.1002/hec.1697
116. Morgan H, Hoddinott P, Thomson G, Crossland N, Farrar S, Yi D, et al. Benefits of Incentives for
Breastfeeding and Smoking cessation in pregnancy (BIBS): a mixed-methods study to inform trial
design. Health Technol Assess 2015;19(30). http://dx.doi.org/10.3310/hta19300
117. Bowen A, Hesketh A, Patchick E, Young A, Davies L, Vail A, et al. Clinical effectiveness,
cost-effectiveness and service users’ perceptions of early, well-resourced communication therapy
following a stroke: a randomised controlled trial (the ACT NoW Study). Health Technol Assess
2012;16(26). http://dx.doi.org/10.3310/hta16260
118. Lanscar E, Burge P. Choice Modelling Research in Health Economics. In Hess S, Daly A, editors.
Handbook of Choice Modelling. Cheltenham: Edward Elgar Publishing; 2014. pp. 675–87.
119. Willis G. Cognitive Interviewing: A Tool for Improving Questionnaire Design. London: Sage; 2005.
http://dx.doi.org/10.4135/9781412983655
120. Kløjgaard ME, Hess S. Understanding the formation and influence of attitudes in patients’
treatment choices for lower back pain: testing the benefits of a hybrid choice model approach.
Soc Sci Med 2014;114:138–50. http://dx.doi.org/10.1016/j.socscimed.2014.05.058
121. Edwards AL, Kenney KC. A comparison of the Thurstone and Likert techniques of attitude scale
construction. J Appl Psychol 1946;30:72–83. http://dx.doi.org/10.1037/h0062418
122. Rose JM, Bliemer MCJ. Stated Choice Experimental Design Theory: The Who, the What and the
Why. In Hess S, Daly A, editors. Handbook of Choice Modelling. Cheltenham: Edward Elgar
Publishing; 2014. pp. 152–77. http://dx.doi.org/10.4337/9781781003152.00013
123. Train KE. Discrete Choice Methods in Simulation. 2nd edn. Cambridge, MA: Cambridge University
Press; 2009. http://dx.doi.org/10.1017/CBO9780511805271
124. Abou-Zeid M, Ben-Akiva M. Hybrid Choice Models. In Hess S, Daly A, editors. Handbook of
Choice Modelling. Cheltenham: Edward Elgar Publishing; 2014. pp. 383–412. http://dx.doi.org/
10.4337/9781781003152.00025
125. Vij A, Walker J. Hybrid Choice Models: The Identification Problem. In Hess S, Daly A, editors.
Handbook of Choice Modelling. Cheltenham: Edward Elgar Publishing; 2014. pp. 519–64.
http://dx.doi.org/10.4337/9781781003152.00031
126. Field A. Discovering Statistics Using IBM SPSS Statistics. 4th edn. London: Sage; 2013.
127. Clark MD, Determann D, Petrou S, Moro D, de Bekker-Grob EW. Discrete choice experiments
in health economics: a review of the literature. PharmacoEconomics 2014;32:883–902.
http://dx.doi.org/10.1007/s40273-014-0170-x
128. Higgins A, Barnett J, Meads C, Singh J, Longworth L. Does convenience matter in health care
delivery? A systematic review of convenience-based aspects of process utility. Value Health
2014;17:877–87. http://dx.doi.org/10.1016/j.jval.2014.08.2670
129. Freeman GK, Olesen F, Hjortdahl P. Continuity of care: an essential element of modern general
practice? Fam Pract 2003;20:623–7. http://dx.doi.org/10.1093/fampra/cmg601
130. Cabana MD, Jee SH. Does continuity of care improve patient outcomes? J Fam Pract
2004;53:974–80.
131. Hill KM. Understanding and Measuring Continuity of Care in Stroke. Leeds: University of
Leeds; 2008.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
132. Harrison M, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice
experiments: a systematic review of the literature. Patient 2014;7:151–70. http://dx.doi.org/
10.1007/s40271-014-0048-1
133. Ajzen I. Residual effects of past on later behaviour. Habituation and reasoned action perspectives.
Pers Soc Psychol Rev 2002;6:107–22. http://dx.doi.org/10.1207/S15327957PSPR0602_02
134. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ
1995;311:376–80. http://dx.doi.org/10.1136/bmj.311.7001.376
135. The Vascular Society of Great Britain and Ireland, Lees T, editor. The National Vascular Database
Report 2009. London: The Vascular Society of Great Britain and Ireland; 2009.
136. Seaton RA, Johal S, Coia JE, Reid N, Cooper S, Jones BL. Economic evaluation of treatment for
MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur J Clin Microbiol Infect
Dis 2014;33:305–11. http://dx.doi.org/10.1007/s10096-013-1956-z
137. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some
lessons from recent UK experience. PharmacoEconomics 2006;24:1055–68. http://dx.doi.org/
10.2165/00019053-200624110-00003
138. Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P. The role of modelling in prioritising and
planning clinical trials. Health Technol Assess 2003;7(23). http://dx.doi.org/10.3310/hta7230
139. Marshall DA, Burgos-Liz L, IJzerman MJ, Osgood ND, Padula WV, Higashi MK, et al. Applying
dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist:
report of the ISPOR simulation modeling emerging good practices task force. Value Health
2015;18:5–16. http://dx.doi.org/10.1016/j.jval.2014.12.001
140. Goldie SJ, Corso PS. Decision Analysis. In Haddix AC, Teutsch SM, Corso PS, editors. Prevention
Effectiveness. A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford
University Press; 2003. pp. 103–26.
141. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices – overview a report of the
ISPOR-SMDM modeling good research practices task force – 1.Med Decis Making 2012;32:667–77.
http://dx.doi.org/10.1177/0272989X12454577
142. Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis.
An application to a policy model of Alzheimer’s disease. Int J Technol Assess Health Care
2001;17:38–55. http://dx.doi.org/10.1017/S0266462301104058
143. Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a hospital in
Scotland. Pharm World Sci 2008;30:854–62. http://dx.doi.org/10.1007/s11096-008-9240-5
144. Forster AJ, Taljaard M, Oake N, Wilson K, Roth V, van Walraven C. The effect of hospital-acquired
infection with Clostridium difficile on length of stay in hospital. Can Med Assoc J 2012;184:37–42.
http://dx.doi.org/10.1503/cmaj.110543
145. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic
burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired
infection. J Hosp Infect 2012;81:1–14. http://dx.doi.org/10.1016/j.jhin.2012.02.004
146. Thwaites GE, United Kingdom Clinical Infection Research Group (UKCIRG). The management of
Staphylococcus aureus bacteremia in the United Kingdom and Vietnam: a multi-centre evaluation.
PLOS ONE 2010;5:e14170. http://dx.doi.org/10.1371/journal.pone.0014170
147. Lillie PJ, Andrews D, Eaves K, Darton TC, Chapman AL. Baseline factors predicting the duration of
intravenous antibiotic therapy for cellulitis in an outpatient setting. Eur J Clin Microbiol Infect Dis
2010;29:347–9. http://dx.doi.org/10.1007/s10096-009-0855-9
148. Department of Health (DH). NHS Reference Costs 2013–14 England: London: DH; 2014.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
149. Curtis LA. Unit Costs of Health and Social Care 2014. Canterbury: Personal Social Services Research
Unit, University of Kent; 2014.
150. Royal College of Nursing. NHS Payscales for NHS Nursing Staff in England, Wales, Scotland and
Northern Ireland from 1 April 2015. URL: www.rcn.org.uk/support/pay_and_conditions/pay-rates-
2015-16 (accessed 15 October 2015).
151. Department of Health (DH). Updated Guidance of the Diagnosis and Reporting of CDI. Best
Practice Guidance. London: DH; 2012.
152. Boyd O, Jackson N. How is risk defined in high-risk surgical patient management? Crit Care
2005;9:390–6. http://dx.doi.org/10.1186/cc3057
153. Prytherch DR, Sutton GL, Boyle JR. Portsmouth POSSUM models for abdominal aortic aneurysm
surgery. Br J Surg 2001;88:958–63. http://dx.doi.org/10.1046/j.0007-1323.2001.01820.x
154. Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, Williams HC. Prophylactic
antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials. PLOS ONE
2014;9:e82694. http://dx.doi.org/10.1371/journal.pone.0082694
155. Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6 weeks
versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority,
randomised, controlled trial. Lancet 2015;385:875–82. http://dx.doi.org/10.1016/S0140-6736(14)
61233-2
156. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing
strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin
Infect Dis 2014;58:1507–14. http://dx.doi.org/10.1093/cid/ciu128
157. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in
moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22–7. http://dx.doi.org/
10.3132/pcrj.2007.00002
158. Drummond MF, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the Economic
Evaluation of Health Care Programmes. New York, NY: Oxford University Press; 2005.
159. Marmor YN, Rohleder TR, Cook DJ, Huschka TR, Thompson JE. Recovery bed planning in
cardiovascular surgery: a simulation case study. Health Care Manag Sci 2013;16:314–27.
http://dx.doi.org/10.1007/s10729-013-9231-5
160. Troy PM, Rosenberg L. Using simulation to determine the need for ICU beds for surgery patients.
Surgery 2009;146:608–17. http://dx.doi.org/10.1016/j.surg.2009.05.021
161. Cipriano LE, Chesworth BM, Anderson CK, Zaric GS. An evaluation of strategies to reduce waiting
times for total joint replacement in Ontario. Med Care 2008;46:1177–83. http://dx.doi.org/
10.1097/MLR.0b013e31817925e8
162. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies and
frequently asked questions. Health Econ 2004;13:405–15. http://dx.doi.org/10.1002/hec.903
163. Wilson EC. A practical guide to value of information analysis. PharmacoEconomics
2015;33:105–21. http://dx.doi.org/10.1007/s40273-014-0219-x
164. Barr D, Seaton R. Outpatient parenteral antimicrobial therapy (OPAT) and the general physician.
Clin Med 2013;13:495–9. http://dx.doi.org/10.7861/clinmedicine.13-5-495
165. Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected value of perfect
information from a probabilistic sensitivity analysis sample: a nonparametric regression approach.
Med Decis Making 2014;34:311–26. http://dx.doi.org/10.1177/0272989X13505910
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
166. Caplan GA, Ward JA, Brennan NJ, Coconis J, Board N, Brown A. Hospital in the home:
a randomised controlled trial. Med J Aust 1999;170:156–60.
167. Li HK, Agweyu A, English M, Bejon P. An unsupported preference for intravenous antibiotics.
PLOS Med 2015;12:e1001825. http://dx.doi.org/10.1371/journal.pmed.1001825
168. Thaler R, Sustein C. Nudge: Improving Decisions about Health, Wealth and Happiness. New York,
NY: Penguin; 2008.
169. Hawkes N. Finding the techniques to nudge the population to better health. BMJ 2011;342:d389.
http://dx.doi.org/10.1136/bmj.d389
170. Bonell C, McKee M, Fletcher A, Wilkinson P, Haines A. One nudge forward, two steps back.
BMJ 2011;342:d401. http://dx.doi.org/10.1136/bmj.d401
171. NHS England, Public Health England, Health Education England, Monitor, Care Quality Commission,
NHS Trust Development Authority. Five Year Forward View. 2014. URL: www.england.nhs.uk/
wp-content/uploads/2014/10/5yfv-web.pdf (accessed 20 October 2015).
172. Davies SC. Annual Report of the Chief Medical Officer, Volume 2, 2011: Infections and the Rise
of Antimicrobial Resistance. London: Department of Health; 2011.
173. Graninger W, Wenisch C, Wiesinger E, Menschik M, Karimi J, Presterl E. Experience with outpatient
intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis
1995;14:643–7. http://dx.doi.org/10.1007/BF01690746
174. Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy and antimicrobial stewardship:
challenges and checklists. J Antimicrob Chemother 2015;70:965–70. http://dx.doi.org/10.1093/
jac/dku517
175. Monitor. Closing the NHS Funding Gap: How to get Better Value Health Care for Patients.
London; Monitor; 2013.
176. Public Health England. Quarterly Analyses: Mandatory MRSA, MSSA and E. coli bacteraemia and
C. difficile in England (up to July-September 2015). London: Public Health England; 2015.
177. Wye L, Brangan E, Cameron A, Gabbay J, Klein J, Pope C. Knowledge Exchange in Health-Care
Commissioning: Case Studies of the Use of Commercial, Not-For-Profit and Public Sector
Agencies, 2011–14. Southampton: Health Services and Delivery Research; 2015.
178. Jones GR, Cumming DVE, Honeywell G, Ball R, Sanderson F, Seaton RA, et al. How is income
generated by outpatient parenteral antibiotic treatment (OPAT) in the UK? Analysis of payment
tariffs for cellulitis. J Antimicrob Chemother 2015;70:1236–40. http://dx.doi.org/10.1093/
jac/dku541
179. Barker KL, Reid M, Minns Lowe CJ. What does the language we use about arthritis mean to people
who have osteoarthritis? A qualitative study. Disabil Rehabil 2014;36:367–72. http://dx.doi.org/
10.3109/09638288.2013.793409
180. Anand V, Levine H, Friedman M, Krespi Y, Panje W, Schettino R, et al. Intravenous antibiotics for
refractory rhinosinusitis in nonsurgical patients: preliminary findings of a prospective study.
Am J Rhinol 2003;17:363–8.
181. Berman SJ, Johnson EW. Out-patient parenteral antibiotic therapy (OPAT): clinical outcomes and
adverse events. Hawaii Med J 2001;60:31–3.
182. Chan DSG, Archuleta S, Llorin RM, Lye DC, Fisher D. Standardized outpatient management of
Klebsiella pneumoniae liver abscesses. Int J Infect Dis 2013;17:e185–8.
183. Dalovisio JR, Juneau J, Baumgarten K, Kateiva J. Financial impact of a home intravenous antibiotic
program on a medicare managed care program. Clin Infect Dis 2000;30:639–42.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
184. Dargan S, Zvonar RK, Saginur R. A review of outpatient parenteral antimicrobial therapy practices
and experience at the Ottawa Hospital. Can J Hosp Pharm 2007;60(3):177–83.
185. Donald M, Marlow N, Swinburn E, Wu M. Emergency department management of home
intravenous antibiotic therapy for cellulitis. Emerg Med J 2005;22:715–7.
186. Esposito S, Leone S, Noviello S, Ianniello F, Russo M, Foti G, et al. Outpatient parenteral antibiotic
therapy in the elderly: an Italian observational multicenter study. J Chemother 2009;21:193–8.
http://dx.doi.org/10.1179/joc.2009.21.2.193
187. Graninger W, Presterl E, Wenisch C, Schwameis E, Breyer S, Vukovich T. Management of serious
staphylococcal infections in the outpatient setting. Drugs 1997;54:21–8. http://dx.doi.org/
10.2165/00003495-199700546-00006
188. Gross R, Graziani AL, Laufer D, Turner JL, Ondercin JP, Macgregor RR. Adverse effects of the use
of intravenous pentamidine in the home. Infect Dis Clin Pract 1996;5:456–58.
189. Ho J, Archuleta S, Sulaiman Z, Fisher D. Safe and successful treatment of intravenous drug users
with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment
service. J Antimicrob Chemother 2010;65:2641–4. http://dx.doi.org/10.1093/jac/dkq355
190. Larioza J, Girard A, Brown RB. Clinical experience with daptomycin for outpatient parenteral
antibiotic therapy. Am J Med Sci 2011;342:486–8.
191. Larioza J, Heung L, Girard A, Brown RB. Management of infective endocarditis in outpatients:
clinical experience with outpatient parenteral antibiotic therapy. Southern Med J 2009;102:575–9.
192. Lopardo G. Management of endocarditis: outpatient parenteral antibiotic treatment in Argentina.
Chemotherapy 2001;47(Suppl. 1):24–32.
193. McMahon JH, O’Keeffe JM, Grayson ML, Victorian Hith Outcomes Study Group. Is hospital-in-the-
home (HITH) treatment of bacterial endocarditis safe and effective? Scand J Infect Dis 2008;40:40–3.
194. Montalto M. An audit of patients admitted for home intravenous therapy directly from the
emergency department. Int J Clin Pract 1997;51:433–7.
195. Morales JO, Von Behren L. Secondary bacterial infections in HIV-infected patients: an alternative
ambulatory outpatient treatment utilizing intravenous cefotaxime. Am J Med 1994;97:9–13.
196. Murray H, Stiell I, Wells G. Treatment failure in emergency department patients with cellulitis.
CJEM 2005;7:228–34.
197. Nathwani D, Barlow GD, Ajdukiewicz K, Gray K, Morrison J, Clift B, et al. Cost-minimization
analysis and audit of antibiotic management of one and joint infections with ambulatory teicoplanin,
in-patient care or outpatient oral linezolid therapy. J Antimicrob Chemother 2003;51:391–6.
http://dx.doi.org/10.1093/jac/dkg061
198. Partridge DG, O’Brien E, Chapman ALN. Outpatient parenteral antibiotic therapy for infective
endocarditis: a review of 4 years’ experience at a UK centre. Postgrad Med J 2012;88:377–81.
199. Pérez-López J, San José Laporte A, Pardos-Gea J, Tapia Melenchón E, Lozano Ortín E,
Barrio Guirado A, Vilardell Tarrés M. Safety and efficacy of home intravenous antimicrobial
infusion therapy in older patients: a comparative study with younger patients. Int J Clin Pract
2008;62:1188–92. http://dx.doi.org/10.1111/j.1742-1241.2008.01747.x
200. Seaton RA, MacConnachie AA. Experience with daptomycin in an infectious diseases service over 1
year: utility in an outpatient parenteral antibiotic programme. Int J Antimicrob Agents 2008;31:492–7.
201. Seaton RA, Sharp E, Bezlyak V, Weir CJ. Factors associated with outcome and duration of therapy
in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int
J Antimicrob Agents 2011;38:243–8. http://dx.doi.org/10.1016/j.ijantimicag.2011.05.008
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
130
202. South R. Retrospective study of teicoplanin as home continuation of hospital-initiated therapy.
Int J Antimicrob Agents 1998;9:219–25.
203. Theocharis G, Rafailidis PI, Rodis D, Kontopidis I, Barbas SG, Falagas ME. Outpatient parenteral
antibiotic therapy (OPAT) at home in Attica, Greece. Eur J Clin Microbiol Infect Dis
2012;31:2957–61. http://dx.doi.org/10.1007/s10096-012-1647-1
204. Upton A, Ellis-Pegler RB, Woodhouse A. Outpatient Parenteral Antimicrobial Therapy (OPAT):
a review of experience at Auckland Hospital. N Z Med J 2004;117:U1020.
205. Walton AL, Howden BP, Grayson LM, Korman TM. Continuous-infusion penicillin home-based
therapy for serious infections due to penicillin-susceptible pathogens. Int J Antimicrob Agents
2007;29:544–8. http://dx.doi.org/10.1016/j.ijantimicag.2006.10.018
206. White HA, Davis JS, Kittler P, Currie BJ. Outpatient parenteral antimicrobial therapy-treated bone
and joint infections in a tropical setting. Intern Med J 2011;41:668–73. http://dx.doi.org/10.1111/
j.1445-5994.2009.02136.x
207. White B, Seaton RA, Evans TJ. Management of suspected Lyme borreliosis: experience from an
outpatient parenteral antibiotic therapy service. QJM 2013; 106:133–8. http://dx.doi.org/10.1093/
qjmed/hcs189
208. Yadlapalli NG, Vaishnav A, Sheehan P. Conservative management of diabetic foot ulcers
complicated by osteomyelitis. Wounds 2002;14:31–5.
209. Htin AK, Friedman ND, Hughes A, O’Brien DP, Huffam S, Redden AM, Athan E. Outpatient
parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis:
a retrospective cohort study. Intern Med J 2013;43:700–5. http://dx.doi.org/10.1111/imj.12081
210. Lai A, Tran T, Nguyen HM, Fleischmann J, Beenhouwer DO, Graber CJ. Outpatient parenteral
antimicrobial therapy at large Veterans Administration medical center. Am J Manag Care
2013;19:e317–24.
211. Mohammadi S, MacKay K, Ward TT, Forrest GN. Clinical outcomes of a veterans affairs outpatient
antimicrobial treatment program. South Med J 2013;106:345–9. http://dx.doi.org/10.1097/
SMJ.0b013e3182967e8f
212. Sims AL, Baker P, Bellamy R, McMurtry IA. Outpatient parenteral antibiotic therapy in primary
hip and knee arthroplasty infection managed with debridement and retention of prosthesis:
a retrospective cohort study. Surg Infect 2013;14:293–6. http://dx.doi.org/10.1089/sur.2012.078
213. Subedi S, Looke DF, McDougall DA, Sehu MM, Playford EG. Supervised self-administration of
outpatient parenteral antibiotic therapy: a report from a large tertiary hospital in Australia.
Int J Infect Dis 2015;30:161–5. http://dx.doi.org/10.1016/j.ijid.2014.11.021
214. Keller SC, Ciuffetelli D, Bilker W, Norris A, Timko D, Rosen A, et al. The Impact of an Infectious
Diseases Transition Service on the Care of Outpatients on Parenteral Antimicrobial Therapy.
J Pharm Technol 2013;29:205–14. http://dx.doi.org/10.1177/8755122513500922
215. Amodeo MR, Clulow T, Lainchbury J, Murdoch DR, Gallagher K, Dyer A, et al. Outpatient
intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes.
J Infect 2009;59:387–93. http://dx.doi.org/10.1016/j.jinf.2009.09.009
216. Cervera C, Del Rio A, Garcia L, Sala M, Almela M, Moreno A, et al. Efficacy and safety of
outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study.
Enferm Infec Microbiol Clin 2011;29:587–92. http://dx.doi.org/10.1016/j.eimc.2011.05.007
217. Chambers S, Gallagher K, Pithie A. Home intravenous antimicrobial service – twelve months
experience in Christchurch. N Z Med J 2002;115:216–18.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
131
218. Cheong EA, Katelaris CH, Sisson CM, Anderson EA, Byth K. Adverse drug reactions associated
with home parenteral therapy. J Pharm Pract Res 2008;38:267–70. http://dx.doi.org/10.1002/
j.2055-2335.2008.tb00386.x
219. Dobson PM, Boyle M, Loewenthal M. Home intravenous antibiotic therapy and allergic drug
reactions: is there a case for routine supply of anaphylaxis kits? J Infus Nurs 2004;27:425–30.
http://dx.doi.org/10.1097/00129804-200411000-00008
220. Gourdeau M, Deschênes L, Caron M, Desmarais M. Home iv antibiotic therapy through a medical
day care unit. Can J Infect Dis 1993;4:158–62. http://dx.doi.org/10.1155/1993/412737
221. Heintz BH, Halilovic J, Christensen CL. Impact of a multidisciplinary team review of potential
outpatient parenteral antimicrobial therapy prior to discharge from an academic medical center.
Ann Pharmacother 2011;45:1329–37. http://dx.doi.org/10.1345/aph.1Q240
222. Lin JW, Kacker A, Anand VK, Levine H. Catheter- and antibiotic-related complications of ambulatory
intravenous antibiotic therapy for chronic refractory rhinosinusitis. Am J Rhinol 2005;19:365–9.
223. Smego RA, Khan MA, Khowaja K, Rafique R, Datoo F. A university-sponsored Home Health
Nursing Program in Karachi, Pakistan. Home Healthc Nurse 2005;23:710–16. http://dx.doi.org/
10.1097/00004045-200511000-00007
224. Tice AD, Hoaglund PA, Nolet B, McKinnon PS, Mozaffari E. Cost perspectives for outpatient
intravenous antimicrobial therapy. Pharmacotherapy 2002;22:63S–70S. http://dx.doi.org/10.1592/
phco.22.4.63S.33653
225. Allison GM, Muldoon EG, Kent DM, Paulus JK, Ruthazer R, Ren A, Snydman DR. Prediction model
for 30-day hospital readmissions among patients discharged receiving outpatient parenteral
antibiotic therapy. Clin Infect Dis 2014;58:812–19. http://dx.doi.org/10.1093/cid/cit920
226. Barr DA, Irvine S, Ritchie ND, McCutcheon J, Seaton RA. Risk of venous thromboembolism in
patients treated for bacterial infection in the community with outpatient parenteral antimicrobial
therapy. QJM 2014;107:207–11. http://dx.doi.org/10.1093/qjmed/hct239
227. Pajarón M, Fernández-Miera MF, Allende I, Arnaiz AM, Gutiérrez-Cuadra M, Cobo-Belaustegui M,
et al. Self-administered outpatient parenteral antimicrobial therapy (S-OPAT) for infective
endocarditis: a safe and effective model. Eur J Intern Med 2015;26:131–6. http://dx.doi.org/
10.1016/j.ejim.2015.01.001
228. Hess S, Train KE, Polak JW. On the use of a Modified Latin Hypercube Sampling (MLHS) approach
in the estimation of a Mixed Logit model for vehicle choice. Trans Res B 2006;40:147–63.
http://dx.doi.org/10.1016/j.trb.2004.10.005
229. Huber PJ. The Behavior of Maximum Likelihood Estimates under Nonstandard Conditions.
Proc Fifth Berkeley Symp Math Stat Prob 1967;1:221–33.
230. Department of Health. Health and Social Care Act 2012. London: The Stationery Office; 2012.
231. INVOLVE. Briefing Notes for Researchers: Involving the Public in NHS, Public Health and Social
Care Research. Eastleigh: INVOLVE; 2012.
232. Popay J, Collins M, editors, with the PiiAF Study group. The Public Involvement Impact
Assessment Framework Guidance. Universities of Lancaster, Liverpool and Exeter. 2014.
URL: http://piiaf.org.uk/documents/piiaf-guidance-jan14.pdf (accessed 30 September 2015).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
132
Appendix 1 Community IntraVenous Antibiotic
Study systematic review
Sample search A: studies of intravenous antibiotics and known models
of care
Ovid MEDLINE(R)
Date range searched: 1946 to March week 4, 2015.
1. exp Anti-Bacterial Agents/ (497,300)
2. Anti-Infective Agents/ (36,221)
3. exp Anti-infective agents, Urinary/ (28,162)
4. exp antifungal agents/ (126,501)
5. or/1–4 (612,854)
6. Administration, Intravenous/ (151)
7. infusions, intravenous/ (45,941)
8. injections, intravenous/ (75,646)
9. Home infusion therapy/ (579)
10. or/6–9 (120,138)
11. ((parenteral or intravenous or IV or inject* or infusion*) adj5 (antibiotic* or anti-biotic* or
antimicrobial* or anti-microbial* or antifungal* or anti-fungal* or anti-infective* or antiinfective* or
antibiotherap*or anti-biotherap*)).tw. (10,477)
12. (5 and 10) or 11 (20,711)
13. exp Ambulatory Care Facilities/ (41,613)
14. exp Delivery of healthcare/ (739,029)
TABLE 31 Databases searched and sample searches
Database Dates
BSAC Accessed March 2015 (http://bsac.org.uk/)
CINAHL (via EBSCOhost) 1981 to March 2015
The Cochrane Library (via Wiley Online Library) Accessed 25 March 2015
EMBASE Classic + EMBASE (via Ovid) 1947 to 25 March 2015
Health Business Elite (via HDAS, NHS Evidence) 1922 to 25 March 2015
Health Management Information Consortium (via Ovid) 1983 to 25 March 2015
International Pharmaceutical Abstracts (via Ovid) 1970 to March 2015
Ovid MEDLINE(R) 1946 to March Week 4, 2015
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 25 March 2015
Research Papers in Economics Accessed March 2015 (http://ideas.repec.org/)
CEA Registry Accessed March 2015 (https://research.tufts-nemc.org/
cear4/Default.aspx)
Web of Science Conference Proceedings Citation Index – Science
(via Thomson Reuters)
1990 to March 2015
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15. Critical Pathways/ (4202)
16. Ambulatory Care/ (34,170)
17. Emergency Service, Hospital/ (39,312)
18. outpatients/ (7955)
19. inpatients/ (11,488)
20. day care/ (4526)
21. inpatients/ (11,488)
22. hospitalization/ (66,091)
23. community health services/ (25,779)
24. community health nursing/ (17,982)
25. home care services/ (26,544)
26. home care services, hospital-based/ (1552)
27. home nursing/ (7802)
28. home infusion therapy/ (579)
29. or/13–28 (936,219)
30. 12 and 29 (1550)
31. (‘emergency ward*’ or ‘emergency room*’ or ‘accident and emergency’ or ED or ‘emergency
department*’ or A&E).tw. (77,291)
32. outpatient*.tw. (95,608)
33. (home or homes).tw. (141,950)
34. (self adj3 (treat* or care or regime*)).tw. (14,552)
35. ((clinic or clinics) adj3 (treat* or care or regime*)).tw. (11,443)
36. (community adj3 (treat* or care or regime*)).tw. (15,994)
37. (ambulatory adj3 (treat* or care or regime*)).tw. (11,257)
38. ‘district nurs*’.tw. (1351)
39. (‘specialist nurs*’ or ‘nurse specialist*’).tw. (3498)
40. ‘community nurs*’.tw. (2437)
41. ((hospital* or ward or clinic) adj2 (patient or patients)).tw. (58,637)
42. inpatient*.tw. (54,156)
43. (‘care pathway*’ or ‘care model*’ or ‘model* of care’).tw. (6275)
44. or/31–43 (438,938)
45. 44 and 12 (2102)
46. ‘outpatient parenteral antibiotic* therapy’.tw. (103)
47. ‘outpatient antibiotic* therapy’.tw. (64)
48. (ohpat or opat).tw. (116)
49. or/45–48 (2140)
50. 49 or 30 (2678)
Sample search B: reviews of intravenous antibiotic use in cellulitis or
cystic fibrosis
Ovid MEDLINE(R)
Date range searched: 1946 to March week 4, 2015.
1. exp *Anti-Bacterial Agents/or *Anti-Infective Agents/or exp *antifungal agents/or exp *Anti-infective
agents, Urinary/ (380,181)
2. *Administration, Intravenous/or *infusions, intravenous/or *injections, intravenous/or *Home infusion
therapy/ (5005)
3. 1 and 2 (324)
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4. ((parenteral or intravenous or IV or inject* or infusion*) adj5 (antibiotic* or anti-biotic* or
antimicrobial* or anti-microbial* or antifungal* or anti-fungal* or anti-infective* or antiinfective* or
antibiotherap*or anti-biotherap*)).ti. (1464)
5. 3 or 4 (1649)
6. exp Anti-Bacterial Agents/ (498,780)
7. Anti-Infective Agents/ (36,330)
8. exp Anti-infective agents, Urinary/ (28,211)
9. exp antifungal agents/ (126,949)
10. or/6–9 (614,703)
11. Administration, Intravenous/ (177)
12. infusions, intravenous/ (46,068)
13. injections, intravenous/ (75,786)
14. Home infusion therapy/ (580)
15. or/11–14 (120,429)
16. ((parenteral or intravenous or IV or inject* or infusion*) adj5 (antibiotic* or anti-biotic* or
antimicrobial* or anti-microbial* or antifungal* or anti-fungal* or anti-infective* or antiinfective* or
antibiotherap*or anti-biotherap*)).tw. (10,513)
17. (10 and 15) or 16 (20,758)
18. ‘outpatient* parenteral’.tw. [finds more] (189)
19. ‘outpatient parenteral antibiotic* therapy’.tw. (103)
20. ‘outpatient antibiotic* therapy’.tw. (64)
21. (ohpat or opat).tw. (116)
22. Cellulitis/ (6046)
23. cellulitis.tw. (5439)
24. Cystic Fibrosis/ (27,005)
25. (cystic adj fibrosis).tw. (29,491)
26. ‘fibrocystic disease*’.tw. (807)
27. 17 or 19 or 20 or 21 (20,796)
28. or/22–26 (43,980)
29. (5 or (18 or 19 or 20 or 21)) and 28 [major headings or title occurrence of IV Antibiotic terms AND
MINOR Cell/CF terms] (125)
30. 17 and 28 [most sensitive search] (1037)
31. limit 30 to ‘review articles’ (150)
32. 29 or 31 (254)
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TABLE 32 Effect of OPAT on clinical success and safety
OPAT model(s) Inferior Superior No impact Inconclusive
Duration of treatment (all models) ◉
Outpatient attendance vs. inpatient treatment22 ●
SA vs. inpatient treatment42,43,58 ●
GN vs. inpatient treatment12,41 ●
SN vs. inpatient treatment25,56,57 ◉
Rate of cure or improvement (all models) ◉
Outpatient attendance vs. inpatient treatment22 ●
SA vs. inpatient treatment59 ●
GN vs. inpatient treatment12,41 ●
SN vs. inpatient treatment56,57 ◉
Improved lung function in CF (all models) ○
SA vs. inpatient treatment for FEV1
42,43,58,60 ●
SA vs. inpatient treatment for FVC42,43,58,60 ○
SA vs. inpatient treatment for PEFR58,60 ○
Drug-related side effects (all models) ◉
Outpatient attendance vs. inpatient treatment22 ●
SA vs. inpatient treatment42,43,58,59 ●
GN vs. inpatient treatment41 ●
SN vs. inpatient treatment10,56,57,65 ○
Venous access complications (all models) ◉
SA vs. inpatient treatment42,43,59 ◉
GN vs. inpatient treatment41 ●
Hospital admission (all models) ○
SA vs. inpatient treatment42,49 ●
GN vs. inpatient treatment12,41 ●
SN vs. inpatient treatment10,25,57,65 ◉
Deaths (all models) ●
Outpatient attendance vs. inpatient treatment22 ●
SA vs. inpatient treatment42,59 ●
GN vs. inpatient treatment41 ●
SN vs. inpatient treatment25,56 ●
●, found in ≥ 75% studies considering outcome; ◉, found in ≥ 50% studies considering outcome; ○, evidence of effect
supported by < 50% studies considering outcome; CF, cystic fibrosis; FEV, forced expiratory volume; FVC, forced vital
capacity; PEFR, peak expiratory flow rate.
Notes
Green shading indicates the overall effect on an outcome for all OPAT models combined. This includes findings from
studies in which the results for individual OPAT models were not reported separately, and in which the model under study
was not specified.
Blue shading indicates the effect only for studies that specify the model under study and that report on individual findings.
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Appendix 2 Community IntraVenous Antibiotic
Study health-care provider survey and interviews
TABLE 38 Brief overview of OPAT services described by service leads
Number Location SA Business plan Monitoring Evaluation
Patient
pathway
Clinical
governance
001 Urban ✓ ✗ ✓ – ✗ ✓
002 Semi-rural ✓ ✓ ✓ ✓ ✓ ✓
003 Urban ✓ ✓ ✗ ✗ ✓ In dev
004 Urban and semi-rural ✗ In dev ✗ ✗ ✓ ✓
005 Rural ✓ ✓ ✓ ✗ ✗ ✓
006 Urban ✓ ✓ ✓ ✗ ✓ ✓
007 Urban and semi-rural ? In dev ✓ – ? ✓
008 Urban ✗ ✓ ✓ ✓ ✓ ✓
009 Semi-rural ? ✓ ✓ In dev ✓ ✓
010 Urban and semi-rural ✓ In dev ✗ ✗ ✗ ✓
011 Urban ✓ ✓ ✓ ✓ ✓ ✓
012 Urban and semi-rural ✗ ✓ ✓ ✗ ✓ ✓
013 Rural and semi-rural ✗ In dev ✗ ✗ ✗ ✗
014 Urban ✓ ✓ ✓ ✓ ? ✓
015 Semi-rural ✗ ✗ ✗ ✗ ✗ ✓
016 Urban ✓ ✗ ✓ ✗ ✗ ✓
017 Urban and semi-rural ✗ ✓ ✓ ? ✓ ✓
018 Rural and semi-rural ✗ ✗ ✗ ✗ ✗ ✓
019 Urban ✗ ✗ ✓ ✗ ✓ ✓
In dev, in development; –, some evaluation but not for whole service, ✓, described by service lead; ✗, not described or not
provided; ?, unclear from information provided by the participants.
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Appendix 3 Detailed modelling methodology
The analysis of the data made use of mathematical structures known as discrete choice models. Thesemodels explain the choices/preferences of respondents between the three alternatives on the basis of
the presented characteristics. This is done through formulating a utility function for each of the three
alternatives, expressing the gain the respondent would get from choosing that alternative. The assumption
of rational decision-making then postulates that a respondent chooses the alternative that maximises
his/her utility (or minimises his/her disutility).
The first steps in the development of the model structure focus on the role of the explanatory variables
alone, where the utility of alternative i (with i = 1,. . .,3) for respondent n in choice task t is given by:
Vi,n,t = δi
+ βhospitalhospitali,t
+ βnurse homenurse homei,t
+ βone treatmentone treatmenti,t
+ βtwo treatmentstwo treatmentsi,t
+ βthree treatmentsthree treatmentsi,t
+ βno appointmentno appointmenti,t
+ βspecialist nursespecialist nursei,t
+ βgeneral nursegeneral nursei,t
+ βhalf day traininghalf day trainingi,t
+ βsee knownsee knowni,t
+ βspeak knownspeak knowni,t
+ βaf ter noneaf ter nonei,t
+ βaf ter nurseaf ter nursei,t
+ βaf ter GPaf ter GPi,t
+ βrisk 6risk 6i,t
+ βrisk 10risk 10i,t. (2)
The estimation of a discrete choice model is reliant on appropriate normalisation, as only differences in
utilities across alternatives (rather than absolute levels) can influences choices. With this in mind, base levels
were chosen for each of the attributes, and the associated coefficients were fixed to zero, explaining, for
example, the absence of the self-administering treatment from the above equation (with the two remaining
β parameters giving the estimated difference in utility for the other two types of treatments, i.e. hospital and
nurse at home). The δi term captures ordering effects given concerns about an underlying propensity for
respondents to choose options on the left, where, for normalisation, we set δ3 = 0.
Random utility models such as used in our work recognise the inability by analysts to fully capture the
utility of alternative and thus acknowledge the presence of a remaining random component of utility, with
Ui,n,t = Vi,n,t + εi,n,t, where εi,n,t follows a type I extreme value distribution.
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With the above specification, the probability of respondent n choosing alternative i in choice task t is now
given by:
Pi,n,t =
eVi,n,t
∑3j = 1e
V j,n,t
, (3)
where, with the properties of the type I extreme value distribution, the error term εi,n,t drops out.
Sociodemographic interactions
The above specification is making a major assumption in that the preferences are constant across
individual respondents, as represented by the generic model parameters. As a first step, we now interact
the coefficients with sociodemographic characteristics of the respondent. Using sex as an example,
and focusing on the parameter associated with hospital treatment, we would have, for respondent n:
βhospital,n = βhospital + βfemale,hospitalδfemale,n, (4)
where δfemale,n = 1 if respondent n is female, and 0 otherwise. The additional parameter βfemale,hospital then
estimates the difference between men and women in the preference for hospital treatment. We tested for
such sociodemographic interactions for all model parameters and for the following covariates:
l age (< 50 years, 50–65 years, > 65 years)
l sex
l race (white vs. non-white)
l living status (alone vs. not alone)
l education (university vs. not university educated)
l employment status (working vs. not working)
l number of past infections
l long-term vs. short-term infection.
Random heterogeneity and attitudes
Although the above effects allow us to capture a certain degree of heterogeneity across respondents,
we additionally allow for unexplained random differences in preference across respondents for the type of
treatment. In particular, we allow the βhospital and βnurse home to follow a normal distribution across respondents.
Finally, we allow for an influence of underlying attitudes on decision-making. We formulate two latent
attitudes, which are informed by earlier factor analysis work carried out on the same data. In particular,
we have the latent variables αl, with l = 1,. . .,2, hereafter referred to as:
l attitude towards hospitals
l attitude towards health care being a doctor’s responsibility.
Each of these latent attitudes is defined to have a deterministic and a random component, with latent
attitude l for person n being:
αl,n = γlzn + ξl,n, (5)
where the estimates of γl capture the impact of a range of sociodemographic characteristics of person n (zn)
on the latent attitude, and where ξl, is a standard normal variate (mean 0, standard deviation 1), distributed
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across respondents, capturing the random element of the latent attitude. The sociodemographic terms
tested for effects on the latent attitudes were the same as those used in the above direct interactions with
coefficients, allowing for a direct and indirect impact on preferences.
The latent variables are then interacted with the preference for the type of treatment, where we now have:
βhospital,n = βhospital + γhospitalzn + σhospitalξhospital,n +∑
L
l = 1τhospital,lαl,n. (6)
In the above specification, βhospital is an estimated mean preference, γhospital relates to sociodemographic impacts
on this preference (where we earlier showed the example of sex) and σhospital is an estimated standard deviation
for the random variation across respondents, ξhospital,n is a standard normal variate (mean 0, standard deviation 1)
distributed across respondents and τhospital,l measures the impact of the latent attitude αl,n on the preference by
respondent n for hospital treatment. A corresponding specification is used for βnurse home.
An important point needs to be made here. Indeed, all respondent characteristics included in the
deterministic component of the latent attitude have also been included in the covariate effects for βhospital
and βnurse home, thus avoiding a situation in which a sociodemographic effect is erroneously captured as
relating to attitudes when it may just relate to underlying modality preferences, or vice versa. In very much
the same way, the modality parameters now include a random component that relates to the latent
attitudes (through the inclusion of ∑Ll = 1τhospital,lαl,n above in the example of hospital treatment), while a
separate random component (σhospitalξhospital,n) relates to random variations in preferences for treatment type
which cannot be linked to latent attitudes.
This brings us to an additional important point. The specification of the two modality terms (βhospital and βnurse home)
now includes two separate random terms, both following a normal distribution, and both with deterministic
interactions on the mean, some of which relate to the same underlying sociodemographic variables. In the
current form, this would be an overspecification, with two parameters capturing the same effect. What allows
us to separately identify the two components is that one of them, namely the latent variable component, is also
used in a separate measurement model, to which we shall turn our attention next.
Measurement model
We have two latent attitudes in our model and these are used in the measurement model component of
our overall framework to explain the answers that respondents give to a number of attitudinal questions.
In particular, the first (hospital attitude) latent variable is used to explain the answers to the following statements:
l people get better more quickly if treated at home
l I do not like hospitals
l hospitals increased the risk of contracting a new infection
l I would have i.v. at home even if waiting hours for nurse
l being in hospital would make things difficult for family.
The latent attitude towards health-care responsibility is used to explain the answers to the following statements:
l giving myself i.v. would worry me
l doctors not patients are best placed to decide where patients should be cared for
l I would prefer monitoring by a doctor than by a nurse
l I want to be responsible for my own treatment.
All questions use a 5-level Likert scale, with higher values meaning stronger disagreement. We now use
the two latent attitudes to explain the answers to the attitudinal questions. With Is used to refer to a given
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attitudinal question, and letting αl be the associated latent attitude, we use an ordered logit model to
explain the likelihood of the actual observed value of Is for respondent n as:
Lls,n =∑5p = 1 x ls,n,p
etls,p − ζl,sαl,n
1 + etls,p − ζl,sαl,n
−
etls,p − 1 − ζl,sαl,n
1 + etls,p − 1 − ζl,sαl,n
 
, (7)
where Xls,n,p = 1 if and only if respondent n chooses answer p for question s. The tls,p parameters are thresholds
that are to be estimated, with the normalisation that tls,0 = −∞ and tls,5 = +∞. The estimated parameter ζl,s
measures the impact of the latent variable αl on Is. A significant estimate for ζl,s thus shows us that the latent
attitude αl has a statistically significant impact on the answers provided to the attitudinal question Is.
Joint specification
With in,t being the alternative chosen by respondent n in task t (out of T = 8), we have that the likelihood
of the eight observed choices and nine answers to attitudinal questions for respondent n is given by:
Ln = ∫α ∫β∏8t = 1
eVin,t
∑4j = 1e
V j,t
∏9s = 1LIs,nf (α)f (β)dβdα, (8)
where we use a logit kernel for the choice model component, and where LIs,n is defined as above. Both the
component relating to the choices (i.e. the logit kernel) and the component relating to the attitudinal
questions are a function of the vector of latent variables α, while the choice model component is also a
function of the random components used in the marginal utility coefficients (β). This is why the entire
likelihood function is integrated over the distribution of α and β. For estimation, we work with the log-
likelihood function (the logarithm of the above equation) and approximate this using numerical simulation
(i.e. maximising the simulated log-likelihood). In this process, we need to take draws (where we rely on
200 modified Latin hypercube sampling draws per person, see Hess et al.,228) for four normally distributed
random terms. All models were coded in Ox version 6.2 (Timberlake Consultants Press, London, UK) and
the standard errors reported in the results are obtained with the sandwich method (Huber229).
Detailed model results
The results are presented in Table 41.
In summary, we observe the following for the baseline effects:
l ASC_A and ASC_B show that there is a slight preference for left most alternative, but this is not
significant, while the middle alternative is chosen least often, but this is not highly significant
l hospital and nurse_home show that, for a respondent in the base sociodemographic category, there is
no statistically significant difference in preference between HO attendance and SA, with a preference,
albeit with low statistical significance, for nurse treatment at home
l treatm_one, treatm_two and treatm_three show that, with continuous treatment as the base, there is
a strong preference for one treatment only. The differences between two or three treatments and
continuous treatment are not statistically significant, although we see some trend
l appt_time_no shows a strong preference for having an appointment
l who_special and who_general show that, with doctor being the base, the base respondent type has a
preference for a SN over hospital treatment, with no significant difference between doctor and GN
l who_self_half shows that for the base respondent, there is no significant difference between a half-day
and full-day training programme
l comm_see_known shows no difference between seeing someone the patient knows or does not know
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TABLE 41 Detailed estimation results
Parameter Estimation rob t-rat Meaning of parameter
ASC_A 0.2129 0.88 Constant for left alternative (base = right)
ASC_B –0.4938 –1.47 Constant for middle alternative (base = right)
hospital –0.1508 –0.23 Main effect for hospital treatment (base= self)
nurse_home 1.4585 1.57 Main effect for nurse at home treatment (base= self)
treatm_one 0.7074 5.14 Main effect for one treatment (base = continuous)
treatm_two 0.1819 0.70 Main effect for two treatments (base = continuous)
treatm_three –0.2956 –1.04 Main effect for three treatments (base = continuous)
appt_time_no –0.5688 –3.51 Main effect for no appointment (base = appointment)
who_special 0.6091 1.91 Main effect for SN in hospital (base = doctor)
who_general 0.2237 0.59 Main effect for GN in hospital (base = doctor)
who_self_half –0.3578 –0.72 Main effect for SA after half day training (base= full day)
comm_see_known 0.0166 0.12 Main effect for see someone you know
(base = unknown)
comm_speak_known 0.8155 1.47 Main effect for speak to someone you know
(base = unknown)
after_none –0.1562 –1.13 Main effect for no after consultation (base = telephone)
after_hosp_nurse 0.1578 1.05 Main effect for after consultation with hospital nurse
(base = telephone)
after_GP 0.0153 0.09 Main effect for after consultation with GP
(base = telephone)
risk_6_or_10 –0.9880 –6.22 Main effect for 1 in 6 or 1 in 10 relapse (base= 1 in 25)
age_under_50_hospital 1.2314 1.72 Shifts for < 50 years of age (base = 50–65)
age_under_50_who_self_half 1.1833 2.47
age_under_50_comm_see_known 0.4776 2.33
age_over_65_nurse_home 1.5504 2.48 Shifts for ≥ 65 years of age (base = 50–65)
age_over_65_comm_speak_known –1.2197 –3.00
age_over_65_risk_10 0.7145 2.85
alone_who_special –0.6479 –1.54 Shift for living alone (base = not alone)
alone_who_general –0.7355 –1.53
alone_who_self_half –1.0338 –1.85
alone_comm_speak_known –1.0737 –2.04
working_risk_10 0.3493 1.98 Shifts for working (base = not working)
long_appt_time_no 0.4548 2.09 Shifts for long vs. short (base = short)
long_who_self_half 0.7676 1.58
long_comm_see_known 0.3991 2.34
long_comm_speak_known 0.4771 1.03
hospital_sig 2.2462 4.10 Pure random heterogeneity in modality preferences
nurse_sig –1.1869 –1.74
zeta_lv_1_I_1 1.2866 4.17 Impact of first latent on ‘People get better more quickly
treated at home’ (positive means disagree)
zeta_lv_1_I_2 0.8945 4.28 Impact of first latent on ‘I do not like hospitals’
(positive means disagree)
continued
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TABLE 41 Detailed estimation results (continued )
Parameter Estimation rob t-rat Meaning of parameter
zeta_lv_1_I_3 0.8606 3.21 Impact of first latent on ‘Hospitals increased risk
contracting new infection’ (positive means disagree)
zeta_lv_1_I_6 1.8487 3.89 Impact of first latent on ‘Would have i.v. at home even
if waiting hours for nurse’ (positive means disagree)
zeta_lv_1_I_10 1.1457 4.19 Impact of first latent on ‘Being in hospital would make
things difficult for family’ (positive means disagree)
female_lv_1 –0.4954 –2.31 Sociodemographic impacts on first latent variable
nonwhite_lv_1 –0.3323 –1.42
alone_lv_1 0.1887 0.90
tau_lv1_hospital 1.1159 3.16 Impact of first latent attitude on hospital
tau_lv1_nurse –0.8918 –1.87 Impact of first latent attitude on nurse at home
zeta_lv_2_I_4 –2.2614 –4.91 Impact of second latent on ‘Giving own i.v. would
worry me’ (positive means disagree)
zeta_lv_2_I_5 –0.4332 –2.43 Impact of second latent on ‘Doctors not patients best
to decide where patients cared for’ (positive means
disagree)
zeta_lv_2_I_7 –0.5798 –2.82 Impact of second latent on ‘Would prefer monitoring
by doctor than by nurse’ (positive means disagree)
zeta_lv_2_I_8 0.1699 0.99 Impact of second latent on ‘I want to be responsible
for own treatment’ (positive means disagree)
age_over_65_lv_2 0.3700 1.44 Sociodemographic impacts on second latent variable
nonwhite_lv_2 0.8505 4.51
university_lv_2 –0.0933 –0.70
tau_lv2_hospital 3.4171 5.12 Impact of second latent attitude on hospital
tau_lv2_nurse 4.0320 9.25 Impact of second latent attitude on nurse at home
t1_I1 –1.1770 –3.77 Threshold parameters for ‘People get better more
quickly treated at home’
t2_I1 0.3912 1.67
t3_I1 2.0141 5.55
t4_I1 4.1935 6.69
t1_I2 –1.6936 –7.92 Threshold parameters for ‘I do not like hospitals’
t2_I2 –0.2661 –1.44
t3_I2 0.6429 3.17
t4_I2 2.7464 8.35
t1_I3 –0.8715 –4.25 Threshold parameters for ‘Hospitals increased risk
contracting new infection’
t2_I3 0.9017 4.19
t3_I3 1.6472 6.91
t4_I3 3.4597 8.22
t1_I4 –1.6471 –0.75 Threshold parameters for ‘Giving own i.v. would worry
me’
t2_I4 –0.3395 –0.17
t3_I4 0.0544 0.03
t4_I4 1.9610 1.18
t1_I5 –1.8055 –4.31 Threshold parameters for ‘Doctors not patients best to
decide where patients cared for’
t2_I5 –0.1547 –0.41
t3_I5 0.7880 2.04
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l comm_speak_known shows a preference, albeit not highly significant, for speaking to someone the
patient knows
l after_none, after_hosp_nurse and after_GP show that having no after treatment is worse than a
telephone or GP appointment, while a hospital nurse is preferred
l risk_6_or_10 combines the effects for 1 in 6 and 1 in 10 risk levels, which were not significantly
different for the base respondent, but were perceived as significantly worse than a 1 in 25 risk.
Turning to the sociodemographic interactions, we see that:
l younger patients prefer a half-day of training, have a preference for seeing someone they know and
also have a stronger preference for in-hospital treatment
l older patients have a preference for nurse treatment at home, the difference between speaking to
someone they know or does not know disappears (when summing up comm_see_known and
age_over_65_comm_speak_known) and they evaluate a risk of 1 in 10 as being less bad than 1 in 6
(summing up risk_6_or_10 and age_over_65_risk_10)
l those living alone make no distinction between doctors and special nurses but prefer them to GNs
(summing who_special and alone_who_special, and who_general and alone_who_general). They
dislike half-day training and the preference for speaking to someone they know cancels out
(comm_speak_known and alone_comm_speak_known)
l those working understand the distinction between 1 in 6 and 1 in 10 risks
l those on longer treatment care less about having an appointment and have a stronger preference for seeing
someone they know (and speaking to someone they know, although this is not significant). Summing up
who_self_half and long_who_self_half also shows that these respondents have a slight preference for a
half-day training programme, but this is again not statistically significant at high levels.
Turning to the random heterogeneity parameters (i.e. allowing for differences in preferences across
participants who cannot be linked to sociodemographics), the estimates for hospital_sig and nurse_sig
TABLE 41 Detailed estimation results (continued )
Parameter Estimation rob t-rat Meaning of parameter
t4_I5 2.2158 4.99
t1_I6 –2.0871 –3.64 Threshold parameters for ‘Would have i.v. at home
even if waiting hours for nurse’
t2_I6 0.6702 2.32
t3_I6 1.0196 3.42
t4_I6 3.2735 5.58
t1_I7 –2.6319 –4.81 Threshold parameters for ‘Would prefer monitoring by
doctor than by nurse’
t2_I7 –1.4832 –2.84
t3_I7 0.4947 0.97
t4_I7 2.3679 4.59
t1_I8 –0.9482 –4.34 Threshold parameters for ‘I want to be responsible for
own treatment’
t2_I8 0.4399 1.97
t3_I8 1.1794 4.90
t4_I8 2.7860 7.80
t1_I10 –0.6502 –2.64 Threshold parameters for ‘Being in hospital would
make things difficult for family’
t2_I10 0.6962 2.88
t3_I10 1.5152 4.58
t4_I10 4.3082 5.80
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show a significant level of random variation across respondents in their preferences for different treatment
modalities. This heterogeneity is stronger for hospital treatment (i.e. setting it apart from the two at
home treatments).
We next look at the impact of the latent variables on the attitudinal questions. We see that:
l the signs of zeta_lv_1_I_1, zeta_lv_1_I_2, zeta_lv_1_I_3, zeta_lv_1_I_6 and zeta_lv_1_I_10 mean that
the first latent variable is a pro-hospital attitude, as people with a more positive latent variable disagree
more with statements such as ‘People get better more quickly treated at home’
l these respondents are less likely to be female (female_lv_1) or non-white (nonwhite_lv_1) and more
likely to live at home (alone_lv_1), although this last effect is not significant at high levels
l respondents with a more positive pro-hospital attitude (i.e. more positive latent variable) have a
stronger preference for in-hospital treatment in the choice model (tau_lv1_hospital is positive), while
the baseline preference for nurse treatment at home is reduced (tau_lv1_nurse is negative)
l the signs of zeta_lv_2_I_4, zeta_lv_2_I_5, zeta_lv_2_I_7 and zeta_lv_2_I_8 mean that the second latent
variable relates to people seeing health care as a doctor’s responsibility, with those with a more positive latent
variable agreeing, for example, with ‘Giving own i.v. would worry me’. The sociodemographic influences
suggest that people > 65 years see health care more as a doctor’s responsibility, as do non-white
respondents, although this is reduced (although not statistically significant) for people with a university degree
l respondents who are more of the view that health care is a doctor’s responsibility have a stronger
preference for in-hospital treatment in the choice model (tau_lv2_hospital is positive) but the
preference for nurse treatment at home is increased even further (tau_lv2_nurse is positive).
The remaining set of 36 threshold parameters simply capture the distribution of answers to attitudinal
questions in the data.
Discrete choice (stated choice) scenarios
Table 42 contains a list of the 24 choice scenarios used in the survey. The actual ordering of the three
treatment types was randomised across respondents, but kept constant across the eight choices for a given
respondent. In addition, the order of the eight choices within each block was randomised across respondents.
TABLE 42 Choice scenarios included in survey
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 1, choice task 1
Number of treatments each day One Pump provides continuous
treatment
Three
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment at hospital
with nurse
Telephone appointment
with nurse
None
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 25 chance 1 in 10 chance
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 1, choice task 2
Number of treatments each day Two Two Pump provides continuous
treatment
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN GN You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
None Appointment at hospital
with nurse
Telephone appointment
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 25 chance 1 in 10 chance
Block 1, choice task 3
Number of treatments each day Two Two Pump provides continuous
treatment
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
GN You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Telephone appointment
with nurse
Appointment with your
GP
None
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 6 chance 1 in 25 chance
Block 1, choice task 4
Number of treatments each day Two Two Two
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN GN You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Telephone appointment
with nurse
Appointment with your
GP
None
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 25 chance 1 in 10 chance
continued
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 1, choice task 5
Number of treatments each day One Pump provides continuous
treatment
One
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Telephone appointment
with nurse
None Appointment with your
GP
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 6 chance 1 in 10 chance
Block 1, choice task 6
Number of treatments each day One Pump provides continuous
treatment
Two
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
None Telephone appointment
with nurse
Appointment with your
GP
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 6 chance 1 in 10 chance
Block 1, choice task 7
Number of treatments each day Pump provides
continuous treatment
One One
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Telephone appointment
with nurse
Appointment at hospital
with nurse
Appointment at hospital
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 10 chance 1 in 25 chance
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
248
TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 1, choice task 8
Number of treatments each day Pump provides
continuous treatment
One Pump provides continuous
treatment
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Appointment with your
GP
None Telephone appointment
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 10 chance 1 in 6 chance
Block 2, choice task 1
Number of treatments each day One Pump provides continuous
treatment
Three
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment with your
GP
None Appointment with your
GP
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 25 chance 1 in 6 chance
Block 2, choice task 2
Number of treatments each day Pump provides
continuous treatment
One Three
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Telephone appointment
with nurse
None Appointment at hospital
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 6 chance 1 in 6 chance
continued
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 2, choice task 3
Number of treatments each day Pump provides
continuous treatment
One One
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? GN GN You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
None Appointment at hospital
with nurse
Telephone appointment
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 25 chance 1 in 6 chance
Block 2, choice task 4
Number of treatments each day One Pump provides continuous
treatment
Pump provides continuous
treatment
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Appointment at hospital
with nurse
Telephone appointment
with nurse
None
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 10 chance 1 in 6 chance
Block 2, choice task 5
Number of treatments each day Pump provides
continuous treatment
One One
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
GN You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Appointment at hospital
with nurse
Telephone appointment
with nurse
Appointment at hospital
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 10 chance 1 in 6 chance
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 2, choice task 6
Number of treatments each day One Pump provides continuous
treatment
Two
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
None Appointment with your
GP
Appointment with your
GP
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 10 chance 1 in 25 chance
Block 2, choice task 7
Number of treatments each day Pump provides
continuous treatment
One Two
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
GN You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
None Telephone appointment
with nurse
Appointment at hospital
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 25 chance 1 in 6 chance
Block 2, choice task 8
Number of treatments each day Two Two Two
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN GN You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment at hospital
with nurse
None Telephone appointment
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 6 chance 1 in 25 chance
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 3, choice task 1
Number of treatments each day Two Two Three
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment with your
GP
Appointment with your
GP
None
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 10 chance 1 in 25 chance
Block 3, choice task 2
Number of treatments each day Two Two One
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment at hospital
with nurse
Appointment at hospital
with nurse
Telephone appointment
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 25 chance 1 in 10 chance
Block 3, choice task 3
Number of treatments each day Pump provides
continuous treatment
One Pump provides continuous
treatment
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
None Appointment with your
GP
Telephone appointment
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 6 chance 1 in 25 chance
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 3, choice task 4
Number of treatments each day Pump provides
continuous treatment
One One
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Appointment with your
GP
Telephone appointment
with nurse
None
Risk of a problem such as another
infection or having to go into
hospital
1 in 6 chance 1 in 10 chance 1 in 25 chance
Block 3, choice task 5
Number of treatments each day One Pump provides continuous
treatment
Pump provides continuous
treatment
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
GN You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Appointment at hospital
with nurse
Appointment with your
GP
Appointment at hospital
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 6 chance 1 in 25 chance
Block 3, choice task 6
Number of treatments each day Two Two Three
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment with your
GP
Appointment at hospital
with nurse
Appointment with your
GP
Risk of a problem such as another
infection or having to go into
hospital
1 in 25 chance 1 in 6 chance 1 in 10 chance
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TABLE 42 Choice scenarios included in survey (continued )
Nurse gives IVA in
your home
You have your IVA in
hospital
You give IVA to
yourself at home
Block 3, choice task 7
Number of treatments each day One Pump provides continuous
treatment
Three
Appointment times given Daily appointment time
given
Daily appointment time
not given
No appointment needed
Who gives the IVA? GN Specialist i.v. antibiotic
nurse
You give the IVA yourself
after 1 day of training
Communication between you and
HCPs
See a HCP who does not
know you
See a HCP who knows
you
Speak on the telephone
with a HCP who knows
you
Aftercare from HCPs after the end
of treatment
Telephone appointment
with nurse
None Appointment at hospital
with nurse
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 10 chance 1 in 10 chance
Block 3, choice task 8
Number of treatments each day Two Two Two
Appointment times given Daily appointment time
not given
Daily appointment time
given
No appointment needed
Who gives the IVA? Specialist i.v. antibiotic
nurse
Doctor You give the IVA yourself
after half a day of training
Communication between you and
HCPs
See a HCP who knows
you
See a HCP who does not
know you
Speak on the telephone
with a HCP who does not
know you
Aftercare from HCPs after the end
of treatment
Appointment with your
GP
Appointment at hospital
with nurse
Appointment with your
GP
Risk of a problem such as another
infection or having to go into
hospital
1 in 10 chance 1 in 25 chance 1 in 6 chance
HCP, health-care professional.
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Appendix 4 Economic modelling
TABLE 43 Deterministic sensitivity analysis: short-term infections
Outcomes
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN
Effectiveness and risk
Assume same heal time (average 6.14 days)
Costs (£) 1215 765 765 HO vs. GN 2,208,170 –445 GN cost-effective
QALYs 0.172 0.172 0.172 HO vs. SN 2,208,176 –445 SN cost-effective
GN vs. SN N/A 0 Equivalent
Double the CDI risk for all services
Costs (£) 1000 852 779 HO vs. GN 32,343 –57 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 78,570 –165 SN cost-effective
GN vs. SN SN dominates –109 SN cost-effective
Double line infection risk for all services
Costs (£) 1006 863 789 HO vs. GN 20,007 0 GN cost-effective
QALYs 0.169 0.162 0.165 HO vs. SN 49,539 –129 SN cost-effective
GN vs. SN SN dominates –129 SN cost-effective
Half time to resolve CDI and line infection
Costs (£) 993 846 773 HO vs. GN 42,052 –77 GN cost-effective
QALYs 0.177 0.174 0.175 HO vs. SN 100,083 –176 SN cost-effective
GN vs. SN SN dominates –99 SN cost-effective
Assume HO i.v. treatment three times per week
Costs (£) 605 852 779 HO vs. GN HO dominates 339 HO cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN HO dominates 231 HO cost-effective
GN vs. SN SN dominates –108 SN cost-effective
Assume same CDI risk for all (HO risk)
Costs (£) 998 855 781 HO vs. GN 30,493 –49 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 73,904 –158 SN cost-effective
GN vs. SN SN dominates –109 SN cost-effective
Costs
Initial consultant-led review in all services
Costs (£) 998 1089 1016 HO vs. GN HO dominates 184 HO cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN HO dominates 75 HO cost-effective
GN vs. SN SN dominates –108 SN cost-effective
+20% to costs of hospital visit
Costs (£) 1153 899 826 HO vs. GN 54,679 –161 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 113,786 –269 SN cost-effective
GN vs. SN SN dominates –108 SN cost-effective
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TABLE 43 Deterministic sensitivity analysis: short-term infections (continued )
Outcomes
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN
+20% to costs of nurse visit
Costs (£) 998 900 821 HO vs. GN 21,213 –6 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 61,641 –120 SN cost-effective
GN vs. SN SN dominates –114 SN cost-effective
Half cost of treating C. difficile
Costs (£) 997 852 778 HO vs. GN 31,386 –53 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 76,155 –161 SN cost-effective
GN vs. SN SN dominates –108 SN cost-effective
Band 6 nurse for SN visits
Costs (£) 998 1035 941 HO vs. GN HO dominates 129 HO cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 20,042 0 SN cost-effective
GN vs. SN SN dominates –129 SN cost-effective
Wider cost perspective (including patient travel and parking costs and expenses)
Costs (£) 1037 860 787 HO vs. GN 38,131 –84 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 87,056 –193 SN cost-effective
GN vs. SN SN dominates –108 SN cost-effective
Utility
EQ-5D values from discrete choice survey (no infection = 0.683; infection = 0.532)
Costs (£) 998 852 779 HO vs. GN 39,056 –72 GN cost-effective
QALYs 0.162 0.159 0.160 HO vs. SN 94,019 –173 SN cost-effective
GN vs. SN SN dominates –101 SN cost-effective
+50% to utility decrements for all AEs for all services
Costs (£) 998 852 779 HO vs. GN 31,571 –54 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 76,450 –162 SN cost-effective
GN vs. SN SN dominates –109 SN cost-effective
Adding a quality-of-life decrement (0.2) for mild AEs
Costs (£) 998 852 779 HO vs. GN 31,727 –54 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 77,176 –163 SN cost-effective
GN vs. SN SN dominates –109 SN cost-effective
No QALY loss for death
Costs (£) 998 852 779 HO vs. GN 81,792 –111 GN cost-effective
QALYs 0.180 0.179 0.179 HO vs. SN 202,991 –198 SN cost-effective
GN vs. SN SN dominates –87 SN cost-effective
Scenarios
Assume 1 day fewer heal time for HO and 5% relapse rates for nurse services
Costs (£) 847 860 787 HO vs. GN HO dominates 143 HO cost-effective
QALYs 0.176 0.170 0.171 HO vs. SN 12,727 34 HO cost-effective
GN vs. SN SN dominates –109 SN cost-effective
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TABLE 43 Deterministic sensitivity analysis: short-term infections (continued )
Outcomes
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN
Double risks and mortality rates for all AEs for all services
Costs (£) 1006 860 786 HO vs. GN 12,207 93 HO cost-effective
QALYs 0.160 0.148 0.152 HO vs. SN 29,535 –71 SN cost-effective
GN vs. SN SN dominates –164 SN cost-effective
Half C. difficile rate for HO; 5% relapse rate and 20% increase in nurse visit costs GN and SN
Costs (£) 997 909 830 HO vs. GN 18,117 9 HO cost-effective
QALYs 0.175 0.170 0.171 HO vs. SN 54,034 –105 SN cost-effective
GN vs. SN SN dominates –115 SN cost-effective
Utility decrement for mild adverse event (0.2) and cost (daily resource use cost)
Costs (£) 1000 858 785 HO vs. GN 30,520 –49 GN cost-effective
QALYs 0.175 0.170 0.172 HO vs. SN 74,177 –157 SN cost-effective
GN vs. SN SN dominates –108 SN cost-effective
AE, adverse event.
TABLE 44 Deterministic sensitivity analysis: long-term infections
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN SA
Effectiveness and risk
Assume same heal time (average 28.01 days)
Costs (£) 4763 2793 2793 2102 HO vs. GN 2,171,523 –1952 GN cost-effective
QALYs 0.641 0.640 0.640 0.638 HO vs. SN 2,171,523 –1952 SN cost-effective
HO vs. SA 946,897 –2605 SA cost-effective
GN vs. SN N/A 0 Equivalent
GN vs. SA SA dominates –653 SA cost-effective
SN vs. SA 363,117 –653 SA cost-effective
Double the CDI risk for all services
Costs (£) 4636 3096 2578 2133 HO vs. GN 124,483 –1293 GN cost-effective
QALYs 0.643 0.631 0.647 0.637 HO vs. SN SN dominates –2135 SN cost-effective
HO vs. SA 425,431 –2386 SA cost-effective
GN vs. SN SN dominates –842 SN cost-effective
GN vs. SA SA dominates –1093 SA cost-effective
SN vs. SA 45,769 –251 SA cost-effective
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TABLE 44 Deterministic sensitivity analysis: long-term infections (continued )
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN SA
Double line infection risk for SA
Costs (£) 4631 3078 2563 2147 HO vs. GN 128,354 –1310 GN cost-effective
QALYs 0.644 0.631 0.648 0.608 HO vs. SN SN dominates –2149 SN cost-effective
HO vs. SA 69,942 –1773 SA cost-effective
GN vs. SN SN dominates –839 SN cost-effective
GN vs. SA 39,778 –463 SA cost-effective
SN vs. SA 10,514 375 SN cost-effective
Triple risk of anaphylactic shock
Costs (£) 4632 3080 2564 2115 HO vs. GN 103,227 –1251 GN cost-effective
QALYs 0.641 0.626 0.643 0.629 HO vs. SN SN dominates –2110 SN cost-effective
HO vs. SA £211,256 –2278 SA cost-effective
GN vs. SN SN dominates -£859 SN cost-effective
GN vs. SA SA dominates -£1027 SA cost-effective
SN vs. SA £31,998 -£168 SA cost-effective
Assume HO i.v. treatment three times per week
Costs (£) 2770 3078 2563 2114 HO vs. GN HO dominates 550 HO cost-effective
QALYs 0.644 0.631 0.648 0.638 HO vs. SN SN dominates
dominates
–288 SN cost-effective
HO vs. SA 116,845 –544 SA cost-effective
GN vs. SN SN dominates –839 SN cost-effective
GN vs. SA SA dominates –1094 SA cost-effective
SN vs. SA 46,393 –255 SA cost-effective
Assume same CDI risk for all (HO risk)
Costs (£) 4631 3087 2570 2124 HO vs. GN 124,952 –1297 GN cost-effective
QALYs 0.644 0.631 0.647 0.638 HO vs. SN SN dominates –2137 SN cost-effective
HO vs. SA SA dominates –2389 SA cost-effective
GN vs. SN SN dominates –840 SN cost-effective
GN vs. SA SA dominates –1093 SA cost-effective
SN vs. SA 45,995 –253 SA cost-effective
Double anaphylaxis mortality risk for none HO
Costs (£) 4631 3078 2563 2114 HO vs. GN 109,062 –1268 GN cost-effective
QALYs 0.644 0.629 0.646 0.635 HO vs. SN SN dominates –2114 SN cost-effective
HO vs. SA 298,396 –2348 SA cost-effective
GN vs. SN SN dominates –846 SN cost-effective
GN vs. SA SA dominates –1080 SA cost-effective
SN vs. SA 41,788 –234 SA cost-effective
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TABLE 44 Deterministic sensitivity analysis: long-term infections (continued )
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN SA
Costs
Initial consultant-led review all services
Costs (£) 4631 3316 2801 2352 HO vs. GN 108,699 –1073 GN cost-effective
QALYs 0.644 0.631 0.648 0.638 HO vs. SN SN dominates –1911 SN cost-effective
HO vs. SA 405,918 –2167 SA cost-effective
GN vs. SN SN dominates –839 SN cost-effective
GN vs. SA SA dominates –1094 SA cost-effective
SN vs. SA 46,393 –255 SA cost-effective
–20% nurse costs
Costs (£) 4631 2897 2414 2068 HO vs. GN 143,332 –1491 GN cost-effective
QALYs 0.644 0.631 0.648 0.638 HO vs. SN SN dominates –2297 SN cost-effective
HO vs. SA 456,500 –2451 SA cost-effective
GN vs. SN SN dominates –806 SN cost-effective
GN vs. SA SA dominates –959 SA cost-effective
SN vs. SA 35,815 –153 SA cost-effective
Triple SA equipment costs
Costs (£) 4631 3078 2563 2214 HO vs. GN 128,354 –1310 GN cost-effective
QALYs 0.644 0.631 0.648 0.638 HO vs. SN SN dominates –2149 SN cost-effective
HO vs. SA 430,442 –2304 SA cost-effective
GN vs. SN SN dominates –839 SN cost-effective
GN vs. SA SA dominates –994 SA cost-effective
SN vs. SA 36,061 –155 SA cost-effective
Half outpatient consultant visit cost
Costs (£) 4512 2731 2258 1788 HO vs. GN 147,244 –1539 GN cost-effective
QALYs 0.644 0.631 0.648 0.638 HO vs. SN SN dominates –2336 SN cost-effective
HO vs. SA 485,086 –2611 SA cost-effective
GN vs. SN SN dominates –797 SN cost-effective
GN vs. SA SA dominates –1072 SA cost-effective
SN vs. SA 48,463 –275 SA cost-effective
Utility
EQ-5D values from discrete choice survey (no infection = 0.683; infection = 0.532)
Costs (£) 4631 3078 2563 2114 HO vs. GN 227,021 –1415 GN cost-effective
QALYs 0.643 0.636 0.645 0.639 HO vs. SN SN dominates –2102 SN cost-effective
HO vs. SA 584,864 –2430 SA cost-effective
GN vs. SN SN dominates –687 SN cost-effective
GN vs. SA SA dominates –1015 SA cost-effective
SN vs. SA 74,454 –328 SA cost-effective
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TABLE 44 Deterministic sensitivity analysis: long-term infections (continued )
Service
Comparison ICER (£) INMB (£) InterpretationHO GN SN SA
+50% to utility decrements for all AEs for all services
Costs (£) 4631 3078 2563 2114 HO vs. GN 128,321 –1310 GN cost-effective
QALYs 0.6434 0.6313 0.6475 0.6378 HO vs. SN SN dominates –2149 SN cost-effective
HO vs. SA 448,574 –2404 SA cost-effective
GN vs. SN SN dominates –839 SN cost-effective
GN vs. SA SA dominates –1094 SA cost-effective
SN vs. SA 46,367 –255 SA cost-effective
No QALY loss for death
Costs (£) 4631 3078 2563 2114 HO vs. GN 225,852 –1415 GN cost-effective
QALYs 0.673 0.666 0.676 0.671 HO vs. SN SN dominates –2128 SN cost-effective
HO vs. SA 1,395,644 –2480 SA cost-effective
GN vs. SN SN dominates –713 SN cost-effective
GN vs. SA SA dominates –1066 SA cost-effective
SN vs. SA 93,062 –353 SA cost-effective
Scenarios
Assume utility decrement for mild AEs (–0.01), double SA rate of line infection and SA equipment cost
Costs (£) 4631 3078 2563 2197 HO vs. GN 128,354 –1310 GN cost-effective
QALYs 0.644 0.631 0.648 0.608 HO vs. SN SN dominates –2149 SN cost-effective
HO vs. SA 69,165 –1730 SA cost-effective
GN vs. SN –31,899 –839 SN cost-effective
GN vs. SA 38,172 –420 SA cost-effective
SN vs. SA 9329 419 SN cost-effective
Assume 30 days to heal in SA and double SA training costs
Costs (£) 4631 3078 2563 2293 HO vs. GN 128,354 –1310 GN cost-effective
QALYs 0.644 0.631 0.648 0.633 HO vs. SN –508,664 –2149 SN cost-effective
HO vs. SA 215,743 –2121 SA cost-effective
GN vs. SN SN dominates –839 SN cost-effective
GN vs. SA SA dominates –811 SA cost-effective
SN vs. SA 18,146 28 SN cost-effective
AE, adverse event.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
260
Appendix 5 Expert panel summaries
Summary of the systematic review
Aim
This review was undertaken in 2013/14 with an update in May 2015 specifically to identify and evaluate
the existing evidence in the published literature.
We were specifically looking for evidence of:
1. efficacy of treatment within the four potential service models
2. patient safety issues
3. effectiveness of care in the service models
4. cost-effectiveness.
Methods
Databases searched included MEDLINE, EMBASE and Cochrane from 1993 to April 2013 (now May 2015).
Our protocol included all i.v. antibiotic types and method of administration. We excluded children and
non-i.v. antibiotics, for example, oral administration antibiotics. Titles and abstracts were screened and
checked for quality by at least two reviewers. Potential papers were obtained in full text for review.
Results
The number of papers that matched our inclusion and exclusion criteria was 110. The majority were from
the UK, with the remainder from Europe and North America and Australia. There were 12 RCTs. Synthesised
data showed mixed results for cure or improvement in the patient. When OPAT models were considered
individually, HO attendance appears least effective and GN appears most effective. However, these results
need to be considered in relation to the quality of the evidence. Twelve RCTs met our selection criteria;
however, none of these provided a robust description of their methods.
The results from a large number of studies were aggregated, which made it difficult to unpick who got
what and when. Only 19 studies included a usual care comparator (hospital inpatient). Most importantly,
there was often no definition of the kind of OPAT service being reported. For example, the paper reported
that the patients received care from an ‘OPAT’ service with no further explanation.
This systematic review demonstrates that the existing evidence base has been quite poor.
We have been able to describe the literature and present our results, but they could not be used on their
own to inform patients, clinicians and commissioners about which model or models of OPAT are
most effective.
Summary of health professional work package
Aim
To explore the types of OPAT services that have been commissioned and provided in England and to
identify any perceived barriers to implementing this type of service and to establish reasons for current
service configuration.
Method
We carried out a brief electronic survey and contacted 120 individuals/organisations. We had 35 responses,
which give a snapshot of some of the services offered.
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The majority of respondents reported that they offered more than one model of care (i.e. daily hospital
visits or district nurses at home). The survey was also used to inform the selection of professionals who had
agreed to a follow-up telephone interview. We selected those for interview who represented a range of
services provided, geographical location and diversity of populations served.
We completed 20 interviews with a range of relevant staff.
Results
Most services included some hospital provision with community options supplied by GNs/SNs or private
health-care providers. There were differences in the prominence given to the service within organisations.
Some described well-developed administrative systems with designated staff, whereas others described
their service as ad hoc and seemingly reliant on good working relationships with colleagues who could
help when needed. The list of types of infections treated was fairly extensive and included cellulitis, bone
and joint infections, diabetic foot infections, renal infections and respiratory infections.
Patient SA was the norm in one service (with back up if the patient was not able to do this), but other
interviewees were less enthusiastic about this option. Geographical location presented a problem for some
organisations if the patients were some distance from the hospital base. This was particularly problematic
if the patient needed more than two dose administrations per day. This resulted in restricted services
for patients.
Leadership and working relationships
There were notable differences in how this was described by interviewees. Those who had come to the
role as champions of OPAT were perhaps more able to influence development of the service. Others had
been given the role with limited opportunity to take ownership of the service and develop it. Some
organisations had little clinical leadership provision and others had stepped in to take the role to ensure
that the service continued. In the well-developed service model, teams have core medical staff with
expertise in infectious diseases, microbiology, pharmacy and nursing, with input from a wide range of
other relevant professionals. These services had well defined communication and input from the i.v. access
teams and community nurses in primary care.
Finances and resources
Business cases were a feature of most of those with responsibility for OPAT services. Some reported that
their resources were precarious and were dependent on the number of referrals into the service annually.
Financial instability is a common feature and this means in reality that, although services may be delivered
there is limited scope for development and expansion.
One interviewee reported that they had their business case turned down because there was insufficient
reduction in bed occupancy to justify the service. This demonstrated a lack of perception that patient
preference could be a motivator for the development of services, although some reported using patient
satisfaction surveys to support the continuation of the service.
Governance and patient safety issues
All of the interviewees who had input into OPAT services reported some form of monitoring. How this
worked depended on how the service was configured. Those who described their service as using BSAC
surveillance methods tended to have well-defined structures in place to follow up patients and audit
their outcomes.
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However, several interviewees reported problems in the past, whereby patients had not received optimal
care, for example, patients had been on i.v. antimicrobials for unjustified lengths of time, patients had to
be retreated and one patient had a severe reaction to the agent, which may have been avoided.
Less well-developed and resourced services might be perceived as a potential risk to patients.
Cost-effectiveness summary
Aim
To estimate costs and benefits of four OPAT services for two types of patient (short-term and longer-term
infections) using two modelling methods: a Markov model and a Simulation model.
Markov model results
l Short-term infections
¢ HO is the most expensive but most effective service
¢ SN is cheapest and more effective than GN, and the costs of GN and SN were very similar
¢ these results were robust to changes in risks, costs and quality of life values
¢ the results only changed in favour of HO when it was assumed that HO required fewer treatment
days than the alternatives and had lower risks.
l Long-term infections
¢ HO is the most expensive but least effective alternative
¢ the costs and benefits of GN and SN are similar, although the latter is more often cheaper and
more effective than the former
¢ SA is cheaper and more effective than SN making it the preferred service
¢ these results are robust to a number of sensitivity analyses.
Simulation model results
These confirm the results from the Markov model for both short- and long-term infections:
l Short-term infections
¢ SN alone is the most cost-effective strategy for both costing perspectives
¢ combining SN with HO (80 : 20% ratio) is not a cost-effective strategy compared with SN alone but
better than GN alone service (cost per hour)
¢ QALYs affected only when the number of staff is not able to cope with the demand of patients
¢ reducing the number of staff reduces service costs (commissioning)
¢ A service with two nurses is more cost-effective than one with four nurses when covering 300
patients a year (commissioning).
l Long-term infections
¢ SA or SN alone are the most cost-effective strategies for per-hour and commissioning
perspectives, respectively
¢ combining SN with SA was better (in terms of costs and QALYs) than combining SN with HO
(per hour perspective)
¢ costs and QALYs only affected when staffing is insufficient
¢ a SN service can function with only one nurse
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¢ the second best alternative is combining SN with SA. However, the higher the proportion of SA,
the more costly the strategy
¢ QALYs are reduced when the number of staff available is unable to cope with demand making the
service more expensive and less effective.
Value of information: not very informative owing to lack of decision uncertainty in the models as they are
currently formulated.
Executive summary for discrete choice experiment development
(qualitative work)
Aims
l To generate data to ascertain service issues that were important to patients, to inform the development
of the DCE.
l To identify potential attributes and levels, informed by the literature review and qualitative interviews.
l To pilot the draft DCE.
Method
Semistructured interviews and focus group with n = 32 patients.
Eligibility
Adults aged > 18 years who had an infection in the last 3 years that was treated via OPAT.
Data analysis
Thematic analysis.
Key results
Meeting the needs of patients
l Patients want to avoid hospital (fear of infection, and the impact on family and work).
l Past experience, age and health affect views about optimal OPAT model.
Benefits of and barriers to different models of care
l Older people seem to prefer home care, but this is also likely to be influenced by the severity of
infection and/or comorbidities.
l Older participants do not feel daily attendance at hospital is appropriate for the infirm or very old.
l Nurse at home model means patients get the undivided attention of a nurse.
l Attendance at hospital more than once a day was viewed as unacceptable by most people.
l Self-administration was potentially acceptable, especially by those who had repeated infections.
l Geography is important – public transport routes and car parking affect acceptability.
Effectiveness of treatment
l Most patients believe that i.v. antimicrobials are more effective than oral alternatives.
l Patients are concerned if a switch is made from i.v. to oral antimicrobials without their infection being
assessed by a doctor.
l Short-term i.v. patients were often unsure if their infection had cleared by the time their treatment
course had finished.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
264
Communication
l Most patients want to be followed up at the end of their i.v./oral treatment.
l Few participants felt that they knew who they should contact for follow-up.
l Almost all patients received written information about OPAT and/or their infection, but not everyone
was given a contact number in case of emergencies.
l For some patients it was important to have a named person to contact, but others just wanted to
know they could contact staff if they needed to.
Review and follow-up
l Some patients wanted their treatment to be managed (seen by) a doctor. Others were happy to be
managed by a nurse, provided competent and qualified to provide i.v. care.
l Patients want staff to be aware of their infection/treatment plan (continuity of care).
l Patients expressed frustration if appointment times were missed.
Executive summary of the results of the discrete choice survey
and modelling work
Patients recruited for the study took part in a stated choice survey, where they faced eight hypothetical
choices between three models of care (HO attendance, nurse at home, SA), with the characteristics of
each varying across the eight choice tasks. The three treatments were described in terms of:
l the type of treatment (hospital, nurse at home, SA)
l the frequency of treatment (once, twice, three times, continuous)
l whether or not an appointment time is given (not relevant for SA)
l who administers the treatment (doctor, SN or GN; not relevant for SA)
l whether a full or half day of training is given for SA
l whether or not the patient sees a health-care professional she or he knows (not relevant for SA)
l whether or not, if self-administering, the patient speaks (on the telephone) to a health-care
professional that she or he knows
l what type of aftercare is given (none, appointment at hospital with nurse, appointment with GP,
telephone appointment with nurse)
l the risk of a problem (1 in 6, 1 in 10 or 1 in 25).
Our analysis made use of an advanced discrete choice model, which is a mathematical structure used to
explain the influence of explanatory variables (e.g. type of treatment) on choices. The model is based on
the notion of utility maximisation, with respondents choosing the option that gives them the greatest
utility/smallest disutility. With the expectation of major differences in preferences across patients, our work
incorporates three levels of heterogeneity in preferences across patients, namely:
l heterogeneity linked to sociodemographics
l heterogeneity as a function of underlying attitudes (attitude towards hospitals and attitude towards
whose responsibility health care is)
l unexplained ‘random’ differences.
All three are found to have a major role in explaining choices, whereby the level of heterogeneity
attributable to underlying attitudes and other unexplained ‘random’ differences outweighs those variations
that can be linked to observed characteristics. We find that, overall:
l There is a strong preference for the nurse at home model, with the lowest ranked treatment being SA.
However, there is very extensive variation across respondents in these preferences.
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l The type of treatment is far more important to respondents than the characteristics of that treatment
(e.g. in terms of aftercare, where the number of treatments and the level of risk of problems are the
next most important factors in explaining choices).
l There is a preference for a single dose of antimicrobials per day, ahead of two doses, continuous
treatment and three doses.
l Patients prefer to have an appointment time (for hospital or nurse at home treatment); however, the
importance of this is much reduced for long-term patients.
l Those patients not living alone have a preference for being treated by SNs, ahead of GNs and then
doctors, whereas those living alone marginally prefer doctors to SNs, far ahead of GNs.
l Most patients prefer a half-day of training for SA, except those aged < 50 years who live alone and are
short-term patients, those aged > 50 years who live alone and are long-term patients and short-term
patients aged < 50 years.
l Patients prefer seeing someone they know, and this preference is stronger for those aged < 50 years;
those > 50 years of age on short-term treatment place little importance on this.
l When communicating over the telephone, younger patients generally prefer speaking to someone they
know, with the opposite applying for some older patients.
l For aftercare, nurse in hospital is preferred to GP aftercare, which is ranked higher than telephone
aftercare and then no aftercare.
l Patients < 65 years of age who are not working do not distinguish between a risk of 1 in 6 and 1 in 10
of problems.
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Appendix 6 Patient and public involvement
The NIHR and other major funding bodies actively support public involvement throughout the researchcycle, and this has become enshrined as good research practice (Health and Social Care Act,230
INVOLVE231). To support meaningful PPI, bodies such as INVOLVE have devised good practice guidelines
and information. There is, however, no one way in which to involve people, and here we discusses our
approach to involvement and the strategies we used to try to make this meaningful to both patients and
the research team.
Patient and public involvement group
The CIVAS project worked to develop a specially constituted PPI group set up to advise on this project.
Unlike many clinical conditions (e.g. diabetes mellitus or heart disease), there was no existing patient group
with which we could work. Many patients will receive only one course of i.v. antibiotics in their lives and
so the topic is not of great importance to them. Others, such as those with cystic fibrosis and other chronic
conditions, will have repeated courses and, thus, the topic is of greater importance, but their experiences
and priorities may be quite different from those ‘infrequent recipients’. Our aim was to foster a
collaborative approach from the outset and to ensure that the voices of both groups were heard.
Therefore, this appendix describes how the group was set up, the challenges of maintaining such as
group, how roles were negotiated over time and the input provided by our patient group.
Two researchers (MT and CCM) have a long track record of involving patients and the public in research.
In keeping with our previous engagement and involvement activities, a flexible approach was adopted to
enable our members to come into and out of the group as their health and work/care commitments
required, and to allow people to draw on their existing skills to support the research endeavour.
Early days
It is recognised that meaningful PPI starts at the earliest stages of the research process.231 Our involvement
activities during the design of the study included meeting with individual patients to introduce the project,
during which we discussed what taking part in the study would mean for patients (time commitment,
sensitivity of topics discussed, timing of interviews) and we asked them how they would like the PPI group to
run. The patients we met with were supportive of the aims of the study and did not suggest any changes.
One patient (HG) agreed to become co-applicant on the grant.
Before the study started we contacted the patients involved pre award to inform them of the success of
the grant application. This was our first challenge. Although patients were supportive of the study, most
did not feel that they could continue to be involved. OPAT treatment is for many people a transitory
experience and by the time the project was funded two patients no longer felt that the study was of
relevance to them, and one felt that they could not be involved owing to their health. Only one patient
(HG) was in a position to remain involved in the study. We therefore set about constituting a new
PPI group.
Setting up a new patient advisory group
We advertised for new members via the clinicians involved in the study, and through the distribution of an
information sheet to patients in OPAT services in Bradford and Leeds. We received five responses to our
mailings. A PAG was formed, comprising short- (n = 2) and long-term (n = 3) OPAT patients. However,
both of the short-term infection patients dropped out of the group during 2013, as they were unable to
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get time off work to attend meetings. We therefore continued to recruit patients to the PAG throughout
the project, and two new PPI members joined the group in early 2014 (one long-term and one short-term
i.v. patient). During 2014 our lay co-applicant’s health deteriorated and she was no longer able to attend
meetings in person. She and another chronically ill patient therefore became ‘virtual’ members and
contributed as and when they could by e-mail.
Negotiating meeting frequency and types of involvement
The PAG met at key points throughout the project. We wanted members to have as much, or as little,
involvement as they felt was appropriate to them. This approach was taken for two reasons. First, we
wanted to maintain the involvement by those of working age and the chronically ill and felt that the best
way to do this was to allow people to miss meetings without feeling that they were in any way ‘letting the
group down’ by not attending. Second, we wanted patients to be involved at a number of key points and
this could result in patients feeling overburdened, so by taking a ‘menu’ approach to involvement, we
hoped to allow patients to play to their strengths, and not feel that they had to contribute to everything.
During our first meeting we presented an overview of the research project and each of the workstreams
and discussed with members what opportunities for involvement there would be during the project
(i.e. steering group committee membership, reviewing documentation for readability, reviewing interview
findings, contributing to the selection of DCE attributes, commenting on readability of DCE items, testing
our DCE, providing a patient perspective on the health economic modelling). PAG members were briefed
about forthcoming involvement opportunities and told that they would be invited to participate, if they
expressed an interest in being involved.
We also discussed their training needs. We had planned to send PAG members on the Macmillan Involving
People course, but none wished to attend and preferred that we brief them at the start of any activity
about what the task would entail, so this is what we did. In consultation with our lay members it was
agreed that rather than the PAG meet as a standalone group, PAG members would attend relevant
research meetings and engage directly with the researchers engaged on that workstream (with MT or
CCM facilitating the discussion). Between meetings, updates on the project were provided to the group via
e-mail. The lay co-applicant (HG) was invited to quarterly co-applicant meetings and attended steering
committee meetings as a member of the research team. All lay members were reimbursed for their time
and travel expenses. E-mails were used between meetings to update lay members of progress and to
advise them about future meetings.
How the patient advisory group influenced the research
Ethics application and participant materials
Our lay co-applicant had significant input into writing and commenting on the study documentation prior
to ethics review. She helped us to rephrase some of the wording on several sections of the information
sheets, both to improve readability and acceptability. At this point she was the only PPI member directly
involved in the study, so input was sought from an existing PPI generic group within the Leeds NHS Trust,
which also provided feedback on our documentation prior to ethics review.
Piloting topic guides
We piloted our patient interview topic guides on three PAG members. This involved lay members
participating in an interview and providing informal feedback about the phrasing and order of questions.
Feedback from PAG members was that patients would appreciate an opportunity to ‘tell their story’, so the
topic guide was adapted to allow for a more narrative approach. These pilot data were not included in the
corpus of data collected for the study, as informed consent was not taken, and interviews were not recorded,
as we wanted to ensure that there were clear boundaries between PPI and participation in the study.
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The patient interviews
Two PAG members met with the research group to discuss the interpretation of the patient interview data.
They provided feedback on how well the draft DCE items were drawn from the corpus of interview data
and how well they reflected their own experiences as patients. They worked with the research team to
redraft wording for both the DCE items and attitudinal questions based on initial drafts constructed by the
research team. The research team sought the advice of the PAG on improving recruitment of patients from
ethnic minority groups to the interview study. The lay members felt that they were of limited help, as the
group did not include any ethnic minority members.
The discrete choice experiment
Prior to formal piloting of the DCE a paper copy was circulated to six of our lay members via e-mail for
comments. Changes were made in light of their feedback.
l PAG members found it confusing to have eight sets of very similar questions presented to them.
To address this, clear instructions were incorporated into the DCE, and also at their suggestion an
example DCE was presented to participants before the choice options to ensure the participant
understood the procedure.
l Participants also asked for definitions of each service model to be included (e.g. GN vs. SN), and this
suggestion was incorporated.
l Participants noted that there was no option for self-employment, so this was included as an option
for ‘employment’.
l The wording of two attitude questions was revised to improve readability (e.g. ‘administering my own
intravenous antibiotics would worry me’ was changed to ‘giving my own i.v. antibiotics would
worry me’).
l The wording of some factors in the DCE caused some confusion. The term ‘aftercare’, by which
researchers meant ‘care after the infection episode was complete’, was interpreted as care once the
infection was being treated. The wording was clarified in the later version.
l One PAG member was concerned that some patients may become anxious because their specific
circumstances are not covered by the options provided by the questionnaire and so may disengage
with the questionnaire. It was agreed to test this in the pilot study (feedback was very positive on the
measure and no changes were made).
Health economic modelling
Patient advisory group members were invited, along with clinical experts, to three meetings to discuss the
development of the economic model. Two lay members attended the meetings and contributed to a
wide-ranging discussion about the use of health economic modelling. Feedback indicated that both
members found the session interesting and illuminating. At these meetings the health economists
presented the graphics for the preliminary models and provided an oral overview of them. Lay members
took the opportunity to gain insight into the way such models are constructed. The research team sought
guidance from the patients and clinical experts about whether or not the model as presented fitted with
their experience of receiving/giving i.v. antibiotics, and significant health events that may occur. This led to
changes to the preliminary models. At the subsequent meetings later versions of the Markov model were
presented along with the simulation model. PAG members felt that the data generated would be a useful
lever for getting OPAT adopted more widely.
Expert panel
All PAG members were invited to the expert panel which was held in Leeds in September 2015. Three
people agreed to attend. Unfortunately, two lay members had to drop out prior to the meeting owing to
ill health. A third lay member (CT) attended but became unwell and had to leave so was not able to
contribute fully to the discussions. Although we had translated the technical research language into lay
terms for this event, we do think that the amount of reading required prior to the event put some PAG
members off attending (a 10-page report for each workstream). The PAG members were fully involved in
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the development and running of the dissemination event which took place in May 2016 and which was
open to patients as well as professionals.
Discussion
Studies suggest that patient participation in research can occur at three levels: consultation, collaboration
and user involvement. In the development of our project involvement was largely consultative, with some
collaboration, However, during the delivery of the CIVAS project involvement has been collaborative, with
meetings or virtual interactions in which participants contributed to the project, for example in terms of the
development of the DCE.
On reflection, our flexible approach to patient involvement was essential and resulted in support, both
from the research team and PAG. Our collaborative approach was acceptable to members of the patient
group and informal feedback has been very positive, although formal feedback was not sought. Working
with our patient group in this way has facilitated substantive contributions to decision-making at each
stage of the project, in particular to ensure that the DCE was acceptable and understandable to patients.
Evidence of the impact that our PAG made to this work can be seen in particular from the piloting of the
DCE, which patients found to be very easy to use. Both lay members and professionals valued the
interaction and exposure to others’ views, as evidenced by our research team actively requesting meetings
with the PAG members. Involving our PAG in the way we did made a difference to the quality of the
research project.
The project itself has not been without its challenges, and this has meant that there have often been large
gaps between meetings, which possibly contributed to the loss of members from the group, although the
reasons given related to work or health issues. The turnover of attendees has, however, also resulted in
bringing fresh eyes to the project and a more dynamic group. We would have missed out on involving
some eloquent and informed patients had our group been more stable, as we may not have sought
additional participants.
The difficulties maintaining the patient advisory group
We were careful not to cross the line between our PAG members being our collaborators and our study
participants. A strength of the approach we took is that engagement between the lay members was
usually with multiple members of the research team. This served to build a good rapport between the
research team and the lay members, as some members of the research team were involved in several work
strands so got to know the lay members very well and built up trust with the group.
Despite attempts to recruit members from ethnic minorities to the PAG (e.g. direct contact with patients
from ethnic minorities at OPAT clinics, asking community groups catering for ethnic minority groups),
no one came forward. None of the research group had existing links with ethnic minority groups so we
used links via university colleagues to gain access to local community groups but did not identify anyone
who had experience of OPAT who could join the group.
Owing to the ill health of our lay co-applicant, she has not been able to be actively involved in the project
since 2014. Initially she was able to maintain her involvement via e-mail, commenting on documents and
responding to e-mail requests, but her health has meant that this could not be maintained.
Evaluation of involvement
Given the size of the group, and the way in which we involved people (integrating them into our research
meetings), we did not undertake any formal evaluation of the effectiveness of our involvement strategies,
but instead ensured that at the end of every meeting we had an informal discussion with the lay members
at the meeting to find out how they felt it had gone. This approach to involvement does not perhaps lend
itself as well to evaluation as formal workshops or meetings, and we did not put in place a formal
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framework to evaluate its effectiveness, as advocated by Popay’s recent guidance.232 Had this guidance
been in place at the start of our project (early in 2013), we might perhaps have benefited from evaluating
our own perceptions of the purpose of involvement and considering the role our biases play in how
involvement activities were presented to our lay members. Having used the approach taken in this study in
previous research projects, we perhaps presented the opportunities in such a way that members felt this
was the ‘right’ approach. However, the passage of time means this cannot be sensibly tested.
What worked well
l Inviting lay members to research meetings.
l Using a facilitator in meetings (who, although not independent, was not an expert in the topic).
l Support from the research team.
l Agreeing roles at the start of the project.
l Offering a menu of involvement opportunities.
l Providing an induction pack.
What we would do differently
l Advertise more widely.
l Explore the expectations and needs of PAG members more deeply.
l Plan evaluation activities into the design.
l Plan meetings later in the day (evening) to accommodate ‘working’ members, and also be flexible to
accommodate shift workers.
DOI: 10.3310/hsdr05060 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 6
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Minton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
271


Part of the NIHR Journals Library 
www.journalslibrary.nihr.ac.uk
Published by the NIHR Journals Library
This report presents independent research funded by the 
National Institute for Health Research (NIHR). The views 
expressed are those of the author(s) and not necessarily 
those of the NHS, the NIHR or the Department of Health
EME
HS&DR
HTA
PGfAR
PHR
